0001297184-21-000031.txt : 20210507 0001297184-21-000031.hdr.sgml : 20210507 20210507162635 ACCESSION NUMBER: 0001297184-21-000031 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210507 DATE AS OF CHANGE: 20210507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amphastar Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001297184 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330702205 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36509 FILM NUMBER: 21903152 BUSINESS ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 909-980-9484 MAIL ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 10-Q 1 amph-20210331x10q.htm 10-Q
3300000000Amphastar Pharmaceuticals, Inc.--12-31false00012971842021-03-31Q1truefalse0001297184us-gaap:SalesReturnsAndAllowancesMember2021-01-012021-03-310001297184us-gaap:SalesReturnsAndAllowancesMember2020-01-012020-03-310001297184us-gaap:SalesReturnsAndAllowancesMember2021-03-310001297184us-gaap:SalesReturnsAndAllowancesMember2020-12-310001297184us-gaap:SalesReturnsAndAllowancesMember2020-03-310001297184us-gaap:SalesReturnsAndAllowancesMember2019-12-310001297184amph:November2014ShareRepurchasePlanMember2021-01-012021-03-310001297184amph:November2014ShareRepurchasePlanMember2020-01-012020-03-310001297184amph:November2014ShareRepurchasePlanMember2020-08-040001297184us-gaap:TreasuryStockMember2021-01-012021-03-310001297184us-gaap:TreasuryStockMember2020-01-012020-03-310001297184us-gaap:CommonStockMember2020-01-012020-03-310001297184us-gaap:RetainedEarningsMember2021-03-310001297184us-gaap:ParentMember2021-03-310001297184us-gaap:NoncontrollingInterestMember2021-03-310001297184us-gaap:AdditionalPaidInCapitalMember2021-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001297184us-gaap:RetainedEarningsMember2020-12-310001297184us-gaap:ParentMember2020-12-310001297184us-gaap:NoncontrollingInterestMember2020-12-310001297184us-gaap:AdditionalPaidInCapitalMember2020-12-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001297184us-gaap:RetainedEarningsMember2020-03-310001297184us-gaap:ParentMember2020-03-310001297184us-gaap:NoncontrollingInterestMember2020-03-310001297184us-gaap:AdditionalPaidInCapitalMember2020-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001297184us-gaap:RetainedEarningsMember2019-12-310001297184us-gaap:ParentMember2019-12-310001297184us-gaap:NoncontrollingInterestMember2019-12-310001297184us-gaap:AdditionalPaidInCapitalMember2019-12-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001297184amph:EmployeeMemberamph:Anp2018EquityIncentivePlanMember2021-03-310001297184amph:EmployeeStockPurchasePlan2014Member2021-03-310001297184amph:The2015EquityIncentivePlanMember2021-03-310001297184amph:The2015EquityIncentivePlanMember2021-01-012021-01-310001297184us-gaap:RestrictedStockUnitsRSUMember2020-12-310001297184amph:EmployeeMemberamph:Anp2018EquityIncentivePlanMember2019-06-012019-06-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2021-01-012021-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2021-01-012021-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2021-01-012021-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2021-01-012021-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:GlucagonMember2021-01-012021-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2021-01-012021-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2021-01-012021-03-310001297184country:US2021-01-012021-03-310001297184country:FR2021-01-012021-03-310001297184country:CN2021-01-012021-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2020-01-012020-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2020-01-012020-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2020-01-012020-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2020-01-012020-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2020-01-012020-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2020-01-012020-03-310001297184country:US2020-01-012020-03-310001297184country:FR2020-01-012020-03-310001297184country:CN2020-01-012020-03-310001297184us-gaap:MachineryAndEquipmentMember2021-03-310001297184us-gaap:LeaseholdImprovementsMember2021-03-310001297184us-gaap:LandMember2021-03-310001297184us-gaap:ConstructionInProgressMember2021-03-310001297184us-gaap:BuildingMember2021-03-310001297184amph:FurnitureFixturesAndVehiclesMember2021-03-310001297184us-gaap:MachineryAndEquipmentMember2020-12-310001297184us-gaap:LeaseholdImprovementsMember2020-12-310001297184us-gaap:LandMember2020-12-310001297184us-gaap:ConstructionInProgressMember2020-12-310001297184us-gaap:BuildingMember2020-12-310001297184amph:FurnitureFixturesAndVehiclesMember2020-12-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001297184country:US2021-03-310001297184country:FR2021-03-310001297184country:CN2021-03-310001297184country:US2020-12-310001297184country:FR2020-12-310001297184country:CN2020-12-310001297184us-gaap:RetainedEarningsMember2021-01-012021-03-310001297184us-gaap:RetainedEarningsMember2020-01-012020-03-310001297184amph:CommitmentsToPurchaseEquipmentAndRawMaterialsMember2021-01-012021-03-310001297184amph:WorkingCapitalLoanDueJune2021Memberamph:EverbrightBankOfChinaMember2021-03-310001297184amph:MortgagePayableDueOctober2026Memberamph:EastWestBankMember2021-03-310001297184amph:MortgagePayableDueMay2021Memberamph:EastWestBankMember2021-03-310001297184amph:MortgagePayableDueJune2027Memberamph:EastWestBankMember2021-03-310001297184amph:MortgagePayableDueAugust2027Memberamph:CathayBankMember2021-03-310001297184amph:LineOfCreditDueOctober2021Memberamph:BankOfNanjingMember2021-03-310001297184amph:LineOfCreditDueAugust2021Memberamph:ChinaMerchantBankMember2021-03-310001297184amph:FrenchGovernmentLoanDueJuly2021Memberamph:SeineNormandieWaterAgencyMember2021-03-310001297184amph:FrenchGovernmentLoan4DueDecember2026Memberamph:SeineNormandieWaterAgencyMember2021-03-310001297184amph:EquipmentLoanDueJune2021Memberamph:EastWestBankMember2021-03-310001297184amph:EquipmentLoanDueFebruary2024Memberamph:EastWestBankMember2021-03-310001297184amph:EquipmentLoanDueDecember2022Memberamph:EastWestBankMember2021-03-310001297184amph:EquipmentLineOfCreditDueSeptember2025Memberamph:EastWestBankMember2021-03-310001297184amph:AcquisitionLoanDueJune2024Memberamph:CathayBankMember2021-03-310001297184amph:WorkingCapitalLoanDueJune2021Memberamph:EverbrightBankOfChinaMember2020-12-310001297184amph:MortgagePayableDueOctober2026Memberamph:EastWestBankMember2020-12-310001297184amph:MortgagePayableDueMay2021Memberamph:EastWestBankMember2020-12-310001297184amph:MortgagePayableDueJune2027Memberamph:EastWestBankMember2020-12-310001297184amph:MortgagePayableDueAugust2027Memberamph:CathayBankMember2020-12-310001297184amph:LineOfCreditDueOctober2021Memberamph:BankOfNanjingMember2020-12-310001297184amph:LineOfCreditDueAugust2021Memberamph:ChinaMerchantBankMember2020-12-310001297184amph:FrenchGovernmentLoanDueJuly2021Memberamph:SeineNormandieWaterAgencyMember2020-12-310001297184amph:FrenchGovernmentLoan4DueDecember2026Memberamph:SeineNormandieWaterAgencyMember2020-12-310001297184amph:EquipmentLoanDueJune2021Memberamph:EastWestBankMember2020-12-310001297184amph:EquipmentLoanDueFebruary2024Memberamph:EastWestBankMember2020-12-310001297184amph:EquipmentLoanDueDecember2022Memberamph:EastWestBankMember2020-12-310001297184amph:EquipmentLineOfCreditDueSeptember2025Memberamph:EastWestBankMember2020-12-310001297184amph:AcquisitionLoanDueJune2024Memberamph:CathayBankMember2020-12-310001297184amph:AmphastarPharmaceuticalsInc.VsAventisPharmaSaMemberus-gaap:SubsequentEventMember2021-05-032021-05-030001297184amph:AmphastarPharmaceuticalsInc.VsAventisPharmaSaMemberus-gaap:SubsequentEventMember2021-05-012021-05-310001297184amph:RamirezVsAmphastarPharmaceuticalsIncMemberus-gaap:SettledLitigationMemberus-gaap:SubsequentEventMember2021-04-052021-04-050001297184amph:BrenesVsInternationalMedicationSystemsLimitedMember2021-02-092021-02-090001297184amph:AmphastarPharmaceuticalsInc.VsAventisPharmaSaMemberus-gaap:SettledLitigationMember2020-11-132020-11-130001297184amph:RamirezVsAmphastarPharmaceuticalsIncMemberus-gaap:SettledLitigationMember2021-03-310001297184amph:AmphastarPharmaceuticalsInc.VsAventisPharmaSaMember2021-03-310001297184amph:BrenesVsInternationalMedicationSystemsLimitedMember2020-12-310001297184amph:AmphastarPharmaceuticalsInc.VsAventisPharmaSaMember2020-12-310001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2021-03-310001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2020-12-310001297184amph:EnoxaparinMember2021-01-012021-03-310001297184amph:EnoxaparinMember2020-01-012020-03-310001297184us-gaap:TrademarksMember2021-03-310001297184us-gaap:TrademarksMember2020-12-310001297184us-gaap:MunicipalBondsMember2021-03-310001297184us-gaap:CorporateBondSecuritiesMember2021-03-310001297184us-gaap:MunicipalBondsMember2020-12-310001297184us-gaap:CorporateBondSecuritiesMember2020-12-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2021-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2020-12-310001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2021-01-012021-03-310001297184us-gaap:UseRightsMember2021-01-012021-03-310001297184us-gaap:PatentsMember2021-01-012021-03-310001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2020-01-012020-12-310001297184us-gaap:UseRightsMember2020-01-012020-12-310001297184us-gaap:PatentsMember2020-01-012020-12-3100012971842020-01-012020-12-310001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2021-03-310001297184us-gaap:UseRightsMember2021-03-310001297184us-gaap:PatentsMember2021-03-310001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2020-12-310001297184us-gaap:UseRightsMember2020-12-310001297184us-gaap:PatentsMember2020-12-310001297184us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2021-03-310001297184us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2021-03-310001297184us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2020-12-310001297184us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2020-12-310001297184amph:EmployeeConsultantAndDirectorsStockOptionsMember2021-03-310001297184amph:EmployeeConsultantAndDirectorsStockOptionsMember2021-01-012021-03-310001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2021-03-310001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2020-12-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2021-01-012021-03-310001297184amph:ActivePharmaceuticalIngredientSegmentMember2021-01-012021-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2020-01-012020-03-310001297184amph:ActivePharmaceuticalIngredientSegmentMember2020-01-012020-03-310001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001297184amph:McKessonMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001297184amph:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001297184amph:AmerisourceBergenMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001297184amph:AmerisourceBergenMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001297184amph:McKessonMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001297184amph:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001297184amph:AmerisourceBergenMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001297184amph:AmerisourceBergenMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001297184us-gaap:TreasuryStockMember2021-03-310001297184us-gaap:CommonStockMember2021-03-310001297184us-gaap:TreasuryStockMember2020-12-310001297184us-gaap:CommonStockMember2020-12-310001297184us-gaap:TreasuryStockMember2020-03-310001297184us-gaap:CommonStockMember2020-03-310001297184us-gaap:TreasuryStockMember2019-12-310001297184us-gaap:CommonStockMember2019-12-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-03-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-12-310001297184us-gaap:FairValueMeasurementsRecurringMember2021-03-310001297184us-gaap:FairValueInputsLevel2Member2021-03-310001297184us-gaap:FairValueInputsLevel1Member2021-03-310001297184us-gaap:FairValueMeasurementsRecurringMember2020-12-310001297184us-gaap:FairValueInputsLevel2Member2020-12-310001297184us-gaap:FairValueInputsLevel1Member2020-12-310001297184amph:EmployeeMemberamph:Anp2018EquityIncentivePlanMember2021-01-012021-03-310001297184us-gaap:SellingAndMarketingExpenseMember2021-01-012021-03-310001297184us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001297184us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001297184us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001297184us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001297184us-gaap:CostOfSalesMember2021-01-012021-03-310001297184amph:EmployeeStockPurchasePlan2014Member2021-01-012021-03-310001297184amph:EmployeeMemberamph:Anp2018EquityIncentivePlanMember2020-01-012020-03-310001297184us-gaap:SellingAndMarketingExpenseMember2020-01-012020-03-310001297184us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-310001297184us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-310001297184us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-310001297184us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001297184us-gaap:CostOfSalesMember2020-01-012020-03-310001297184amph:EmployeeStockPurchasePlan2014Member2020-01-012020-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2021-01-012021-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2020-01-012020-03-310001297184us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001297184us-gaap:NoncontrollingInterestMember2020-01-012020-03-3100012971842021-05-030001297184us-gaap:ParentMember2021-01-012021-03-310001297184us-gaap:CommonStockMember2021-01-012021-03-310001297184us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001297184us-gaap:ParentMember2020-01-012020-03-310001297184us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001297184us-gaap:RestrictedStockUnitsRSUMember2021-03-310001297184amph:RestrictedStockUnitsIssuedAsCompensationMember2021-01-012021-03-310001297184us-gaap:AccountsReceivableMember2021-01-012021-03-310001297184us-gaap:AccountsPayableAndAccruedLiabilitiesMember2021-01-012021-03-310001297184us-gaap:AccountsReceivableMember2020-01-012020-12-310001297184us-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-01-012020-12-3100012971842020-03-3100012971842019-12-310001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMemberus-gaap:SubsequentEventMember2021-05-012021-05-310001297184amph:AnpMemberus-gaap:SubsequentEventMember2021-05-012021-05-310001297184us-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001297184us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001297184us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-3100012971842020-01-012020-03-310001297184amph:AnpMember2018-07-012018-07-3100012971842021-01-012021-03-310001297184amph:EmployeeAndNonEmployeeStockOptionsMember2021-01-012021-03-310001297184amph:EmployeeAndNonEmployeeStockOptionsMember2020-01-012020-03-3100012971842021-03-3100012971842020-12-31iso4217:USDiso4217:USDxbrli:sharesxbrli:pureamph:itemxbrli:sharesamph:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from             to             

Commission file number 001-36509

AMPHASTAR PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Delaware

 

33-0702205

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer
Identification No.)

11570 6th Street

 

Rancho Cucamonga, CA

 

91730

(Address of principal executive offices)

(zip code)

(909) 980-9484

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No      

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Securities registered pursuant to Section 12(b) of the Act:

T

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

AMPH

The NASDAQ Stock Market LLC

The number of shares outstanding of the registrant’s only class of common stock as of May 3, 2021 was 47,635,351.

AMPHASTAR PHARMACEUTICALS, INC.

TABLE OF CONTENTS

FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021

Special Note About Forward-Looking Statements

Part I. FINANCIAL INFORMATION

PAGE

Item 1. Financial Statements (unaudited)

Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020

1

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2021 and 2020

2

Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three Months Ended March 31, 2021 and 2020

3

Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2021 and 2020

4

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020

5

Notes to Condensed Consolidated Financial Statements

6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

27

Item 3. Quantitative and Qualitative Disclosure about Market Risk

34

Item 4. Controls and Procedures

34

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

35

Item 1A. Risk Factors

35

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

38

Item 3. Defaults Upon Senior Securities

38

Item 4. Mine Safety Disclosures

38

Item 5. Other Information

39

Item 6. Exhibits

39

Signatures

40

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains “forward-looking statements” that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements relate to future events or future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, statements about:

our expectations regarding the sales and marketing of our products;

our expectations regarding our manufacturing and production and the integrity of our supply chain for our products, including the risks associated with our single source suppliers;
the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations;
interruptions to our manufacturing and production as a result of natural catastrophic events or other causes beyond our control such as power disruptions or widespread disease outbreaks, such as the COVID-19 pandemic;
global, national and local economic and market conditions, specifically with respect to geopolitical uncertainty, and the COVID-19 pandemic;

the timing and likelihood of U.S. Food and Drug Administration, or FDA, approvals and regulatory actions on our product candidates, manufacturing activities and product marketing activities;

our ability to advance product candidates in our platforms into successful and completed clinical trials and our subsequent ability to successfully commercialize our product candidates;

our ability to compete in the development and marketing of our products and product candidates;
our expectations regarding the business expansion plans for our Chinese subsidiary, ANP, including its restructuring;

the potential for adverse application of environmental, health and safety and other laws and regulations on our operations;

our expectations for market acceptance of our new products and proprietary drug delivery technologies, as well as those of our active pharmaceutical ingredient, or API, customers;

the potential for our marketed products to be withdrawn due to patient adverse events or deaths, or if we fail to secure FDA approval for products subject to the Prescription Drug Wrap-Up program;

our expectations in obtaining insurance coverage and adequate reimbursement for our products from third-party payers;

the amount of price concessions or exclusion of suppliers adversely affecting our business;

our ability to establish and maintain intellectual property protection for our products and our ability to successfully defend our intellectual property in cases of alleged infringement;

the implementation of our business strategies, product development strategies and technology utilization;

the potential for exposure to product liability claims;

future acquisitions, divestitures or investments, including the anticipated benefits of such acquisitions, divestitures or investments;

our ability to expand internationally;

economic and industry trends and trend analysis;

our ability to remain in compliance with laws and regulations that currently apply or become applicable to our business both in the United States and internationally;
the impact of trade tariffs, export or import restrictions, or other trade barriers;
the impact of Patient Protection and Affordable Care Act (as amended) and other legislative and regulatory healthcare reforms in the countries in which we operate including the potential for drug price controls;
the impact of global and domestic tax reforms, including the Tax Cuts and Jobs Act of 2017, or the Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act;

the timing for completion and the validation of the new construction at our ANP and Amphastar facilities;
the timing and extent of share buybacks; and

our financial performance expectations, including our expectations regarding our backlog, revenue, cost of revenue, gross profit or gross margin, operating expenses, including changes in research and development, sales and marketing and general and administrative expenses, and our ability to achieve and maintain future profitability.

You should read this Quarterly Report and the documents that we reference elsewhere in this Quarterly Report completely and with the understanding that our actual results may differ materially from what we expect as expressed or implied by our forward-looking statements. In light of the significant risks and uncertainties to which our forward-looking statements are subject, you should not place undue reliance on or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. In particular, the extent of COVID-19’s impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, all of which continue to evolve and remain uncertain at this time. We discuss many of these risks and uncertainties in greater detail in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2020, particularly in Item 1A. “Risk Factors.” These forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report regardless of the time of delivery of this Quarterly Report, and such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Quarterly Report.

Unless expressly indicated or the context requires otherwise, references in this Quarterly Report to “Amphastar,” “the Company,” “we,” “our,” and “us” refer to Amphastar Pharmaceuticals, Inc. and our subsidiaries.

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

    

March 31, 

    

December 31, 

 

2021

2020

 

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$

101,601

$

92,642

Restricted cash

235

1,865

Short-term investments

13,531

12,977

Restricted short-term investments

 

2,200

 

2,200

Accounts receivable, net

 

77,938

 

66,005

Inventories

 

97,110

 

96,831

Income tax refunds and deposits

 

800

 

385

Prepaid expenses and other assets

 

6,749

 

6,777

Total current assets

 

300,164

 

279,682

Property, plant, and equipment, net

 

253,265

 

260,055

Finance lease right-of-use assets

594

612

Operating lease right-of-use assets

19,280

20,042

Goodwill and intangible assets, net

 

40,243

 

40,615

Other assets

 

7,212

 

5,250

Deferred tax assets

 

24,980

 

24,980

Total assets

$

645,738

$

631,236

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$

108,545

$

95,504

Income taxes payable

 

2,676

 

1,077

Current portion of long-term debt

 

12,173

 

12,263

Current portion of operating lease liabilities

3,702

3,357

Total current liabilities

 

127,096

 

112,201

Long-term reserve for income tax liabilities

 

4,709

 

4,709

Long-term debt, net of current portion

 

32,334

 

34,186

Long-term operating lease liabilities, net of current portion

16,464

17,464

Deferred tax liabilities

 

755

 

741

Other long-term liabilities

 

13,420

 

13,212

Total liabilities

 

194,778

 

182,513

Commitments and contingencies

Stockholders’ equity:

Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding

 

 

Common stock: par value $0.0001; 300,000,000 shares authorized; 55,184,000 and 47,718,003 shares issued and outstanding as of March 31, 2021 and 54,760,922 and 47,495,439 shares issued and outstanding as of December 31, 2020, respectively

 

6

 

5

Additional paid-in capital

 

413,926

 

410,061

Retained earnings

 

122,814

 

117,773

Accumulated other comprehensive loss

 

(5,642)

 

(3,721)

Treasury stock

 

(125,546)

 

(121,812)

Total Amphastar Pharmaceuticals, Inc. stockholders’ equity

 

405,558

 

402,306

Non-controlling interests

45,402

46,417

Total equity

450,960

448,723

Total liabilities and stockholders’ equity

$

645,738

$

631,236

See Accompanying Notes to Condensed Consolidated Financial Statements.

-1-

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited; in thousands, except per share data)

Three Months Ended

 

March 31, 

    

2021

    

2020

 

Net revenues

$

103,020

$

84,688

Cost of revenues

 

58,074

 

47,865

Gross profit

 

44,946

 

36,823

Operating expenses:

Selling, distribution, and marketing

 

4,537

 

3,294

General and administrative

 

15,338

 

10,746

Research and development

 

14,765

 

15,303

Total operating expenses

 

34,640

 

29,343

Income from operations

 

10,306

 

7,480

Non-operating (expenses) income:

Interest income

 

161

 

153

Interest expense

 

(104)

 

(76)

Other expenses, net

 

(5,249)

 

(1,752)

Total non-operating (expenses) income, net

 

(5,192)

 

(1,675)

Income before income taxes

 

5,114

 

5,805

Income tax provision

 

1,155

 

2,280

Net income

$

3,959

$

3,525

Net loss attributable to non-controlling interests

$

(1,082)

$

(424)

Net income attributable to Amphastar Pharmaceuticals, Inc.

$

5,041

$

3,949

Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders:

Basic

$

0.11

$

0.09

Diluted

$

0.10

$

0.08

Weighted-average shares used to compute net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders:

Basic

 

47,520

 

46,408

Diluted

 

49,518

 

48,248

See Accompanying Notes to Condensed Consolidated Financial Statements.

-2-

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited; in thousands)

Three Months Ended

March 31, 

    

2021

    

2020

 

Net income attributable to Amphastar Pharmaceuticals, Inc.

$

5,041

$

3,949

Other comprehensive loss attributable to Amphastar Pharmaceuticals, Inc., net of income taxes

Foreign currency translation adjustment

 

(1,921)

 

(774)

Total other comprehensive loss attributable to Amphastar Pharmaceuticals, Inc.

 

(1,921)

 

(774)

Total comprehensive income attributable to Amphastar Pharmaceuticals, Inc.

$

3,120

$

3,175

See Accompanying Notes to Condensed Consolidated Financial Statements.

-3-

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited; in thousands, except share data)

Common Stock

Accumulated

Treasury Stock

Total

Additional

Other

Amphastar

Non-

Paid-in

Retained

Comprehensive

Stockholders'

controlling

Shares

Amount

Capital

Earnings

loss

Shares

Amount

Equity

Interest

Total

Balance as of December 31, 2020

 

54,760,922

$

5

$

410,061

$

117,773

$

(3,721)

 

(7,265,483)

$

(121,812)

$

402,306

$

46,417

$

448,723

Net income attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

5,041

 

 

 

 

5,041

 

 

5,041

Other comprehensive loss attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

 

(1,921)

 

 

 

(1,921)

 

 

(1,921)

Net loss attributable to non-controlling interest

(1,082)

(1,082)

Purchase of treasury stock

 

 

 

 

 

 

(204,698)

(3,783)

(3,783)

 

(3,783)

Issuance of treasury stock in connection with the Company's equity plans

(49)

4,184

49

Issuance of common stock in connection with the Company's equity plans

 

423,078

 

1

 

(853)

 

 

 

 

 

(852)

 

 

(852)

Share-based compensation expense

 

 

 

4,767

 

 

 

 

 

4,767

 

67

 

4,834

Balance as of March 31, 2021

 

55,184,000

$

6

$

413,926

$

122,814

$

(5,642)

 

(7,465,997)

$

(125,546)

$

405,558

$

45,402

$

450,960

Common Stock

Accumulated

Treasury Stock

Total

Additional

Other

Amphastar

Non-

Paid-in

Retained

Comprehensive

Stockholders'

controlling

Shares

Amount

Capital

Earnings

loss

Shares

Amount

Equity

Interest

Total

Balance as of December 31, 2019

 

52,495,483

$

5

$

367,305

$

116,370

$

(4,687)

 

(5,918,515)

$

(97,627)

$

381,366

$

46,162

$

427,528

Net income attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

3,949

 

 

 

 

3,949

 

 

3,949

Other comprehensive loss attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

 

(774)

 

 

 

(774)

 

 

(774)

Net loss attributable to non-controlling interest

(424)

(424)

Purchase of treasury stock

 

 

 

 

 

 

(647,246)

(10,950)

(10,950)

 

(10,950)

Issuance of treasury stock in connection with the Company's equity plans

(84)

6,873

84

Issuance of common stock in connection with the Company's equity plans

 

369,508

 

 

(1,238)

 

 

 

 

 

(1,238)

 

 

(1,238)

Share-based compensation expense

 

 

 

5,161

 

 

 

 

 

5,161

 

121

 

5,282

Balance as of March 31, 2020

 

52,864,991

$

5

$

371,144

$

120,319

$

(5,461)

 

(6,558,888)

$

(108,493)

$

377,514

$

45,859

$

423,373

See Accompanying Notes to Condensed Consolidated Financial Statements

-4-

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; in thousands)

Three Months Ended

March 31, 

    

2021

    

2020

 

Cash Flows From Operating Activities:

Net income

$

3,959

$

3,525

Reconciliation to net cash provided by operating activities:

Loss on disposal of assets

 

6

 

14

Depreciation of property, plant, and equipment

 

5,686

 

4,716

Amortization of product rights, trademarks, and patents

 

276

 

258

Operating lease right-of-use asset amortization

863

848

Share-based compensation expense

 

4,834

 

5,282

Changes in deferred taxes, net

 

 

1,638

Changes in operating assets and liabilities:

Accounts receivable, net

 

(12,078)

 

(12,487)

Inventories

 

(1,144)

 

2,241

Prepaid expenses and other assets

 

1,119

 

1,494

Income tax refunds, deposits, and payable, net

 

1,182

 

451

Operating lease liabilities

(754)

(824)

Accounts payable and accrued liabilities

 

18,876

 

(5,679)

Net cash provided by operating activities

 

22,825

 

1,477

Cash Flows From Investing Activities:

Purchases and construction of property, plant, and equipment

 

(7,618)

 

(8,006)

Sales of short-term investments

 

 

21

Purchase of short-term investments

(4,501)

(4,561)

Maturity of short-term investments

3,944

4,030

Payment of deposits and other assets

 

(520)

 

(206)

Net cash used in investing activities

 

(8,695)

 

(8,722)

Cash Flows From Financing Activities:

Proceeds from equity plans, net of withholding tax payments

 

(854)

 

(1,238)

Purchase of treasury stock

 

(3,783)

 

(10,950)

Proceeds from issuance of long-term debt

 

 

3,067

Principal payments on long-term debt

 

(2,002)

 

(2,328)

Net cash used in financing activities

 

(6,639)

 

(11,449)

Effect of exchange rate changes on cash

 

(162)

 

(146)

Net increase (decrease) in cash, cash equivalents, and restricted cash

 

7,329

 

(18,840)

Cash, cash equivalents, and restricted cash at beginning of period

 

94,507

 

75,550

Cash, cash equivalents, and restricted cash at end of period

$

101,836

$

56,710

Noncash Investing and Financing Activities:

Capital expenditure included in accounts payable

$

6,238

$

5,840

Operating lease right-of-use assets

$

103

$

Equipment acquired under finance leases

$

74

$

Supplemental Disclosures of Cash Flow Information:

Interest paid, net of capitalized interest

$

508

$

559

Income taxes paid

$

30

$

209

See Accompanying Notes to Condensed Consolidated Financial Statements.

-5-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. General

Amphastar Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, hereinafter referred to as the “Company”) is a bio-pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products, including products with high technical barriers to market entry. Additionally, the Company sells insulin active pharmaceutical ingredient, or API, products. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company’s insulin API products are sold to other pharmaceutical companies for use in their own products and are being used by the Company in the development of injectable finished pharmaceutical products. The Company’s inhalation product, Primatene Mist® is primarily distributed through drug retailers.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2020 and the notes thereto as filed with the Securities and Exchange Commission, or SEC, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles, or GAAP, have been condensed or omitted from the accompanying condensed consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from the audited financial statements. The accompanying interim financial statements are unaudited, but reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the Company’s consolidated financial position, results of operations, comprehensive income (loss), stockholders’ equity, and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. The Company’s results of operations, comprehensive income (loss) and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with United States generally accepted accounting principles, or GAAP. Certain prior period amounts have been reclassified within the investing activities of the statement of cash flows to conform to the current period presentation. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.

The Company’s subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals, Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Nanjing Letop Biological Technology Co., Ltd., or Letop, (5) Nanjing Hanxin Pharmaceutical Technology Co., Ltd., or Hanxin, (6) Nanjing Hanxin Biomedical Testing Service Co., Ltd., or Hanxin Biomedical, (7) Nanjing Baixin Trading Co., Ltd., or Baixin, (8) Amphastar France Pharmaceuticals, S.A.S., or AFP, (9) Amphastar UK Ltd., or AUK, and (10) International Medication Systems (UK) Limited, or IMS UK.

In July 2018, the Company’s Chinese subsidiary, ANP, completed a private placement of its common equity interest to accredited investors and received approximately $56.3 million of cash proceeds, a portion of which was received in 2019. The Company has retained approximately 58% of the equity interest in ANP following the private placement and continues to consolidate the financial results of ANP with the Company’s results of operations. ANP’s net income after July 2, 2018, was attributed to the Company in accordance with the Company’s equity interest of approximately 58% in ANP.

-6-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

COVID-19 Pandemic

The Company is subject to risks and uncertainties as a result of the ongoing novel coronavirus pandemic, or COVID-19. The complete extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the information is constantly evolving. The Company considered the impact of COVID-19 on the assumptions and estimates used to determine the results reported and asset valuations as of March 31, 2021.

All of the Company’s production facilities continued to operate during the quarter as they had prior to the COVID-19 pandemic with very little change, other than for enhanced safety measures intended to prevent the spread of the virus.

It is not possible at this time to estimate the complete impact that COVID-19 could have on the Company’s business, including its customers and suppliers, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. The Company will continue to monitor the impact of COVID-19 on all aspects of its business.

Use of Estimates

The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for credit losses, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to their net realizable values, impairment of long-lived and intangible assets and goodwill, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.

Foreign Currency

The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the US Dollar. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company’s condensed consolidated statements of operations.

The Company’s French subsidiary, AFP, maintains its book of record in euros. ANP’s subsidiaries maintain their books of record in Chinese yuan. AUK’s subsidiary, IMS UK, maintains its book of record in British pounds. These local currencies have been determined to be the subsidiaries’ respective functional currencies. These books of record are translated into USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other accumulated comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature for the three months ended March 31, 2021 and 2020 were $1.5 million loss and $0.6 million loss, respectively.

Comprehensive Income (Loss)

For the three months ended March 31, 2021 and 2020, the Company included its foreign currency translation gain or loss as part of its comprehensive income (loss). No income tax expense (benefit) was allocated to other comprehensive income (loss) for the three months ended March 31, 2021 and 2020.

-7-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Advertising Expense

Advertising expenses, primarily associated with Primatene Mist®, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Company’s condensed consolidated statement of operations. For the three months ended March 31, 2021 and 2020, advertising expense was $2.2 million and $1.0 million, respectively.

Financial Instruments

The carrying amounts of cash and cash equivalents, short-term investments, restricted cash and short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. The majority of the Company’s long-term obligations consist of variable rate debt, and their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. The Company at times enters into fixed interest rate swap contracts to exchange the variable interest rates for fixed interest rates without the exchange of the underlying notional debt amounts. Such interest rate swap contracts are recorded at their fair values.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments purchased with original maturities of three months or less.

Short-Term Investments

Short-term investments as of March 31, 2021 and December 31, 2020 consisted of certificates of deposit and investment grade debt securities with original expiration dates within 12 months.

Restricted Cash

Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of March 31, 2021 and December 31, 2020, the restricted cash balance was $0.2 million and $1.9 million, respectively.

Restricted Short-Term Investments

Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workers’ compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of March 31, 2021 and December 31, 2020, the balance of restricted short-term investments was $2.2 million.

Deferred Income Taxes

The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized.

Recent Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU,

-8-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

No. 2019-12 Simplifying the Accounting for Income Taxes (Topic 740). The amendment removes certain exceptions for performing intra-period tax allocations, recognizing deferred taxes for investment, and calculating income taxes in interim periods. The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods. The guidance is effective for the Company’s interim and annual reporting periods during the year ended December 31, 2021. The adoption of this accounting guidance did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

 

Note 3. Revenue Recognition

In accordance with Accounting Standard Codification, or ASC, 606 Revenue from Contracts with Customers, revenue is recognized at the time that the Company’s customers obtain control of the promised goods.

Generally, revenue is recognized at the time of product delivery to the Company’s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements.

The consideration the Company receives in exchange for its goods or services is only recognized when it is probable that a significant reversal will not occur. The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration. The Company makes significant estimates for related variable consideration at the point of sale, including chargebacks, rebates, product returns, other discounts and allowances.

The Company’s payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customers, but payment is generally required in a term ranging from 30 to 75 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.

Provisions for estimated chargebacks, rebates, discounts, product returns and credit losses are made at the time of sale and are analyzed and adjusted, if necessary, at each balance sheet date.

Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers, and after the customer has accepted test samples of the products to be shipped.

The Company’s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. The Company does not have any revenue arrangements with multiple performance obligations.

Provision for Chargebacks and Rebates

The provision for chargebacks and rebates is a significant estimate used in the recognition of revenue. Wholesaler chargebacks relate to sales terms under which the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products that wholesalers resell under the Company’s various contractual arrangements with third parties such as hospitals and group purchasing organizations in the United States. Rebates include primarily amounts paid to retailers, payers, and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements. The Company estimates chargebacks and rebates using the expected value method at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback and rebate rates, and current contract pricing.

-9-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The provision for chargebacks and rebates is reflected as a component of net revenues. The following table is an analysis of the chargeback and rebate provision:

Three Months Ended

 

March 31, 

2021

2020

 

(in thousands)

 

Beginning balance

    

$

20,380

    

$

21,644

Provision for chargebacks and rebates

 

47,031

 

35,987

Credits and payments issued to third parties

 

(46,881)

 

(39,353)

Ending balance

$

20,530

$

18,278

Changes in the chargeback provision from period to period are primarily dependent on the Company’s sales to its wholesalers, the level of inventory held by wholesalers, and the wholesalers’ customer mix. Changes in the rebate provision from period to period are primarily dependent on retailer’s and other indirect customers’ purchases. The approach that the Company uses to estimate chargebacks has been consistently applied for all periods presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and rebates and makes adjustments when it believes that the actual chargebacks and rebates may differ from the estimates. The settlement of chargebacks and rebates generally occurs within 30 days to 60 days after the sale to wholesalers. Accounts receivable and/or accounts payable and accrued liabilities are reduced and/or increased by the chargebacks and rebate amounts depending on whether the Company has the right to offset with the customer. Of the provision for chargebacks and rebates as of March 31, 2021 and December 31, 2020, $16.4 million and $16.4 million were included in accounts receivable, net, on the condensed consolidated balance sheets, respectively. The remaining provision as of March 31, 2021 and December 31, 2020 of $4.1 million and $4.0 million, respectively, were included in accounts payable and accrued liabilities.

Accrual for Product Returns

The Company offers most customers the right to return qualified excess or expired inventory for partial credit; however, API product sales are generally non-returnable. The Company’s product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for product returns estimated using the expected value method. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and the introduction of new competition. Although these factors do not normally give the Company’s customers the right to return products outside of the regular return policy, the Company realizes that such factors could ultimately lead to increased returns. The Company analyzes these situations on a case-by-case basis and makes adjustments to the product return reserve as appropriate.

The provision for product returns is reflected as a component of net revenues. The following table is an analysis of the product return liability:

Three Months Ended

 

March 31, 

2021

2020

 

(in thousands)

 

Beginning balance

    

$

14,204

    

$

10,339

Provision for product returns

 

3,233

 

3,099

Credits issued to third parties

 

(2,517)

 

(2,239)

Ending balance

$

14,920

$

11,199

-10-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Of the provision for product returns as of March 31, 2021 and December 31, 2020, $10.7 million and $10.2 million, were included in accounts payable and accrued liabilities on the condensed consolidated balance sheets, respectively. The remaining provision as of March 31, 2021 and December 31, 2020 of $4.2 million and $4.0 million, respectively, were included in other long-term liabilities. For the three months ended March 31, 2021 and 2020, the Company’s aggregate product return rate was 1.4% and 1.1% of qualified sales, respectively.

Note 4. Income per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders

Basic net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders gives effect to all potential dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Company’s Employee Stock Purchase Plan, or ESPP and the reallocation of net income attributable to non-controlling interest from the assumed dilutive effect of stock options issued under the 2018 ANP Equity Incentive Plan, or the 2018 Plan.

For the three months ended March 31, 2021, options to purchase 1,899,833 shares of stock with a weighted-average exercise price of $20.85 per share, and the reallocation of net income attributable to non-controlling interests were excluded in the computation of diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders because the effect would be anti-dilutive.

For the three months ended March 31, 2020, options to purchase 1,999,083 shares of stock with a weighted-average exercise price of $20.81 per share, and the reallocation of net income attributable to non-controlling interest were excluded in the computation of diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders because the effect would be anti-dilutive.

The following table provides the calculation of basic and diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders for each of the periods presented:

Three Months Ended

March 31, 

2021

2020

(in thousands, except per share data)

Basic and dilutive numerator:

    

    

    

    

 

Net income attributable to Amphastar Pharmaceuticals, Inc.

$

5,041

$

3,949

Denominator:

Weighted-average shares outstanding — basic

 

47,520

 

46,408

Net effect of dilutive securities:

Incremental shares from equity awards

 

1,998

 

1,840

Weighted-average shares outstanding — diluted

 

49,518

 

48,248

Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — basic

$

0.11

$

0.09

Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — diluted

$

0.10

$

0.08

Note 5. Segment Reporting

The Company’s business is the development, manufacture, and marketing of pharmaceutical products. The Company has identified two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC

-11-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

280, Segment Reporting. The Company’s performance is assessed and resources are allocated by the CODM based on the following two reportable segments:

Finished pharmaceutical products
API

The finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.

Selected financial information by reporting segment is presented below:

Three Months Ended

March 31, 

2021

2020

(in thousands)

Net revenues:

    

    

    

    

 

Finished pharmaceutical products

$

97,882

$

81,298

API

 

5,138

3,390

Total net revenues

 

103,020

 

84,688

Gross profit (loss):

Finished pharmaceutical products

 

45,286

 

38,810

API

 

(340)

(1,987)

Total gross profit

 

44,946

 

36,823

Operating expenses

 

34,640

 

29,343

Income from operations

 

10,306

 

7,480

Non-operating expense

 

(5,192)

 

(1,675)

Income before income taxes

$

5,114

$

5,805

The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. The Company does not identify total assets by segment for internal purposes, as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

-12-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The amount of net revenues in the finished pharmaceutical product segment is presented below:

Three Months Ended

March 31, 

2021

2020

(in thousands)

Finished pharmaceutical products net revenues:

    

    

    

    

 

Primatene Mist®

$

18,383

$

12,877

Epinephrine

15,578

3,990

Enoxaparin

10,658

9,168

Phytonadione

 

9,565

 

11,029

Lidocaine

9,071

10,657

Glucagon

7,984

Naloxone

6,341

8,875

Other finished pharmaceutical products

 

20,302

 

24,702

Total finished pharmaceutical products net revenues

$

97,882

$

81,298

The amount of depreciation and amortization expense included in cost of revenues, by reporting segments is presented below:

Three Months Ended

March 31, 

2021

2020

(in thousands)

Depreciation and amortization expense

    

    

    

    

 

Finished pharmaceutical products

$

1,435

$

1,464

API

 

1,048

 

582

Total depreciation and amortization expense

$

2,483

$

2,046

Net revenues and carrying values of long-lived assets by geographic regions are as follows:

Net Revenue

Long-Lived Assets

 

Three Months Ended

 

March 31, 

March 31, 

December 31, 

2021

2020

2021

2020

 

(in thousands)

 

United States

    

$

99,170

    

$

81,065

    

$

125,861

    

$

129,401

China

 

1,121

228

 

97,847

 

98,538

France

 

2,729

3,395

 

49,431

 

52,770

Total

$

103,020

$

84,688

$

273,139

$

280,709

Note 6. Customer and Supplier Concentration

Customer Concentrations

Three large wholesale drug distributors, AmerisourceBergen Corporation, or AmerisourceBergen, Cardinal Health, Inc., or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. The Company considers these three customers to be its major customers, as each individually, and these customers collectively, represented a significant percentage of the Company’s net revenue for the three months ended March 31, 2021 and 2020 and accounts receivable as of March 31, 2021 and

-13-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

December 31, 2020, respectively. The following table provides accounts receivable and net revenue information for these major customers:

% of Total Accounts

% of Net

Receivable

Revenue

Three Months Ended

March 31, 

December 31, 

March 31, 

    

2021

    

2020

    

2021

    

2020

    

AmerisourceBergen

 

14

%

9

%

25

%

24

%

McKesson

 

21

%

24

%

20

%

22

%

Cardinal Health

 

16

%

17

%

15

%

19

%

Supplier Concentrations

The Company depends on suppliers for raw materials, APIs, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Company’s business, financial condition, and results of operations.

Note 7. Fair Value Measurements

GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below:

Level 1 – Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities;

Level 2 – Inputs to measure fair value are based on the following: a) quoted prices in active markets on similar assets or liabilities, b) quoted prices for identical or similar instruments in inactive markets, or c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; and

Level 3 – Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on best information available in the circumstances.

As of March 31, 2021, cash equivalents include money market accounts. Short-term investments consist of certificates of deposit as well as investment-grade corporate and municipal bonds with original expiration dates within 12 months. The certificates of deposit are carried at amortized cost in the Company’s condensed consolidated balance sheet, which approximates their fair value determined based on Level 2 inputs. The corporate and municipal bonds are classified as held-to-maturity and are carried at amortized cost net of allowance for credit losses, which approximates their fair value determined based on Level 2 inputs. The restrictions on restricted cash and short-term investments have a negligible effect on the fair value of these financial assets.

-14-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The fair value of the Company’s financial assets and liabilities measured on a recurring basis as of March 31, 2021 and December 31, 2020, are as follows:

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

 

(in thousands)

 

Cash equivalents - money market

$

76,536

$

76,536

$

$

Restricted cash - money market

235

235

Short-term investments - certificates of deposit

9,284

9,284

Restricted short-term investments - certificates of deposit

 

2,200

 

 

2,200

 

Corporate and municipal bonds

4,199

4,199

Interest rate swap liabilities related to variable rate loans

(723)

(723)

Fair value measurement as of March 31, 2021

$

91,731

$

76,771

$

14,960

$

Cash equivalents - money market

$

58,710

$

58,710

$

$

Restricted cash - money market

1,865

1,865

Short-term investments - certificates of deposit

9,089

9,089

Restricted short-term investments - certificates of deposit

 

2,200

 

 

2,200

 

Corporate and municipal bonds

3,855

3,855

Interest rate swap liabilities related to variable rate loans

(902)

(902)

Fair value measurement as of December 31, 2020

$

74,817

$

60,575

$

14,242

$

The Company does not hold any Level 3 instruments that are measured at fair value on a recurring basis.

Nonfinancial assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include long-lived assets, goodwill, and intangible assets for which the fair value of assets is determined as part of the related impairment test. As of March 31, 2021 and December 31, 2020, there were no significant adjustments to fair value for nonfinancial assets or liabilities.

Note 8. Investments

A summary of the Company’s investments that are classified as held-to-maturity are as follows:

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

    

Cost

    

Gains

    

Losses

    

Value

(in thousands)

Corporate bonds

$

1,053

$

$

(1)

$

1,052

Municipal bonds

3,148

(1)

3,147

Total investments as of March 31, 2021

$

4,201

$

$

(2)

$

4,199

Corporate bonds

$

1,560

$

$

(1)

$

1,559

Municipal bonds

2,297

(1)

2,296

Total investments as of December 31, 2020

$

3,857

$

$

(2)

$

3,855

At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting neither a significant deterioration since purchase nor any other factors that would indicate a material credit loss.

The Company measures expected credit losses on held-to-maturity investments on a collective basis. All the Company’s held-to-maturity investments were considered to be one pool. The estimate for credit losses considers historical loss

-15-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

information that is adjusted for current conditions and reasonable and supportable forecasts. Expected credit losses on held-to-maturity investments were not material to the condensed consolidated financial statements.

Note 9. Goodwill and Intangible Assets

The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification:

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

IMS (UK) international product rights

10

$

9,640

$

4,499

$

5,141

Patents

 

12

 

486

308

 

178

Land-use rights

 

39

 

2,540

634

 

1,906

Subtotal

 

12

 

12,666

 

5,441

 

7,225

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,793

 

 

3,793

Subtotal

 

*

 

33,018

 

 

33,018

As of March 31, 2021

 

*

$

45,684

$

5,441

$

40,243

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

IMS (UK) international product rights

10

$

9,561

$

4,223

$

5,338

Patents

 

12

 

486

297

 

189

Land-use rights

 

39

 

2,540

617

 

1,923

Subtotal

 

12

 

12,587

 

5,137

 

7,450

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,940

 

 

3,940

Subtotal

 

*

 

33,165

 

 

33,165

As of December 31, 2020

 

*

$

45,752

$

5,137

$

40,615

*

Intangible assets with indefinite lives have an indeterminable average life.

Goodwill

The changes in the carrying amounts of goodwill were as follows:

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Beginning balance

    

$

3,940

    

$

3,634

Currency translation

 

(147)

 

306

Ending balance

$

3,793

$

3,940

-16-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Primatene® Trademark

In January 2009, the Company acquired the exclusive rights to the trademark, domain name, website and domestic marketing, distribution and selling rights related to Primatene Mist®, an over-the-counter bronchodilator product, recorded at the allocated fair value of $29.2 million, which is its carrying value as of March 31, 2021.

The trademark was determined to have an indefinite life. In determining its indefinite life, the Company considered the following: the expected use of the intangible; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors.

Note 10. Inventories

Inventories consist of the following:

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Raw materials and supplies

    

$

43,258

    

$

47,051

Work in process

 

35,081

 

37,257

Finished goods

 

18,771

 

12,523

Total inventories

$

97,110

$

96,831

Charges of $9.5 million and $2.1 million were included in the cost of revenues in the Company’s condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020, respectively, to adjust the Company’s inventory and related firm purchase commitments to their net realizable value.

Losses on firm purchase commitments related to raw materials on order were $8.6 million and $2.1 million as of March 31, 2021 and 2020, respectively.

Note 11. Property, Plant, and Equipment

Property, plant, and equipment consist of the following:

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Buildings

    

$

124,952

    

$

124,326

Leasehold improvements

 

30,093

 

30,028

Land

 

7,659

 

7,719

Machinery and equipment

 

210,776

 

211,666

Furniture, fixtures, and automobiles

 

26,862

 

26,482

Construction in progress

 

42,165

 

43,981

Total property, plant, and equipment

 

442,507

 

444,202

Less accumulated depreciation

 

(189,242)

 

(184,147)

Total property, plant, and equipment, net

$

253,265

$

260,055

-17-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 12. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following:

March 31, 

December 31, 

2021

2020

(in thousands)

Accrued customer fees and rebates

$

10,466

$

9,029

Accrued payroll and related benefits

26,742

24,597

Accrued product returns, current portion

10,676

10,190

Accrued loss on firm purchase commitments

8,625

1,223

Accrued litigation and settlements

19,449

13,780

Other accrued liabilities

9,600

12,328

Total accrued liabilities

 

85,558

 

71,147

Accounts payable

 

22,987

 

24,357

Total accounts payable and accrued liabilities

$

108,545

$

95,504

-18-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 13. Debt

Debt consists of the following:

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Line of Credit Facilities

    

    

    

    

Line of credit facility with China Everbright Bank due June 2021

$

763

$

764

Line of credit facility with China Merchant Bank due August 2021

381

382

Line of credit facility with Bank of Nanjing due October 2021

153

153

Line of credit facility with Cathay Bank due May 2022

 

 

Line of credit facility with East West Bank due December 2022

Equipment line of credit facility with East West Bank due September 2025

3,216

3,216

Mortgage Loans

Mortgage payable with East West Bank due May 2021

3,282

3,306

Mortgage payable with East West Bank due October 2026

3,317

3,334

Mortgage payable with East West Bank due June 2027

8,472

8,510

Mortgage payable with Cathay Bank due August 2027

 

7,220

 

7,268

Equipment Loans

Equipment loan with East West Bank due June 2021

306

612

Equipment loan with East West Bank due December 2022

3,500

4,000

Equipment loan with East West Bank due February 2024

4,839

5,254

Other Loans and Payment Obligations

Acquisition loan with Cathay Bank due June 2024

 

8,137

 

8,710

French government loan due July 2021

64

64

French government loans due December 2026

338

350

Equipment under Finance Leases

 

519

 

526

Total debt

 

44,507

 

46,449

Less current portion of long-term debt

 

12,173

 

12,263

Long-term debt, net of current portion

$

32,334

$

34,186

As of March 31, 2021, the fair value of the loans listed above approximated their carrying amount. The interest rate used in the fair value estimation was determined to be a Level 2 input. For certain loans with East West Bank, the Company has entered into fixed interest rate swap contracts to exchange the variable interest rates for fixed interest rates over the life of certain debt instruments without the exchange of the underlying notional debt amount.

Covenants

At March 31, 2021 and December 31, 2020, the Company was in compliance with its debt covenants.

-19-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 14. Income Taxes

The following table sets forth the Company’s income tax provision for the periods indicated:

Three Months Ended

March 31, 

    

2021

    

2020

    

(in thousands)

Income before taxes

$

5,114

$

5,805

Income tax provision

1,155

 

2,280

Net income

$

3,959

$

3,525

Income tax provision as a percentage of income before income taxes

22.6

%

 

39.3

%

The Company’s effective tax rate for the three months ended March 31, 2021 decreased in comparison to the three months ended March 31, 2020, primarily due to differences in pre-tax income positions and timing of discrete tax items.

Valuation Allowance

In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will be realized. Ultimately, realization depends on the existence of future taxable income. Management considers sources of taxable income such as income in prior carryback periods, future reversal of existing deferred taxable temporary differences, tax-planning strategies, and projected future taxable income.

The Company continues to record a full valuation allowance on the net deferred income tax assets of its subsidiaries AFP and Hanxin and will continue to do so until the subsidiaries generate sufficient taxable income to realize their respective deferred income tax assets.

For purposes of computing its annual effective tax rate, the Company did not benefit from its losses in the states where it files separately. This increased the Company’s income tax expense by $0.1 million and $0.2 million during the three months ended March 31, 2021 and 2020, respectively.

Note 15. Stockholders' Equity

Share Buyback Program

Pursuant to the Company’s existing share buyback program, the Company purchased 204,698 and 646,715 shares of its common stock during the three months ended March 31, 2021 and 2020, totaling $3.8 million and $10.9 million, respectively.

In August 2020, the Company’s Board of Directors authorized an increase of $20.0 million to the Company’s share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs.

Purchases are made through open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the SEC and applicable laws. The timing and actual number of treasury share purchases will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. These treasury share purchases are accounted for under the cost method and are included as a component of treasury stock in the Company’s condensed consolidated balance sheets.

-20-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Amended and Restated 2015 Equity Incentive Plan

As of March 31, 2021, the Company reserved an aggregate of 6,181,926 shares of common stock for future issuance under the Amended and Restated 2015 Equity Incentive Plan, or the 2015 Plan, including 1,187,386 shares, which were reserved in January 2021 pursuant to the evergreen provision in the 2015 Plan.

2014 Employee Stock Purchase Plan

As of March 31, 2021, the Company has issued 807,550 shares of common stock under the ESPP and 1,192,450 shares of its common stock remains available for issuance under the ESPP.

For the three months ended March 31, 2021 and 2020, the Company recorded ESPP expense of $0.1 million and $0.1 million, respectively.

Share-Based Award Activity and Balances (excluding the ANP Equity Plan)

The Company accounts for share-based compensation payments in accordance with ASC 718, which requires measurement and recognition of compensation expense at fair value for all share-based payment awards made to employees and directors. Under these standards, the fair value of option awards and the option components of the Employee Stock Purchase Plan awards are estimated at the grant date using the Black-Scholes option-pricing model. The fair value of RSUs is estimated at the grant date using the Company’s common share price. The portion that is ultimately expected to vest is amortized and recognized in compensation expense on a straight-line basis over the requisite service period, generally from the grant date to the vesting date.

The weighted-averages for key assumptions used in determining the fair value of options granted during the three months ended March 31, 2021 and 2020, are as follows:

Three Months Ended

March 31, 

    

2021

    

2020

    

Average volatility

 

42.2

%  

43.0

%  

Average risk-free interest rate

 

1.3

%  

0.8

%  

Weighted-average expected life in years

 

6.3

5.8

Dividend yield rate

 

%  

%  

A summary of option activity for the three months ended March 31, 2021, is presented below:

Weighted-Average

 

Weighted-Average

Remaining

Aggregate

 

Exercise

Contractual

Intrinsic

 

Options

Price

Term (Years)

Value(1)

 

(in thousands)

 

Outstanding as of December 31, 2020

    

8,580,475

    

$

15.00

    

    

    

    

Options granted

 

1,166,702

 

17.99

Options exercised

 

(173,436)

 

12.64

Options cancelled

 

(51,506)

 

15.67

Options expired

 

(31,854)

 

11.66

Outstanding as of March 31, 2021

 

9,490,381

$

15.42

 

5.63

$

32,322

Exercisable as of March 31, 2021

 

6,588,157

$

14.83

 

4.28

$

26,310

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s common stock for those awards that have an exercise price below the estimated fair value at March 31, 2021.

-21-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

For the three months ended March 31, 2021 and 2020, the Company recorded an expense of $2.4 million and $2.6 million, respectively, related to stock options granted under all plans.

Information relating to option grants and exercises is as follows:

Three Months Ended

 

March 31, 

    

2021

    

2020

 

(in thousands, except per share data)

 

Weighted-average grant date fair value per option share

$

7.66

$

5.33

Intrinsic value of options exercised

 

1,029

 

488

Cash received from options exercised

 

2,169

 

1,251

Total fair value of the options vested during the year

 

6,772

 

7,432

A summary of the status of the Company’s non-vested options as of March 31, 2021, and changes during the three months ended March 31, 2021, is presented below:

    

    

Weighted-Average

 

Grant Date

 

Options

Fair Value

 

Non-vested as of December 31, 2020

2,825,652

$

6.50

Options granted

 

1,166,702

7.66

Options vested

 

(1,038,624)

6.52

Options forfeited

 

(51,506)

6.77

Non-vested as of March 31, 2021

 

2,902,224

 

6.96

As of March 31, 2021, there was $16.3 million of total unrecognized compensation cost, net of forfeitures, related to non-vested stock option based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 3.0 years and will be adjusted for future changes in estimated forfeitures.

Restricted Stock Units

The Company grants restricted stock units, or RSUs, to certain employees and members of the Board of Directors with a vesting period of up to five years. The grantee receives one share of common stock at a specified future date for each RSU awarded. The RSUs may not be sold or otherwise transferred until certificates of common stock have been issued, recorded, and delivered to the participant. The RSUs do not have any voting or dividend rights prior to the issuance of certificates of the underlying common stock. The share-based expense associated with these grants was based on the Company’s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period using the straight-line method. During the three months ended March 31, 2021 and 2020, the Company recorded expenses of $2.2 million and $2.4 million, respectively, related to RSU awards granted under all plans.

As of March 31, 2021, there was $17.6 million of total unrecognized compensation cost, net of forfeitures, related to non-vested RSU-based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 3.0 years and will be adjusted for future changes in estimated forfeitures.

-22-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Information relating to RSU grants and deliveries is as follows:

Total Fair Market

 

Value of RSUs

 

Issued

 

Total RSUs

as

 

    

Issued

    

Compensation(1)

 

(in thousands)

 

RSUs outstanding at December 31, 2020

 

1,156,518

RSUs granted

 

496,742

$

8,936

RSUs forfeited

 

(22,627)

RSUs vested(2)

 

(416,973)

RSUs outstanding at March 31, 2021

 

1,213,660

(1)The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.
(2)Of the vested RSUs, 161,147 shares of common stock were surrendered to fulfill tax withholding obligations.

The 2018 ANP Equity Incentive Plan

In December 2018, ANP’s board of directors approved the 2018 Plan, which is set to expire in December 2023. The 2018 Plan permits the grant of stock options and other equity awards in ANP shares to ANP employees. As of March 31, 2021, ANP granted 6,082,377 stock options to its employees under the 2018 Plan. The number of stock options outstanding as of March 31, 2021 was 5,037,280. The options vest over a period of approximately four years and have up to a 10 year contractual term. For the three months ended March 31, 2021 and 2020, the Company recorded expense of $0.1 million and $0.1 million related to stock options issued by ANP under the 2018 Plan, respectively.

Share-based Compensation Expense

The Company recorded share-based compensation expense, which is included in the Company’s condensed consolidated statement of operations as follows:

Three Months Ended

March 31, 

2021

2020

(in thousands)

Cost of revenues

    

$

1,146

    

$

1,359

Operating expenses:

Selling, distribution, and marketing

 

127

 

107

General and administrative

 

2,968

 

3,219

Research and development

 

593

 

597

Total share-based compensation

$

4,834

$

5,282

Note 16. Employee Benefits

401(k) Plan

The Company has a defined contribution 401(k) plan, or the Plan, whereby eligible employees voluntarily contribute up to a defined percentage of their annual compensation. The Company matches contributions at a rate of 50% on the first 6% of employee contributions, and pays the administrative costs of the Plan. Total employer contributions for the three months ended March 31, 2021 and 2020, were approximately $0.5 million and $0.5 million, respectively.

-23-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Defined Benefit Pension Plan

The Company’s subsidiary, AFP, has an obligation associated with a defined-benefit plan for its eligible employees. This plan provides benefits to the employees from the date of retirement and is based on the employee’s length of time employed by the Company. The calculation is based on a statistical calculation combining a number of factors that include the employee’s age, length of service, and AFP employee turnover rate.

The liability under the plan is based on a discount rate of 0.30% as of March 31, 2021 and December 31, 2020. The liability is included in accrued liabilities in the accompanying condensed consolidated balance sheets. The plan is currently unfunded, and the benefit obligation under the plan was $2.9 million and $3.0 million at March 31, 2021 and December 31, 2020. The Company recorded an immaterial amount of expense under the plan for the three months ended March 31, 2021 and 2020.

Deferred Compensation Plan

In December 2019, the Company established a non-qualified deferred compensation plan. The deferred compensation plan allows certain eligible participants to defer a portion of their cash compensation and provides a matching contribution at the discretion of the Company. The plan obligations are payable upon retirement, termination of employment and/or certain other times in a lump-sum distribution or in installments, as elected by the participant in accordance with the plan. Participants can allocate their deferred compensation amongst various investment options with earnings accruing to the participant. The Company has established a Rabbi Trust to fund the plan obligations and to hold the plan assets. Eligible participants began contributing to the plan in January 2020. As of March 31, 2021, the plan assets and liabilities were valued at approximately $2.0 million and $2.1 million, respectively. As of December 31, 2020, the plan assets and liabilities were valued at approximately $1.6 million and $1.7 million, respectively.

Note 17. Commitments and Contingencies

Purchase Commitments

As of March 31, 2021, the Company has entered into commitments to purchase equipment and raw materials for an aggregate amount of approximately $52.4 million. The Company anticipates that most of these commitments with a remaining term in excess of one year will be fulfilled by 2022.

Note 18.   Litigation

Amphastar Pharmaceuticals, Inc. v. Aventis Pharma, SA

In January 2009, the Company filed a qui tam complaint in the U.S. District Court for the Central District of California, alleging that Aventis Pharma S.A., or Aventis, through its acquisition of a patent through false and misleading statements to the U.S. Patent and Trademark Office, as well as through false and misleading statements to the FDA, overcharged the federal and state governments for its Lovenox® product.

On May 11, 2017, the Company’s lawsuit against Aventis was dismissed for lack of jurisdiction. On July 14, 2017, Aventis filed an application with the District Court for entitlement to attorneys’ fees and expenses. On November 20, 2017, the District Court issued its order granting Aventis’ application for fees.

On November 13, 2020, the Court issued an Order (“November Order”) awarding Aventis $12.1 million in attorneys’ fees and $0.7 million in costs and expenses, and ordered Aventis to submit updated calculations on accrued interest.

-24-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

On May 3, 2021, the Court issued a further Order based upon supplemental application to the Court seeking fees, expenses, and interest for the period after, and not covered by, the November Order. The Court awarded Aventis an additional $4.4 million bringing the total awarded Aventis to $17.2 million.

The Company had previously accrued $12.8 million as of December 31, 2020, based upon the November Order. As a result of the most recent ruling, the Company recorded an additional charge of $4.4 million for the three months ended March 31, 2021, in other income (expenses), in the condensed consolidated statement of operations. This amount represents management’s best estimate of the probable loss at this time. There is a reasonable possibility that the final fee award could change; however, at this time, the range of loss cannot be estimated. The Company intends to continue to vigorously defend against any imposition of attorneys’ fees and expenses in this case.

Regadenoson (0.4 mg/5 mL, 0.08 mg/mL) Patent Litigation

On February 25, 2020, Astellas US LLC, Astellas Pharma US, Inc., and Gilead Sciences, Inc. (collectively, “Astellas-Gilead”) filed a Complaint in the United States District Court for the District of Delaware against IMS for infringement of U.S. Patent Nos. 8,106,183 (the “‘183 patent”), RE47,301 (the “‘301 patent”), and 8,524,883 (the “‘883 patent”) (collectively, “Astellas-Gilead Patents”) with regard to IMS’s ANDA No. 214,252 for approval to manufacture and sell 0.4 mg/5 mL (0.08 mg/mL) intravenous solution of Regadenoson. On March 4, 2020, IMS filed its Answer and Counterclaims. On March 30, 2020, the Court issued an Order allowing the Company to join pending consolidated litigation with five other generic Regadenoson ANDA filers involving similar claims. Trial is currently scheduled for June 14, 2021. The Company’s 30-month FDA stay expires August 10, 2022. The Company intends to vigorously defend this patent lawsuit.

Employee Litigation

Brenes v. International Medication Systems, Limited

On September 11, 2019, a former employee, Raquel Brenes, (“Brenes”), initiated an employment litigation against IMS et al. by filing a Complaint in the Superior Court of California, Los Angeles County alleging individual and class action claims for alleged violations of various California labor laws pertaining to wage and hour, and other state laws. On September 18, 2019, Brenes filed a First Amended Complaint maintaining the individual and class action claims.

On January 21, 2020, Brenes filed a Second Amended Complaint that alleges only Private Attorney General Act, or PAGA, claims and omitted the individual and class action claims. On February 9, 2021, the parties reached a settlement for $1.0 million. The settlement was approved by the Court on April 7, 2021. The Company accrued the amount of $1.0 million for this litigation as of December 31, 2020.

Navarrette v. International Medication Systems, Limited

On January 30, 2020, a former employee, Robert Navarrette (“Navarrette”), provided written notice, through his counsel to IMS that he intends to file a PAGA lawsuit for alleged violation of various California labor laws pertaining to wage and hour. On April 7, 2020, Navarrette filed his PAGA lawsuit against IMS and Amphastar Pharmaceuticals, Inc. in the Superior Court of California, Los Angeles County, Central District. As to IMS, the Brenes settlement subsumes the claims of Navarrette.

Ramirez v. Amphastar Pharmaceuticals, Inc.

On May 29, 2020, Priscilla Ramirez, (“Ramirez”), a former employee filed a PAGA lawsuit for alleged violations of various California labor laws pertaining to wage and hour against the Company. On April 5, 2021, the parties reached a settlement for $1.0 million. The agreement is still subject to approval by the Court. The Company accrued the amount of

-25-

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

$1.0 million for this litigation as of March 31, 2021.

Other Litigation

The Company is also subject to various other claims, arbitrations, and lawsuits from time to time arising in the ordinary course of business.

The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In the opinion of management, the ultimate resolution of any such matters is not expected to have a material adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable and the Company’s view of these matters may change in the future. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

Note 19.   Subsequent Events

In May 2021, the board of directors approved a plan for the restructuring of the equity ownership of ANP, whereby the Company will purchase an additional ownership interest in ANP from certain equity holders of ANP (the “Sellers”), and spin-off of certain subsidiaries of ANP.

The Company entered into three agreements relating to the restructuring of the equity ownership of ANP and its subsidiaries and the spin-off of certain subsidiaries of ANP:

The Company entered into a Share Purchase Agreement, or SPA, to acquire an additional approximately 18% of ownership interest in ANP for approximately $29.4 million from the Sellers, who had initially acquired shares in the previously disclosed July 2018 private placement, or the ANP Private Placement.
ANP entered into a Share Repurchase Agreement, or SRA, with the Sellers and Nanjing Qianqia Enterprise Management Consulting LLP, or Qianqia, to issue shares in Hanxin, including Hanxin’s existing subsidiaries, Baixin and Letop, both of which will be included in the spin-off of Hanxin, in exchange for an additional approximately 9% of ownership interest in ANP.
ANP entered into a Separation Agreement with Hanxin which sets forth certain assets to be held by each entity, as well as certain responsibilities and obligations of ANP and Hanxin following completion of the spin-off.

Upon completion of the restructuring, the Company will own approximately 85% of ANP, and ANP will retain approximately 20% of ownership interest in Hanxin.

Certain of the Sellers are the Company’s executive officers, directors and other related parties. The Sellers who are participating in the SPA include William J. Peters, Rong Zhou, Jacob Liawatidewi, Howard Lee, Richard Koo, Stephen Shohet, Henry Zhang, Qingqing Chen, Chongqing Zhang, Lu Zhang, and James Luo. Neither Dr. Mary Luo nor Dr. Jack Zhang are participating in the SPA.

The Sellers who are participating in the SRA include Dr. Mary Luo, Dr Jack Zhang, Henry Zhang, Qingqing Chen, Chongqing Zhang, Bill Zhang, and Lu Zhang.

As part of the restructuring, the Company will terminate the 2018 ANP Equity Incentive Plan.

-26-

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is a discussion and analysis of the consolidated operating results, financial condition, liquidity and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the “Condensed Consolidated Financial Statements” and the related notes thereto included in this Quarterly Report on Form 10-Q, or Quarterly Report. This discussion contains forward-looking statements that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements. These risks, uncertainties, and other factors include, among others, those identified under the “Special Note About Forward-Looking Statements,” above and described in greater detail elsewhere in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2020, particularly in Item 1A. “Risk Factors”.

Overview

We are a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products as well as insulin API products. We currently manufacture and sell over 20 products.

We are currently developing a portfolio of 12 generic abbreviated new drug applications, or ANDAs, three biosimilar insulin product candidates and four proprietary product candidates, which are in various stages of development and target a variety of indications. Five of the ANDAs and one NDA are currently on file with the FDA.

Our largest products by net revenues currently include Primatene Mist®, glucagon, epinephrine, enoxaparin sodium injection, phytonadione, lidocaine jelly and sterile solution, and naloxone hydrochloride injection. During the second quarter of 2020, we launched our epinephrine injection, USP 30mg/mL multiple dose vial product. In December 2020, the FDA granted approval of our glucagon for injection emergency kit, 1mg, which we launched in February 2021.

To complement our internal growth and expertise, we have made several strategic acquisitions of companies, products and technologies. These acquisitions collectively have strengthened our core injectable and inhalation product technology infrastructure by providing additional manufacturing, marketing, and research and development capabilities, including the ability to manufacture raw materials, API and other components for our products.

Included in these acquisitions are marketing authorizations for 33 products in the UK, Ireland, Australia, and New Zealand, representing 11 different injectable chemical entities. We are in the process of transferring the manufacturing of these products to our facilities in California, which will require approvals from the UK Medicines and Healthcare products Regulatory Agency before we can relaunch the products.

In July 2018, our Chinese subsidiary, ANP, completed a private placement of its common equity interest and received approximately $56.3 million of cash proceeds. We have retained approximately 58% of the equity interest in ANP following the private placement. ANP’s net income or loss after July 2, 2018, is attributed to us in accordance with our equity interest of approximately 58% in ANP.

In May 2021, the board of directors approved a plan for the restructuring of the equity ownership of ANP, whereby we would purchase additional ownership interest in ANP from certain equity holders of ANP (the “Sellers”), and spin-off certain subsidiaries of ANP. The Sellers include some of the Company’s executive officers, directors and other related parties who participated in the ANP Private Placement in 2018.

As part of the transaction, we will pay approximately $29.4 million in cash and contribute approximately 80% of Hanxin Pharmaceutical Technology Co., Ltd, or Hanxin, to the Sellers in exchange for additional ownership interest in ANP, such that we will own approximately 85% of ANP and ANP will retain approximately 20% of ownership in Hanxin after the completion of the restructuring.

-27-

Hanxin’s wholly owned subsidiaries, Nanjing Baixin Trading Co., Ltd., and Nanjing Letop Biological Technology Co., Ltd., will be included in the spin-off of Hanxin.

COVID-19 Pandemic

In March 2020, the World Health Organization declared the outbreak of a novel coronavirus, or COVID-19, as a pandemic, which continues to spread throughout the world, including locations where we operate, such as the United States, China and France. We have been actively monitoring the COVID-19 pandemic and its impact globally. Currently, our production facilities in all of our locations continue to operate as they had prior to the COVID-19 pandemic with few changes, other than for enhanced safety measures intended to prevent the spread of the virus.

As a result of the COVID-19 pandemic, during the first half of 2020, sales of Primatene Mist® and certain hospital products increased, while sales of certain products frequently used in elective procedures, such as Cortrosyn® and lidocaine products decreased. We saw these trends continue in late 2020 and early 2021 when COVID cases trended higher. Some of our ongoing clinical trials experienced short-term interruptions in the recruitment of patients due to the COVID-19 pandemic, as hospitals prioritize their resources towards the COVID-19 pandemic and governments impose travel restrictions. Some clinical trials experienced increased expenses due to new protocols to protect participants from COVID-19. Additionally, certain suppliers had difficulties meeting their delivery commitments.

It is not possible at this time to estimate the complete impact that COVID-19 could have on our business, including our customers and suppliers, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. Infections may resurge or become more widespread and the limitation on our ability to travel and timely sell and distribute our products, as well as any closures or supply disruptions, may be extended for longer periods of time, all of which would have a negative impact on our business, financial condition and operating results.

The COVID-19 pandemic has and will continue to adversely affect global economies and financial markets, resulting in an economic downturn that could affect demand for our products and impact our operating results. Even after the COVID-19 pandemic has subsided, we may continue to experience an adverse impact to our business as a result of the continued global economic impact of the pandemic. We cannot anticipate all of the ways in which health epidemics such as COVID-19 could adversely impact our business. See the Risk Factors section for further discussion of the possible impact of the COVID-19 pandemic on our business.

Business Segments

As of March 31, 2021, our performance is assessed and resources are allocated based on the following two reportable segments: (1) finished pharmaceutical products and (2) API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Information reported herein is consistent with how it is reviewed and evaluated by our chief operating decision maker. Factors used to identify our segments include markets, customers and products.

For more information regarding our segments, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Segment Reporting.”

-28-

Results of Operations

Three Months Ended March 31, 2021 Compared to Three Months Ended March 31, 2020

Net revenues

Three Months Ended

 

March 31, 

Change

    

2021

    

2020

    

Dollars

    

%

 

(in thousands)

 

Net revenues

Finished pharmaceutical products

$

97,882

$

81,298

$

16,584

20

%

API

 

5,138

 

3,390

 

1,748

 

52

%

Total net revenues

$

103,020

$

84,688

$

18,332

 

22

%

Cost of revenues

Finished pharmaceutical products

$

52,596

$

42,488

$

10,108

 

24

%

API

 

5,478

 

5,377

 

101

 

2

%

Total cost of revenues

$

58,074

$

47,865

$

10,209

 

21

%

Gross profit

$

44,946

$

36,823

$

8,123

22

%

as % of net revenues

 

44

%  

 

43

%  

The increase in net revenues of the finished pharmaceutical products for the three months ended March 31, 2021, was due to the following changes:

Three Months Ended

 

March 31, 

Change

    

2021

    

2020

    

Dollars

    

%

 

(in thousands)

 

Finished pharmaceutical products net revenues

Primatene Mist®

$

18,383

$

12,877

$

5,506

43

%

Epinephrine

15,578

3,990

11,588

290

%

Enoxaparin

10,658

9,168

1,490

16

%

Phytonadione

9,565

11,029

(1,464)

(13)

%

Lidocaine

9,071

10,657

(1,586)

(15)

%

Glucagon

7,984

7,984

N/A

Naloxone

6,341

8,875

(2,534)

(29)

%

Other finished pharmaceutical products

 

20,302

 

24,702

 

(4,400)

 

(18)

%

Total finished pharmaceutical products net revenues

$

97,882

$

81,298

$

16,584

 

20

%

In February 2021, we launched our glucagon for injection emergency kit, 1mg, which was approved by the FDA in December 2020.

The increase in sales of Primatene Mist® for the three months ended March 31, 2021, was a result of the continued success of our nationwide digital, television and radio campaign, which will continue throughout 2021 as well as an expansion of our distribution channels throughout 2020 and during the first quarter of 2021, including Target which began selling Primatene Mist® in March 2021. The increase in sales of epinephrine was primarily due to the launch of our epinephrine injection, USP 30mg/30mL multiple dose vial product in the second quarter of 2020, as well as an increase in unit volumes, as a result of higher demand due to a market shortage for pre-filled syringe. The increase in sales of enoxaparin was primarily due to an increase in unit volume, as a result of a competitor leaving the market. The decrease in sales of Naloxone was split evenly between lower unit volume and lower average selling price as a result of a competitor entering the market. The decrease in sales of phytonadione and lidocaine products was primarily due to lower unit volumes as a result of decreased market demand. The decrease in other finished pharmaceutical products was primarily due to lower unit volumes as a result of competitors returning to their normal distribution levels.

-29-

We anticipate that sales of naloxone and enoxaparin will continue to fluctuate in the future as a result of changing levels of competition.

Sales of API primarily depend on the timing of customer purchases. We anticipate that sales of API will continue to fluctuate and may decrease due to the inherent uncertainties related to sales to MannKind Corporation pursuant to our supply agreement with them. In addition, most of our API sales are denominated in euros, and the fluctuation in the value of euros versus the U.S. dollar has had, and will continue to have, an impact on API sales revenues in the near term.

A significant portion of our customer shipments in any period relate to orders received and shipped in the same period, generally resulting in low product backlog relative to total shipments at any time. We had no significant backlog as of March 31, 2021. Historically, our backlog has not been a meaningful indicator in any given period of our ability to achieve any particular level of overall revenue or financial performance.

Gross Margins

The increase in sales of Primatene Mist®, the launch of glucagon for injection emergency kit during the first quarter of 2021, as well as, the launch of our epinephrine injection multiple dose vial in the second quarter of 2020, which are higher-margin products, helped increase our gross margins for the three months ended March 31, 2021. These increases in gross margins were offset by lower pricing and increased costs for enoxaparin, particularly the cost for heparin raw materials, which is used as the starting material for enoxaparin.

The cost of heparin is expected to increase further, putting downward pressure on our gross margins. However, we believe that this trend will be offset by sales of our higher-margin products, such as Primatene Mist®, and epinephrine multi dose vials, which were launched over the past few years and by glucagon which was launched in 2021. Additionally, we have not seen significant supply disruptions due to the COVID-19 pandemic at this time, but we are continuing to monitor our supply chain for any potential problems.

Selling, distribution and marketing, and general and administrative

Three Months Ended

 

March 31, 

Change

2021

2020

Dollars

%

 

(in thousands)

 

Selling, distribution, and marketing

    

$

4,537

    

$

3,294

    

$

1,243

    

38

%

General and administrative

$

15,338

$

10,746

$

4,592

 

43

%

The increase in selling, distribution, and marketing expenses was primarily due to marketing and distribution expenses related to Primatene Mist®, including the cost of creating a new commercial for our national digital, television and radio marketing campaign. The increase in general and administrative expense was primarily due to an increase in legal expenses, including a reserve of $1.3 million to settle employment litigation, subsequent to the end of the first quarter.

We expect that selling, distribution and marketing expenses will increase due to the increase in marketing expenditures for Primatene Mist®. We expect that general and administrative expenses will increase on an annual basis due to increased costs associated with ongoing compliance with public company reporting obligations. Legal fees may fluctuate due to the timing of patent challenges and other litigation matters.

-30-

Research and development

Three Months Ended

 

March 31, 

Change

    

2021

    

2020

    

Dollars

    

%

 

(in thousands)

 

Salaries and personnel-related expenses

$

6,979

$

6,220

$

759

 

12

%

Clinical trials

 

738

 

2,455

 

(1,717)

 

(70)

%

FDA fees

 

40

 

44

 

(4)

 

(9)

%

Testing, operating and lab supplies

 

2,153

 

2,688

 

(535)

 

(20)

%

Depreciation

 

2,938

 

2,348

 

590

 

25

%

Other expenses

 

1,917

 

1,548

 

369

 

24

%

Total research and development expenses

$

14,765

$

15,303

$

(538)

(4)

%

Clinical trial expense decreased due to the completion of one of our clinical trial studies at the end of 2020 and delays in other studies. This was partially offset by an increase in salaries and personnel-related expenses as well as depreciation expense.

Research and development costs consist primarily of costs associated with the research and development of our product candidates including the cost of developing APIs. We expense research and development costs as incurred.

We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. We expect that research and development expenses will increase on an annual basis due to increased clinical trial costs related to our biosimilar and inhalation product candidates. These expenditures will include costs of APIs developed internally as well as APIs purchased externally, the cost of purchasing reference listed drugs and the costs of performing the clinical trials. As we undertake new and challenging research and development projects, we anticipate that the associated costs will increase significantly over the next several quarters and years. Some of our ongoing clinical trials have experienced short term interruptions in the recruitment of patients due to the COVID-19 pandemic, as hospitals prioritize their resources towards the COVID-19 pandemic and governments impose travel restrictions. These conditions may in turn delay spending and delay the results of these trials.

Other income (expense), net

Three Months Ended

 

March 31, 

Change

2021

2020

Dollars

%

 

(in thousands)

 

Other income (expenses), net

    

$

(5,249)

    

$

(1,752)

    

$

3,497

    

NM

In March 2021, we recorded an additional $4.4 million of expense in connection with the Aventis litigation. For more information regarding our litigation matters, see Note 18 to the condensed consolidated financial statements.

Income tax provision

Three Months Ended

 

March 31, 

Change

    

2021

    

2020

    

Dollars

    

%

 

(in thousands)

 

Income tax provision

$

1,155

$

2,280

$

(1,125)

(49)

%

Effective tax rate

23

%  

 

39

%  

Our effective tax rate for the three months ended March 31, 2021 decreased in comparison to the three months ended March 31, 2020, primarily due to differences in pre-tax income positions and timing of discrete tax items.

-31-

Liquidity and Capital Resources

Cash Requirements and Sources

We need capital resources to maintain and expand our business. We expect our cash requirements to increase significantly in the foreseeable future as we sponsor clinical trials for, seek regulatory approvals of, and develop, manufacture and market our current development-stage product candidates and pursue strategic acquisitions of businesses or assets. Our future capital expenditures include projects to upgrade, expand, and improve our manufacturing facilities in the United States, China, and France. Our cash obligations include the principal and interest payments due on our existing loans and lease payments, as described below and throughout this Quarterly Report. 

As of March 31, 2021, our foreign subsidiaries collectively held $12.6 million in cash and cash equivalents. Cash or cash equivalents held at foreign subsidiaries are not available to fund the parent company’s operations in the United States. We believe that our cash reserves, operating cash flows, and borrowing availability under our credit facilities will be sufficient to fund our operations for at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q. We expect additional cash flows to be generated in the longer term from future product introductions, although there can be no assurance as to the receipt of regulatory approval for any product candidates that we are developing or the timing of any product introductions, which could be lengthy or ultimately unsuccessful.

We maintain a shelf registration statement on Form S-3 pursuant to which we may, from time to time, sell up to an aggregate of $250 million of our common stock, preferred stock, depositary shares, warrants, units, or debt securities. If we require or elect to seek additional capital through debt or equity financing in the future, we may not be able to raise capital on terms acceptable to us or at all. To the extent we raise additional capital through the sale of equity or convertible debt securities, the issuance of such securities will result in dilution to our stockholders. If we are required and unable to raise additional capital when desired, our business, operating results and financial condition may be adversely affected.

 

Working capital increased $5.6 million to $173.1 million at March 31, 2021, compared to $167.5 million at December 31, 2020.

Cash Flows from Operations

The following table summarizes our cash flows used in operating, investing, and financing activities for the three months ended March 31, 2021 and 2020:

Three Months Ended March 31, 

 

    

2021

2020

 

(in thousands) 

 

Statement of Cash Flow Data:

Net cash provided by (used in)

Operating activities

$

22,825

$

1,477

Investing activities

 

(8,695)

 

(8,722)

Financing activities

 

(6,639)

 

(11,449)

Effect of exchange rate changes on cash

 

(162)

 

(146)

Net increase (decrease) in cash, cash equivalents, and restricted cash

$

7,329

$

(18,840)

Sources and Use of Cash

Operating Activities

Net cash provided by operating activities was $22.8 million for the three months ended March 31, 2021, which included net income of $4.0 million. Non-cash items comprised primarily of $6.0 million of depreciation and amortization, and $4.8 million of share-based compensation expense.

-32-

Additionally, for the three months ended March 31, 2021, there was a net cash inflow from changes in operating assets and liabilities of $7.2 million, which resulted from an increase in accounts payable and accrued liabilities which was partially offset by an increase in accounts receivable. Accounts payable and accrued liabilities increased primarily due to the timing of payments. The increase in accounts receivable was due to both increases in sales and the timing of sales.

Net cash provided by operating activities was $1.5 million for the three months ended March 31, 2020, which included net income of $3.5 million. Non-cash items were primarily comprised of $5.0 million of depreciation and amortization, and $5.3 million of share-based compensation expense. Additionally, there was a net cash outflow from changes in operating assets and liabilities of $14.8 million, which resulted from an increase in accounts receivable and a decrease in accounts payable and accrued liabilities, which was partially offset by a decrease in inventory. The increase in accounts receivable was due to the timing of sales, including the increase in sales of Primatene Mist® towards the end of the quarter as a result of the COVID-19 pandemic. Accounts payable and accrued liabilities decreased primarily due to the timing of payments.

Investing Activities

Net cash used in investing activities was $8.7 million for the three months ended March 31, 2021, primarily as a result of $7.6 million in purchases of property, plant, and equipment, which included $2.6 million incurred in the United States, $0.1 million in France, and $4.9 million in China.

Net cash used in investing activities was $8.7 million for the three months ended March 31, 2020, primarily as a result of $8.0 million in purchases of property, plant, and equipment, which included $1.5 million incurred in the United States, $1.1 million in France, and $5.4 million in China.

Financing Activities

Net cash used in financing activities was $6.6 million for the three months ended March 31, 2021, primarily as a result of $3.8 million used to purchase treasury stock and $0.9 million in net proceeds used to settle share-based compensation awards under our equity plans. Additionally, we also made $2.0 million in principal payments on our long-term.

Net cash used in financing activities was $11.4 million for the three months ended March 31, 2020, primarily as a result of $11.0 million used to purchase treasury stock, and $1.2 million in net proceeds used to settle share-based compensation awards under our equity plans. Additionally, we received $3.1 million from borrowings on an equipment line of credit that converted into an equipment loan during the quarter and made $2.3 million in principal payments on our long-term debt.

Indebtedness

For more information regarding our outstanding indebtedness, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Debt”.

Contractual Obligations

There have been no material changes outside the ordinary course of our business in the contractual obligations disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020, except that our outstanding debt obligations have changed as follows:

March 31, 

December 31, 

 

    

2021

    

2020

    

Change

 

(in thousands)

 

Short-term debt and current portion of long-term debt

$

12,173

$

12,263

$

(90)

Long-term debt

 

32,334

 

34,186

 

(1,852)

Total debt

$

44,507

$

46,449

$

(1,942)

-33-

As of March 31, 2021, we had $56.0 million in unused borrowing capacity under revolving lines of credit and equipment lines of credit with Cathay Bank, East West Bank, and China Merchant Bank.

Critical Accounting Policies

The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2020.

Recent Accounting Pronouncements

For information regarding recent accounting pronouncements, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Summary of Significant Accounting Policies”.

Off-Balance Sheet Arrangements

We do not have any relationships or financial partnerships with unconsolidated entities, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

Government Regulation

Our products and facilities are subject to regulation by a number of federal and state governmental agencies. The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of our products.  The Drug Enforcement Administration, or DEA, maintains oversight over our products that are considered controlled substances.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Except for the broad, ongoing effects of the COVID-19 pandemic as a result of its negative impact on the global economy and financial markets, there have been no material changes in market risk from the information provided in our Annual Report on Form 10-K for the year ended December 31, 2020. We are exposed to market risk in the ordinary course of business. Market risk represents the potential loss arising from adverse changes in the value of financial instruments. The risk of loss is assessed based on the likelihood of adverse changes in fair values, cash flows or future earnings. We are exposed to market risk for changes in the market values of our investments (Investment Risk), the impact of interest rate changes (Interest Rate Risk), and the impact of foreign currency exchange changes (Foreign Currency Exchange Risk).

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that as of such date, our disclosure controls and procedures were effective (a) to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b) to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is

-34-

accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).

Inherent Limitations of Internal Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

For information regarding legal proceedings, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Litigation”.

ITEM 1A. RISK FACTORS

Except as noted below, there were no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 15, 2021.

Our business may be adversely affected by the ongoing COVID-19 pandemic or other epidemics.

In March 2020, the World Health Organization declared the outbreak of a novel coronavirus, or COVID-19, as a pandemic, which continues to spread throughout the world, including locations where we operate, such as the United States, China and France. We have been actively monitoring the COVID-19 pandemic and its impact globally. In late January 2020, China implemented extensive curfews and travel restrictions to control the outbreak, and started easing these restrictions in March. In March 2020, France also implemented a stay-at-home order limiting movement and restricting travel. In March 2020, the Governors of the States of California and Massachusetts declared a health emergency and issued orders to close all nonessential businesses. As a bio-pharmaceutical company we are deemed to be an essential business. Since then, the governments in the United States, China and France, have re-opened and re-imposed restrictions on travel and business as the pandemic recedes and grows.

Over the ensuing year, this contagious disease outbreak has continued to impact worldwide economic activity and financial markets. While three vaccines have received Emergency Use Authorization from the FDA, the COVID-19 pandemic remains a challenge to our business until it is abated. Mass and rapid production of the vaccines, for example, has placed increased pressure on the availability of supplies that are also used in our products, such as glass vials and

-35-

needles. The COVID-19 pandemic is imposing additional burdens on our business to comply with regulations imposed by the State of California. The COVID-19 pandemic may also disrupt the operations of our customers, suppliers and partners for an indefinite period of time, including as a result of travel restrictions and/or business shutdowns, all of which could negatively impact our business and results of operations, including cash flows. Disruptions to our manufacturing partners and suppliers could result in disruption to the production of our products and failure to satisfy demand. More generally, the outbreak of COVID-19 could adversely affect economies and financial markets globally and nationally, potentially leading to an economic downturn, which could decrease spending and adversely affect demand for our products and harm our business and results of operations. Even after the COVID-19 pandemic has subsided, we may continue to experience an adverse impact to our business as a result of its global economic impact, including any recession that has occurred or may occur in the future. Specifically, difficult macroeconomic conditions, increased and prolonged unemployment or a decline in business confidence as a result of the COVID-19 pandemic, could have a continuing adverse effect on the demand for some of our products. The degree of impact of the COVID-19 pandemic on our business will depend on several factors, such as the duration and the extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time.

As a result of the consequences of the COVID-19 pandemic, FDA has issued various COVID-19 related guidance documents applicable to biopharmaceutical manufacturers and clinical trial sponsors. For example, in March 2020, the FDA issued a guidance, which the FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the clinical trial, among others. The FDA also issued a guidance on good manufacturing practice considerations for responding to COVID-19 infection in employees in drug products manufacturing, and a guidance on review timelines for applicant responses to Complete Response Letters when a facility assessment is needed during the COVID-19 public health emergency. These and future guidance documents and regulatory requirements, including future legislation, may require us to develop and implement new policies and procedures, make significant adjustments to our clinical trials, or increase the amount time and resources needed for regulatory compliance, which may impact our clinical development plans and timelines.

Some of our ongoing clinical trials have experienced short term interruptions in the recruitment of patients due to the COVID-19 pandemic, as hospitals prioritize their resources toward the COVID-19 pandemic and governments impose travel restrictions. Additionally, protocols at certain clinical sites have changed which could slow down the pace of clinical trials while also increasing their cost. These conditions may in turn delay spending and delay the results of these trials. Additionally, certain suppliers have delayed shipments to us in 2020 and 2021. These delays may have been caused by manufacturing disruptions due to the COVID-19 pandemic. None of these delays caused delays in our manufacturing to date, but future delays could cause manufacturing disruptions at our factories and could also cause lost sales.

It is not possible at this time to estimate the complete impact that the COVID-19 pandemic could have on our business, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. Infections may resurge or become more widespread and the limitation on our ability to travel and timely sell and distribute our products, as well as any closures or supply disruptions, may be extended for longer periods of time, all of which would have a negative impact on our business, financial condition and operating results. We will continue to monitor the impact of the COVID-19 pandemic on all aspects of our business.

Because a portion of our manufacturing takes place in China, a significant disruption in the construction or operation of our manufacturing facility in China, political unrest in China, tariffs, impact of outbreaks of health epidemics, such as the COVID-19 pandemic, or changes in social, political, trade, health, economic, environmental, or climate-related conditions or in laws, regulations and policies governing foreign trade could materially and adversely affect our business, financial condition and results of operations.

We currently manufacture the starting material for Amphadase® and enoxaparin as well as the APIs for isoproterenol and nitroprusside at our manufacturing facility in China, and we plan to use this facility to manufacture several of the APIs for products in our pipeline. Additionally, we intend to continue to invest in the expansion of this manufacturing facility. Our manufacturing facility and operations in China involve significant risks, including:

-36-

disruptions in the construction of the manufacturing facility;
interruptions to our operations in China or the inability of our manufacturing facility to produce adequate quantities of raw materials or APIs to meet our needs as a result of natural catastrophic events or other causes beyond our control such as power disruptions or widespread disease outbreaks, including the recent outbreaks that impact animal-derived products, such as the importation of pig-derived crude heparin from countries impacted by the African swine flu, and outbreak of the COVID-19 pandemic, which has resulted in and may in the future result in, business closures, transportation restrictions, import and export complications, and otherwise cause shortages in the supply of raw materials or cause disruptions in our manufacturing capability;
product supply disruptions and increased costs as a result of heightened exposure to changes in the policies of the Chinese government, political unrest or unstable economic conditions in China;
the imposition of tariffs or other trade barriers as a result of changes in social, political, and economic conditions or in laws, regulations, and policies governing foreign trade, including the tariffs previously implemented and additional tariffs that have been proposed by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods, the scope and duration of which, if implemented, remain uncertain;
the nationalization or other expropriation of private enterprises or intellectual property by the Chinese government, which could result in the total loss of our investment in China; and
interruptions to our manufacturing or business operations resulting from geo-political actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods, and fires, or outbreaks of health epidemics such as coronavirus, or outbreaks in livestock or animals that impact or restrict importation, use, or distribution of animal-derived products.

Any of these matters could materially and adversely affect our business and results of operations. These interruptions or failures could impair our ability to operate our business, impede the commercialization of our product candidates or delay the introduction of new products, impact our product quality, or impair our competitive position.

We are actively monitoring and assessing the potential impact of the COVID-19 pandemic. This includes evaluating the impact on our employees, suppliers, and logistics providers as well as evaluating governmental actions being taken to curtail the spread of the virus. While the Chinese government has been relaxing work restrictions, at this time, it is unclear if the Chinese government will reinstate restrictions or if further restrictions will be put into place by the government. In addition, many countries have placed significant bans on travel to and from China, with many countries and airlines suspending flights to and from mainland China. Any material adverse effect on our employees, suppliers, and logistics providers could have a material adverse effect on our manufacturing operations in China or the supply of raw materials or APIs originating from China.

Our epinephrine prefilled syringe product is marketed without FDA approval and may be subject to enforcement actions by the FDA.

Our epinephrine prefilled syringe prescription product is marketed without FDA approval. This product, like many other prescription drugs on the market that have not been formally evaluated as being effective by the FDA, contain active ingredients that were first marketed prior to the enactment of the Federal Food, Drug, and Cosmetic Act, or FFDCA. The FDA has assessed this product in a program known as the “Prescription Drug Wrap-Up” and has stated that this drug cannot be lawfully marketed unless they comply with certain “grandfather” exceptions to the definition of “new drug” in the FFDCA. These exceptions have been strictly construed by FDA and by the courts, and the FDA has stated that it is unlikely that any of the unapproved prescription drugs on the market, including our drug, qualify for the exceptions. At any time, the FDA may require that our unapproved prescription drug be submitted for approval and may direct us to recall this product and/or cease marketing the product until they are approved. The FDA may also take enforcement actions based on our marketing of this unapproved product, including but not limited to the issuance of an untitled letter or a warning letter, judicial action seeking an injunction, product seizure and/or civil or criminal penalties. The enforcement posture could change at any time and our ability to market such drugs could terminate with little or no

-37-

notice. Moreover, if our competitors seek and obtain approval and market FDA-approved prescription products that compete against our unapproved prescription product, we would be subject to a higher likelihood that the FDA may seek to take action against our unapproved product. Such competitors have brought and may bring claims against us alleging unfair competition or related claims.

As a result of our meetings with the FDA in 2009, we decided to discontinue all of our products that were subject to the Prescription Drug Wrap-Up program, with the exception of epinephrine in vial form. These products were all produced at our subsidiary, IMS. During the third quarter of 2010, the FDA requested that we reintroduce several of the withdrawn products to help address a national drug shortage, while we prepared and filed applications for approval of the products. Between August and October 2010, we reintroduced our epinephrine prefilled syringes.

In February 2017, the FDA requested that we discontinue the manufacturing and distribution of our epinephrine injection, USP vial product, which had been marketed under the “grandfather” exception to the “FDA’s Prescription Drug Wrap-Up program”. We discontinued selling this product in the second quarter of 2017. In April 2020, the FDA granted approval of our Epinephrine Injection, USP 30mg/mL Multiple Dose Vial, and launched the product in May 2020.

The FDA granted approval of our Atropine Sulfate Injection 0.1mg/mL in the 10mL Luer-Jet® Prefilled Syringe in October 2020, our Dextrose Injection 50% in the 50mL Luer-Jet® Prefilled Syringe in March 2021 and our Morphine Sulfate Injection USP, 1mg/mL 30mL in April 2021.

Our only unapproved product currently on the market is epinephrine prefilled syringes. For the years ended December 31, 2020, 2019, 2018, we recorded net revenues of $13.2 million, $13.9 million, $10.1 million, respectively, for epinephrine prefilled syringes and for the three months ended March 31, 2021 and 2020, we recorded net revenues of $9.3 million, and $4.0 million, respectively, for this product. We have filed an NDA with respect to our remaining unapproved product in order to mitigate all risk associated with the marketing of unapproved drug products. Prior to the approval of our NDA submission, we continue to operate in compliance with the FDA Compliance Policy Guide, CPG Sec. 440.100 Marketed New Drugs Without Approved NDAs and ANDAs.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(c)Issuer Purchases of Equity Securities

The table below provides information with respect to repurchases of our common stock.

    

    

    

Total Number of Shares

    

Maximum Number of

 

Average

Purchased as Part of

Shares that May Yet Be

 

Total Number of Shares

Price Paid

Publicly Announced Plans

Purchased Under the Plans

 

Period

Purchased (1)

per Share

or Programs

or Programs

 

January 1 – January 31, 2021

 

48,705

 

$

19.36

48,705

 

February 1 – February 28, 2021

 

53,328

18.57

 

53,328

 

March 1 – March 31, 2021

 

102,665

17.98

 

102,665

 

(1)During the first quarter of 2021, we repurchased shares of our common stock as part of the share buyback program authorized by our Board of Directors on August 4, 2020. As of March 31, 2021, $13.6 million remained available for repurchase under such program.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

-38-

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

Exhibit
No.

    

Description

31.1

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1#

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2#

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

101.INS

XBRL Instance Document – The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definitions Linkbase Document

104

Cover Page Interactive File (Formatted as Inline XBRL and contained in Exhibit 101)

# The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act (including this Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.

-39-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMPHASTAR PHARMACEUTICALS, INC.
(Registrant)

By:

/s/ JACK Y. ZHANG

Jack Y. Zhang

Chief Executive Officer
(Principal Executive Officer)

Date: May 7, 2021

AMPHASTAR PHARMACEUTICALS, INC.
(Registrant)

By:

/s/ WILLIAM J. PETERS

William J. Peters

Chief Financial Officer
(Principal Financial and Accounting Officer)

Date: May 7, 2021

-40-

EX-31.1 2 amph-20210331ex311bc3af2.htm EX-31.1

Exhibit 31.1

Certification

I, Jack Y. Zhang, Ph.D., certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Amphastar Pharmaceuticals, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 7, 2021

By:

/s/ JACK Y. ZHANG

Jack Y. Zhang

Chief Executive Officer

(Principal Executive Officer)


EX-31.2 3 amph-20210331ex312400750.htm EX-31.2

Exhibit 31.2

Certification

I, William J. Peters, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Amphastar Pharmaceuticals, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 7, 2021

By:

/s/ WILLIAM J. PETERS

William J. Peters

Chief Financial Officer

(Principal Financial and Accounting Officer)


EX-32.1 4 amph-20210331ex32127a626.htm EX-32.1

Exhibit 32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted

pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned officer of Amphastar Pharmaceuticals, Inc. (the “Company”), hereby certifies, to the best of such officer’s knowledge, that:

(i) the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Date: May 7, 2021

By:

/s/ JACK Y. ZHANG

Jack Y. Zhang

Chief Executive Officer

(Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. §1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-32.2 5 amph-20210331ex32219a512.htm EX-32.2

Exhibit 32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted

pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned officer of Amphastar Pharmaceuticals, Inc. (the “Company”), hereby certifies, to the best of such officer’s knowledge, that:

(i) the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Date: May 7, 2021

By:

/s/ WILLIAM J. PETERS

William J. Peters

Chief Financial Officer

(Principal Financial and Accounting Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. §1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-101.SCH 6 amph-20210331.xsd EX-101.SCH 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Investments (Held-to_Maturity) (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Goodwill and Intangible Assets (Summary of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - General link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Customer and Supplier Concentration link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Property, Plant, and Equipment link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Employee Benefits link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11801 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 11901 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Customer and Supplier Concentration (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Property, Plant, and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Revenue Recognition (Analysis of the Chargeback Provision) (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Revenue Recognition (Analysis of Product Return Liability) (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Segment Reporting (Selected Financial Information by Reporting Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Segment Reporting (Summary of Net Revenues by Product Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Segment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Customer and Supplier Concentration (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Debt (Schedule of Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - Debt (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Income Taxes (Summary of Income Before Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Stockholders' Equity (Share Buyback Program) (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - Stockholders' Equity (The 2015 Equity Incentive Plan) (Details) link:presentationLink link:calculationLink link:definitionLink 41503 - Disclosure - Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details) link:presentationLink link:calculationLink link:definitionLink 41504 - Disclosure - Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details) link:presentationLink link:calculationLink link:definitionLink 41505 - Disclosure - Stockholders' Equity (Summary of Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 41506 - Disclosure - Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details) link:presentationLink link:calculationLink link:definitionLink 41507 - Disclosure - Stockholders' Equity (Summary of Nonvested Options) (Details) link:presentationLink link:calculationLink link:definitionLink 41508 - Disclosure - Stockholders' Equity (Restricted Stock Units) (Details) link:presentationLink link:calculationLink link:definitionLink 41509 - Disclosure - Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details) link:presentationLink link:calculationLink link:definitionLink 41510 - Disclosure - Stockholders' Equity (The 2018 ANP Equity Incentive Plan) (Details) link:presentationLink link:calculationLink link:definitionLink 41511 - Disclosure - Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Employee Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - Commitments and Contingencies (Purchase Commitments) (Details) link:presentationLink link:calculationLink link:definitionLink 41801 - Disclosure - Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 41901 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 amph-20210331_cal.xml EX-101.CAL EX-101.DEF 8 amph-20210331_def.xml EX-101.DEF EX-101.LAB 9 amph-20210331_lab.xml EX-101.LAB EX-101.PRE 10 amph-20210331_pre.xml EX-101.PRE XML 11 amph-20210331x10q_htm.xml IDEA: XBRL DOCUMENT 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2021-01-01 2021-03-31 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2020-01-01 2020-03-31 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2021-03-31 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2020-12-31 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2020-03-31 0001297184 us-gaap:SalesReturnsAndAllowancesMember 2019-12-31 0001297184 amph:November2014ShareRepurchasePlanMember 2021-01-01 2021-03-31 0001297184 amph:November2014ShareRepurchasePlanMember 2020-01-01 2020-03-31 0001297184 amph:November2014ShareRepurchasePlanMember 2020-08-04 0001297184 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001297184 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001297184 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001297184 us-gaap:RetainedEarningsMember 2021-03-31 0001297184 us-gaap:ParentMember 2021-03-31 0001297184 us-gaap:NoncontrollingInterestMember 2021-03-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001297184 us-gaap:RetainedEarningsMember 2020-12-31 0001297184 us-gaap:ParentMember 2020-12-31 0001297184 us-gaap:NoncontrollingInterestMember 2020-12-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001297184 us-gaap:RetainedEarningsMember 2020-03-31 0001297184 us-gaap:ParentMember 2020-03-31 0001297184 us-gaap:NoncontrollingInterestMember 2020-03-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001297184 us-gaap:RetainedEarningsMember 2019-12-31 0001297184 us-gaap:ParentMember 2019-12-31 0001297184 us-gaap:NoncontrollingInterestMember 2019-12-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001297184 amph:EmployeeMember amph:Anp2018EquityIncentivePlanMember 2021-03-31 0001297184 amph:EmployeeStockPurchasePlan2014Member 2021-03-31 0001297184 amph:The2015EquityIncentivePlanMember 2021-03-31 0001297184 amph:The2015EquityIncentivePlanMember 2021-01-01 2021-01-31 0001297184 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001297184 amph:EmployeeMember amph:Anp2018EquityIncentivePlanMember 2019-06-01 2019-06-30 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:PhytonadioneMember 2021-01-01 2021-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:OtherFinishedPharmaceuticalProductsMember 2021-01-01 2021-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:NaloxoneMember 2021-01-01 2021-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:LidocaineMember 2021-01-01 2021-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:GlucagonMember 2021-01-01 2021-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:EpinephrineMember 2021-01-01 2021-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:EnoxaparinMember 2021-01-01 2021-03-31 0001297184 country:US 2021-01-01 2021-03-31 0001297184 country:FR 2021-01-01 2021-03-31 0001297184 country:CN 2021-01-01 2021-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:PhytonadioneMember 2020-01-01 2020-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:OtherFinishedPharmaceuticalProductsMember 2020-01-01 2020-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:NaloxoneMember 2020-01-01 2020-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:LidocaineMember 2020-01-01 2020-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:EpinephrineMember 2020-01-01 2020-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:EnoxaparinMember 2020-01-01 2020-03-31 0001297184 country:US 2020-01-01 2020-03-31 0001297184 country:FR 2020-01-01 2020-03-31 0001297184 country:CN 2020-01-01 2020-03-31 0001297184 us-gaap:MachineryAndEquipmentMember 2021-03-31 0001297184 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001297184 us-gaap:LandMember 2021-03-31 0001297184 us-gaap:ConstructionInProgressMember 2021-03-31 0001297184 us-gaap:BuildingMember 2021-03-31 0001297184 amph:FurnitureFixturesAndVehiclesMember 2021-03-31 0001297184 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001297184 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001297184 us-gaap:LandMember 2020-12-31 0001297184 us-gaap:ConstructionInProgressMember 2020-12-31 0001297184 us-gaap:BuildingMember 2020-12-31 0001297184 amph:FurnitureFixturesAndVehiclesMember 2020-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001297184 country:US 2021-03-31 0001297184 country:FR 2021-03-31 0001297184 country:CN 2021-03-31 0001297184 country:US 2020-12-31 0001297184 country:FR 2020-12-31 0001297184 country:CN 2020-12-31 0001297184 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001297184 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001297184 amph:CommitmentsToPurchaseEquipmentAndRawMaterialsMember 2021-01-01 2021-03-31 0001297184 amph:WorkingCapitalLoanDueJune2021Member amph:EverbrightBankOfChinaMember 2021-03-31 0001297184 amph:MortgagePayableDueOctober2026Member amph:EastWestBankMember 2021-03-31 0001297184 amph:MortgagePayableDueMay2021Member amph:EastWestBankMember 2021-03-31 0001297184 amph:MortgagePayableDueJune2027Member amph:EastWestBankMember 2021-03-31 0001297184 amph:MortgagePayableDueAugust2027Member amph:CathayBankMember 2021-03-31 0001297184 amph:LineOfCreditDueOctober2021Member amph:BankOfNanjingMember 2021-03-31 0001297184 amph:LineOfCreditDueAugust2021Member amph:ChinaMerchantBankMember 2021-03-31 0001297184 amph:FrenchGovernmentLoanDueJuly2021Member amph:SeineNormandieWaterAgencyMember 2021-03-31 0001297184 amph:FrenchGovernmentLoan4DueDecember2026Member amph:SeineNormandieWaterAgencyMember 2021-03-31 0001297184 amph:EquipmentLoanDueJune2021Member amph:EastWestBankMember 2021-03-31 0001297184 amph:EquipmentLoanDueFebruary2024Member amph:EastWestBankMember 2021-03-31 0001297184 amph:EquipmentLoanDueDecember2022Member amph:EastWestBankMember 2021-03-31 0001297184 amph:EquipmentLineOfCreditDueSeptember2025Member amph:EastWestBankMember 2021-03-31 0001297184 amph:AcquisitionLoanDueJune2024Member amph:CathayBankMember 2021-03-31 0001297184 amph:WorkingCapitalLoanDueJune2021Member amph:EverbrightBankOfChinaMember 2020-12-31 0001297184 amph:MortgagePayableDueOctober2026Member amph:EastWestBankMember 2020-12-31 0001297184 amph:MortgagePayableDueMay2021Member amph:EastWestBankMember 2020-12-31 0001297184 amph:MortgagePayableDueJune2027Member amph:EastWestBankMember 2020-12-31 0001297184 amph:MortgagePayableDueAugust2027Member amph:CathayBankMember 2020-12-31 0001297184 amph:LineOfCreditDueOctober2021Member amph:BankOfNanjingMember 2020-12-31 0001297184 amph:LineOfCreditDueAugust2021Member amph:ChinaMerchantBankMember 2020-12-31 0001297184 amph:FrenchGovernmentLoanDueJuly2021Member amph:SeineNormandieWaterAgencyMember 2020-12-31 0001297184 amph:FrenchGovernmentLoan4DueDecember2026Member amph:SeineNormandieWaterAgencyMember 2020-12-31 0001297184 amph:EquipmentLoanDueJune2021Member amph:EastWestBankMember 2020-12-31 0001297184 amph:EquipmentLoanDueFebruary2024Member amph:EastWestBankMember 2020-12-31 0001297184 amph:EquipmentLoanDueDecember2022Member amph:EastWestBankMember 2020-12-31 0001297184 amph:EquipmentLineOfCreditDueSeptember2025Member amph:EastWestBankMember 2020-12-31 0001297184 amph:AcquisitionLoanDueJune2024Member amph:CathayBankMember 2020-12-31 0001297184 amph:AmphastarPharmaceuticalsInc.VsAventisPharmaSaMember us-gaap:SubsequentEventMember 2021-05-03 2021-05-03 0001297184 amph:AmphastarPharmaceuticalsInc.VsAventisPharmaSaMember us-gaap:SubsequentEventMember 2021-05-01 2021-05-31 0001297184 amph:RamirezVsAmphastarPharmaceuticalsIncMember us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2021-04-05 2021-04-05 0001297184 amph:BrenesVsInternationalMedicationSystemsLimitedMember 2021-02-09 2021-02-09 0001297184 amph:AmphastarPharmaceuticalsInc.VsAventisPharmaSaMember us-gaap:SettledLitigationMember 2020-11-13 2020-11-13 0001297184 amph:RamirezVsAmphastarPharmaceuticalsIncMember us-gaap:SettledLitigationMember 2021-03-31 0001297184 amph:AmphastarPharmaceuticalsInc.VsAventisPharmaSaMember 2021-03-31 0001297184 amph:BrenesVsInternationalMedicationSystemsLimitedMember 2020-12-31 0001297184 amph:AmphastarPharmaceuticalsInc.VsAventisPharmaSaMember 2020-12-31 0001297184 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001297184 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001297184 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001297184 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001297184 amph:EnoxaparinMember 2021-01-01 2021-03-31 0001297184 amph:EnoxaparinMember 2020-01-01 2020-03-31 0001297184 us-gaap:TrademarksMember 2021-03-31 0001297184 us-gaap:TrademarksMember 2020-12-31 0001297184 us-gaap:MunicipalBondsMember 2021-03-31 0001297184 us-gaap:CorporateBondSecuritiesMember 2021-03-31 0001297184 us-gaap:MunicipalBondsMember 2020-12-31 0001297184 us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2021-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2020-12-31 0001297184 amph:InternationalMedicationSystemsUkLimitedMember amph:AcquiredInternationalProductRightsMember 2021-01-01 2021-03-31 0001297184 us-gaap:UseRightsMember 2021-01-01 2021-03-31 0001297184 us-gaap:PatentsMember 2021-01-01 2021-03-31 0001297184 amph:InternationalMedicationSystemsUkLimitedMember amph:AcquiredInternationalProductRightsMember 2020-01-01 2020-12-31 0001297184 us-gaap:UseRightsMember 2020-01-01 2020-12-31 0001297184 us-gaap:PatentsMember 2020-01-01 2020-12-31 0001297184 2020-01-01 2020-12-31 0001297184 amph:InternationalMedicationSystemsUkLimitedMember amph:AcquiredInternationalProductRightsMember 2021-03-31 0001297184 us-gaap:UseRightsMember 2021-03-31 0001297184 us-gaap:PatentsMember 2021-03-31 0001297184 amph:InternationalMedicationSystemsUkLimitedMember amph:AcquiredInternationalProductRightsMember 2020-12-31 0001297184 us-gaap:UseRightsMember 2020-12-31 0001297184 us-gaap:PatentsMember 2020-12-31 0001297184 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-03-31 0001297184 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2021-03-31 0001297184 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001297184 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001297184 amph:EmployeeConsultantAndDirectorsStockOptionsMember 2021-03-31 0001297184 amph:EmployeeConsultantAndDirectorsStockOptionsMember 2021-01-01 2021-03-31 0001297184 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001297184 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001297184 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001297184 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2021-01-01 2021-03-31 0001297184 amph:ActivePharmaceuticalIngredientSegmentMember 2021-01-01 2021-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2020-01-01 2020-03-31 0001297184 amph:ActivePharmaceuticalIngredientSegmentMember 2020-01-01 2020-03-31 0001297184 amph:McKessonMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001297184 amph:McKessonMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001297184 amph:CardinalHealthMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001297184 amph:CardinalHealthMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001297184 amph:AmerisourceBergenMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001297184 amph:AmerisourceBergenMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001297184 amph:McKessonMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001297184 amph:CardinalHealthMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001297184 amph:AmerisourceBergenMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001297184 amph:McKessonMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001297184 amph:CardinalHealthMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001297184 amph:AmerisourceBergenMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001297184 us-gaap:TreasuryStockMember 2021-03-31 0001297184 us-gaap:CommonStockMember 2021-03-31 0001297184 us-gaap:TreasuryStockMember 2020-12-31 0001297184 us-gaap:CommonStockMember 2020-12-31 0001297184 us-gaap:TreasuryStockMember 2020-03-31 0001297184 us-gaap:CommonStockMember 2020-03-31 0001297184 us-gaap:TreasuryStockMember 2019-12-31 0001297184 us-gaap:CommonStockMember 2019-12-31 0001297184 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001297184 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001297184 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001297184 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001297184 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001297184 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001297184 us-gaap:FairValueInputsLevel1Member 2021-03-31 0001297184 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001297184 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001297184 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001297184 amph:EmployeeMember amph:Anp2018EquityIncentivePlanMember 2021-01-01 2021-03-31 0001297184 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001297184 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001297184 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001297184 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001297184 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001297184 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001297184 amph:EmployeeStockPurchasePlan2014Member 2021-01-01 2021-03-31 0001297184 amph:EmployeeMember amph:Anp2018EquityIncentivePlanMember 2020-01-01 2020-03-31 0001297184 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-03-31 0001297184 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001297184 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001297184 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001297184 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001297184 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001297184 amph:EmployeeStockPurchasePlan2014Member 2020-01-01 2020-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:PrimatenemistMember 2021-01-01 2021-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:PrimatenemistMember 2020-01-01 2020-03-31 0001297184 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001297184 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001297184 2021-05-03 0001297184 us-gaap:ParentMember 2021-01-01 2021-03-31 0001297184 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001297184 us-gaap:ParentMember 2020-01-01 2020-03-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001297184 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001297184 amph:RestrictedStockUnitsIssuedAsCompensationMember 2021-01-01 2021-03-31 0001297184 us-gaap:AccountsReceivableMember 2021-01-01 2021-03-31 0001297184 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2021-01-01 2021-03-31 0001297184 us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001297184 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2020-01-01 2020-12-31 0001297184 2020-03-31 0001297184 2019-12-31 0001297184 amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember us-gaap:SubsequentEventMember 2021-05-01 2021-05-31 0001297184 amph:AnpMember us-gaap:SubsequentEventMember 2021-05-01 2021-05-31 0001297184 us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001297184 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001297184 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001297184 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001297184 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001297184 2020-01-01 2020-03-31 0001297184 amph:AnpMember 2018-07-01 2018-07-31 0001297184 2021-01-01 2021-03-31 0001297184 amph:EmployeeAndNonEmployeeStockOptionsMember 2021-01-01 2021-03-31 0001297184 amph:EmployeeAndNonEmployeeStockOptionsMember 2020-01-01 2020-03-31 0001297184 2021-03-31 0001297184 2020-12-31 iso4217:USD iso4217:USD shares pure amph:item shares amph:segment 3 3 0 0 0 0 0 0 0 0 Amphastar Pharmaceuticals, Inc. --12-31 false 0001297184 2021-03-31 Q1 true false 10-Q 2021 001-36509 DE 33-0702205 11570 6th Street Rancho Cucamonga CA 91730 909 980-9484 Yes Yes Accelerated Filer false false false Common Stock, par value $0.0001 per share AMPH NASDAQ 47635351 101601000 92642000 235000 1865000 13531000 12977000 2200000 2200000 77938000 66005000 97110000 96831000 800000 385000 6749000 6777000 300164000 279682000 253265000 260055000 594000 612000 19280000 20042000 40243000 40615000 7212000 5250000 24980000 24980000 645738000 631236000 108545000 95504000 2676000 1077000 12173000 12263000 3702000 3357000 127096000 112201000 4709000 4709000 32334000 34186000 16464000 17464000 755000 741000 13420000 13212000 194778000 182513000 0.0001 0.0001 20000000 20000000 0.0001 0.0001 300000000 300000000 55184000 47718003 54760922 47495439 6000 5000 413926000 410061000 122814000 117773000 -5642000 -3721000 125546000 121812000 405558000 402306000 45402000 46417000 450960000 448723000 645738000 631236000 103020000 84688000 58074000 47865000 44946000 36823000 4537000 3294000 15338000 10746000 14765000 15303000 34640000 29343000 10306000 7480000 161000 153000 104000 76000 -5249000 -1752000 -5192000 -1675000 5114000 5805000 1155000 2280000 3959000 3525000 -1082000 -424000 5041000 3949000 0.11 0.09 0.10 0.08 47520000 46408000 49518000 48248000 5041000 3949000 -1921000 -774000 -1921000 -774000 3120000 3175000 54760922 5000 410061000 117773000 -3721000 -7265483 -121812000 402306000 46417000 448723000 5041000 5041000 5041000 -1921000 -1921000 -1921000 1082000 1082000 204698 3783000 3783000 3783000 -49000 4184 49000 423078 1000 -853000 -852000 -852000 4767000 4767000 67000 4834000 55184000 6000 413926000 122814000 -5642000 -7465997 -125546000 405558000 45402000 450960000 52495483 5000 367305000 116370000 -4687000 -5918515 -97627000 381366000 46162000 427528000 3949000 3949000 3949000 -774000 -774000 -774000 424000 424000 647246 10950000 10950000 10950000 -84000 6873 84000 369508 -1238000 -1238000 -1238000 5161000 5161000 121000 5282000 52864991 5000 371144000 120319000 -5461000 -6558888 -108493000 377514000 45859000 423373000 3959000 3525000 -6000 -14000 5686000 4716000 276000 258000 863000 848000 4834000 5282000 -1638000 12078000 12487000 1144000 -2241000 -1119000 -1494000 -1182000 -451000 -754000 -824000 18876000 -5679000 22825000 1477000 7618000 8006000 21000 4501000 4561000 3944000 4030000 520000 206000 -8695000 -8722000 854000 1238000 3783000 10950000 3067000 2002000 2328000 -6639000 -11449000 -162000 -146000 7329000 -18840000 94507000 75550000 101836000 56710000 6238000 5840000 103000 74000 508000 559000 30000 209000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 1. Genera</b><b style="font-weight:bold;">l</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:23.05pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amphastar Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, hereinafter referred to as the “Company”) is a bio-pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products, including products with high technical barriers to market entry. Additionally, the Company sells insulin active pharmaceutical ingredient, or API, products. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company’s insulin API products are sold to other pharmaceutical companies for use in their own products and are being used by the Company in the development of injectable finished pharmaceutical products. The Company’s inhalation product, Primatene Mist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> is primarily distributed through drug retailers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2020 and the notes thereto as filed with the Securities and Exchange Commission, or SEC, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles, or GAAP, have been condensed or omitted from the accompanying condensed consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from the audited financial statements. The accompanying interim financial statements are unaudited, but reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the Company’s consolidated financial position, results of operations, comprehensive income (loss), stockholders’ equity, and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. The Company’s results of operations, comprehensive income (loss) and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 2. Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Basis of Presentation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with United States generally accepted accounting principles, or GAAP. Certain prior period amounts have been reclassified within the investing activities of the statement of cash flows to conform to the current period presentation. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements.<span style="font-size:12pt;"> </span>In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company’s subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals, Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Nanjing Letop Biological Technology Co., Ltd., or Letop, (5) Nanjing Hanxin Pharmaceutical Technology Co., Ltd., or Hanxin, (6) Nanjing Hanxin Biomedical Testing Service Co., Ltd., or Hanxin Biomedical, (7) Nanjing Baixin Trading Co., Ltd., or Baixin, (8) Amphastar France Pharmaceuticals, S.A.S., or AFP, (9) Amphastar UK Ltd., or AUK, and (10) International Medication Systems (UK) Limited, or IMS UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In July 2018, the Company’s Chinese subsidiary, ANP, completed a private placement of its common equity interest to accredited investors and received approximately $56.3 million of cash proceeds, a portion of which was received in 2019. The Company has retained approximately 58% of the equity interest in ANP following the private placement and continues to consolidate the financial results of ANP with the Company’s results of operations. ANP’s net income after July 2, 2018, was attributed to the Company in accordance with the Company’s equity interest of approximately 58% in ANP.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">COVID-19 Pandemic</i></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#212529;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company is subject to risks and uncertainties as a result of the ongoing novel coronavirus pandemic, or COVID-19. The complete extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the information is constantly evolving. The Company considered the impact of COVID<i style="font-style:italic;">-</i>19 on the assumptions and estimates used to determine the results reported and asset valuations as of March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All of the Company’s production facilities continued to operate during the quarter as they had prior to the COVID-19 pandemic with very little change, other than for enhanced safety measures intended to prevent the spread of the virus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">It is not possible at this time to estimate the complete impact that COVID-19 could have on the Company’s business, including its customers and suppliers, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. The Company will continue to monitor the impact of COVID-19 on all aspects of its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for credit losses, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to their net realizable values, impairment of long-lived and intangible assets and goodwill, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Foreign Currency </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the US Dollar. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company’s condensed consolidated statements of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company’s French subsidiary, AFP, maintains its book of record in euros. ANP’s subsidiaries maintain their books of record in Chinese yuan. AUK’s subsidiary, IMS UK, maintains its book of record in British pounds. These local currencies have been determined to be the subsidiaries’ respective functional currencies. These books of record are translated into USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other accumulated comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature for the three months ended March 31, 2021 and 2020 were $1.5 million loss and $0.6<span style="white-space:pre-wrap;"> million loss, respectively. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Comprehensive Income (Loss)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the three months ended March 31, 2021 and 2020, the Company included its foreign currency translation gain or loss as part of its comprehensive income (loss). No income tax expense (benefit) was allocated to other comprehensive income (loss) for the three months ended March 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Advertising Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advertising expenses, primarily associated with Primatene Mist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Company’s condensed consolidated statement of operations. For the three months ended March 31, 2021 and 2020, advertising expense was $2.2 million and $1.0 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;"> </i><span style="font-style:italic;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Financial Instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The carrying amounts of cash and cash equivalents, short-term investments, restricted cash and short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. The majority of the Company’s long-term obligations consist of variable rate debt, and their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. The Company at times enters into fixed interest rate swap contracts to exchange the variable interest rates for fixed interest rates without the exchange of the underlying notional debt amounts. Such interest rate swap contracts are recorded at their fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Cash and Cash Equivalents</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments purchased with original maturities of three months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Short-Term Investments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments as of March 31, 2021 and December 31, 2020 consisted of certificates of deposit and investment grade debt securities with original expiration dates within 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Restricted Cash </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of March 31, 2021 and December 31, 2020, the restricted cash balance was $0.2 million and $1.9 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Restricted Short-Term Investments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workers’ compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of March 31, 2021 and December 31, 2020, the balance of restricted short-term investments was $2.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Deferred Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Recent Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2019, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No. 2019-12 <i style="font-style:italic;">Simplifying the Accounting for Income Taxes (Topic 740)</i>. The amendment removes certain exceptions for performing intra-period tax allocations, recognizing deferred taxes for investment, and calculating income taxes in interim periods. The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods. The guidance is effective for the Company’s interim and annual reporting periods during the year ended December 31, 2021. The adoption of this accounting guidance did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Basis of Presentation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with United States generally accepted accounting principles, or GAAP. Certain prior period amounts have been reclassified within the investing activities of the statement of cash flows to conform to the current period presentation. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements.<span style="font-size:12pt;"> </span>In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company’s subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals, Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Nanjing Letop Biological Technology Co., Ltd., or Letop, (5) Nanjing Hanxin Pharmaceutical Technology Co., Ltd., or Hanxin, (6) Nanjing Hanxin Biomedical Testing Service Co., Ltd., or Hanxin Biomedical, (7) Nanjing Baixin Trading Co., Ltd., or Baixin, (8) Amphastar France Pharmaceuticals, S.A.S., or AFP, (9) Amphastar UK Ltd., or AUK, and (10) International Medication Systems (UK) Limited, or IMS UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In July 2018, the Company’s Chinese subsidiary, ANP, completed a private placement of its common equity interest to accredited investors and received approximately $56.3 million of cash proceeds, a portion of which was received in 2019. The Company has retained approximately 58% of the equity interest in ANP following the private placement and continues to consolidate the financial results of ANP with the Company’s results of operations. ANP’s net income after July 2, 2018, was attributed to the Company in accordance with the Company’s equity interest of approximately 58% in ANP.</p> 56300000 0.58 0.58 <p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">COVID-19 Pandemic</i></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#212529;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company is subject to risks and uncertainties as a result of the ongoing novel coronavirus pandemic, or COVID-19. The complete extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the information is constantly evolving. The Company considered the impact of COVID<i style="font-style:italic;">-</i>19 on the assumptions and estimates used to determine the results reported and asset valuations as of March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All of the Company’s production facilities continued to operate during the quarter as they had prior to the COVID-19 pandemic with very little change, other than for enhanced safety measures intended to prevent the spread of the virus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">It is not possible at this time to estimate the complete impact that COVID-19 could have on the Company’s business, including its customers and suppliers, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. The Company will continue to monitor the impact of COVID-19 on all aspects of its business.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for credit losses, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to their net realizable values, impairment of long-lived and intangible assets and goodwill, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Foreign Currency </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the US Dollar. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company’s condensed consolidated statements of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company’s French subsidiary, AFP, maintains its book of record in euros. ANP’s subsidiaries maintain their books of record in Chinese yuan. AUK’s subsidiary, IMS UK, maintains its book of record in British pounds. These local currencies have been determined to be the subsidiaries’ respective functional currencies. These books of record are translated into USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other accumulated comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature for the three months ended March 31, 2021 and 2020 were $1.5 million loss and $0.6<span style="white-space:pre-wrap;"> million loss, respectively. </span></p> -1500000 -600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Comprehensive Income (Loss)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the three months ended March 31, 2021 and 2020, the Company included its foreign currency translation gain or loss as part of its comprehensive income (loss). No income tax expense (benefit) was allocated to other comprehensive income (loss) for the three months ended March 31, 2021 and 2020.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Advertising Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advertising expenses, primarily associated with Primatene Mist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Company’s condensed consolidated statement of operations. For the three months ended March 31, 2021 and 2020, advertising expense was $2.2 million and $1.0 million, respectively.</p> 2200000 1000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Financial Instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The carrying amounts of cash and cash equivalents, short-term investments, restricted cash and short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. The majority of the Company’s long-term obligations consist of variable rate debt, and their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. The Company at times enters into fixed interest rate swap contracts to exchange the variable interest rates for fixed interest rates without the exchange of the underlying notional debt amounts. Such interest rate swap contracts are recorded at their fair values.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Cash and Cash Equivalents</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments purchased with original maturities of three months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Short-Term Investments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments as of March 31, 2021 and December 31, 2020 consisted of certificates of deposit and investment grade debt securities with original expiration dates within 12 months.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Restricted Cash </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of March 31, 2021 and December 31, 2020, the restricted cash balance was $0.2 million and $1.9 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p> 200000 1900000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Restricted Short-Term Investments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workers’ compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of March 31, 2021 and December 31, 2020, the balance of restricted short-term investments was $2.2 million.</p> 2200000 2200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Deferred Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Recent Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2019, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No. 2019-12 <i style="font-style:italic;">Simplifying the Accounting for Income Taxes (Topic 740)</i>. The amendment removes certain exceptions for performing intra-period tax allocations, recognizing deferred taxes for investment, and calculating income taxes in interim periods. The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods. The guidance is effective for the Company’s interim and annual reporting periods during the year ended December 31, 2021. The adoption of this accounting guidance did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 3. Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In accordance with Accounting Standard Codification, or ASC, 606 <i style="font-style:italic;">Revenue from Contracts with Customers</i>, revenue is recognized at the time that the Company’s customers obtain control of the promised goods. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Generally, revenue is recognized at the time of product delivery to the Company’s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The consideration the Company receives in exchange for its goods or services is only recognized when it is probable that a significant reversal will not occur. The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration. The Company makes significant estimates for related variable consideration at the point of sale, including chargebacks, rebates, product returns, other discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company’s payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customers, but payment is generally required in a term ranging from 30 to 75 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provisions for estimated chargebacks, rebates, discounts, product returns and credit losses are made at the time of sale and are analyzed and adjusted, if necessary, at each balance sheet date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers, and after the customer has accepted test samples of the products to be shipped.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company’s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. The Company does not have any revenue arrangements with multiple performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Provision for Chargebacks and Rebates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The provision for chargebacks and rebates is a significant estimate used in the recognition of revenue. Wholesaler chargebacks relate to sales terms under which the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products that wholesalers resell under the Company’s various contractual arrangements with third parties such as hospitals and group purchasing organizations in the United States. Rebates include primarily amounts paid to retailers, payers, and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements. The Company estimates chargebacks and rebates using the expected value method at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback and rebate rates, and current contract pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The provision for chargebacks and rebates is reflected as a component of net revenues. The following table is an analysis of the chargeback and rebate provision: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.08%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,380</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,644</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision for chargebacks and rebates</p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,031</p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,987</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credits and payments issued to third parties</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,881)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,353)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,530</p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,278</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in the chargeback provision from period to period are primarily dependent on the Company’s sales to its wholesalers, the level of inventory held by wholesalers, and the wholesalers’ customer mix. Changes in the rebate provision from period to period are primarily dependent on retailer’s and other indirect customers’ purchases. The approach that the Company uses to estimate chargebacks has been consistently applied for all periods presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and rebates and makes adjustments when it believes that the actual chargebacks and rebates may differ from the estimates. The settlement of chargebacks and rebates generally occurs within 30 days to 60 days after the sale to wholesalers. Accounts receivable and/or accounts payable and accrued liabilities are reduced and/or increased by the chargebacks and rebate amounts depending on whether the Company has the right to offset with the customer. Of the provision for chargebacks and rebates as of March 31, 2021 and December 31, 2020, $16.4 million and $16.4 million were included in accounts receivable, net, on the condensed consolidated balance sheets, respectively. The remaining provision as of March 31, 2021 and December 31, 2020 of $4.1 million and $4.0 million, respectively, were included in accounts payable and accrued liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Accrual for Product Returns</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company offers most customers the right to return qualified excess or expired inventory for partial credit; however, API product sales are generally non-returnable. The Company’s product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for product returns estimated using the expected value method. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and the introduction of new competition. Although these factors do not normally give the Company’s customers the right to return products outside of the regular return policy, the Company realizes that such factors could ultimately lead to increased returns. The Company analyzes these situations on a case-by-case basis and makes adjustments to the product return reserve as appropriate.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The provision for product returns is reflected as a component of net revenues. The following table is an analysis of the product return liability:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,204</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,339</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision for product returns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credits issued to third parties</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,517)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,239)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Of the provision for product returns as of March 31, 2021 and December 31, 2020, $10.7 million and $10.2 million, were included in accounts payable and accrued liabilities on the condensed consolidated balance sheets, respectively. The remaining provision as of March 31, 2021 and December 31, 2020 of $4.2 million and $4.0 million, respectively, were included in other long-term liabilities. For the three months ended March 31, 2021 and 2020, the Company’s aggregate product return rate was 1.4% and 1.1% of qualified sales, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.08%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:24.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,380</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,644</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision for chargebacks and rebates</p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,031</p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,987</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credits and payments issued to third parties</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,881)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,353)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,530</p></td><td style="vertical-align:bottom;white-space:normal;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,278</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 20380000 21644000 47031000 35987000 46881000 39353000 20530000 18278000 16400000 16400000 4100000 4000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,204</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,339</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision for product returns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credits issued to third parties</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,517)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,239)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 14204000 10339000 3233000 3099000 2517000 2239000 14920000 11199000 10700000 10200000 4200000 4000000.0 0.014 0.011 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 4. Income per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders gives effect to all potential dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Company’s Employee Stock Purchase Plan, or ESPP and the reallocation of net income attributable to non-controlling interest from the assumed dilutive effect of stock options issued under the 2018 ANP Equity Incentive Plan, or the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the three months ended March 31, 2021, options to purchase 1,899,833 shares of stock with a weighted-average exercise price of $20.85<span style="white-space:pre-wrap;"> per share, and the reallocation of net income attributable to non-controlling interests were excluded in the computation of diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders because the effect would be anti-dilutive. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the three months ended March 31, 2020, options to purchase 1,999,083 shares of stock with a weighted-average exercise price of $20.81 per share, and the reallocation of net income attributable to non-controlling interest were excluded in the computation of diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table provides the calculation of basic and diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders for each of the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="background-color:#cceeff;vertical-align:bottom;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share data)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and dilutive numerator:</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income attributable to Amphastar Pharmaceuticals, Inc.</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,041</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,949</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares outstanding — basic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,520</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,408</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net effect of dilutive securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Incremental shares from equity awards</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,998</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,840</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares outstanding — diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,518</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,248</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — basic</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.11</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.09</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.10</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.08</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 1899833 20.85 1999083 20.81 <p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="background-color:#cceeff;vertical-align:bottom;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share data)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and dilutive numerator:</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income attributable to Amphastar Pharmaceuticals, Inc.</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,041</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,949</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares outstanding — basic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,520</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,408</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net effect of dilutive securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Incremental shares from equity awards</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,998</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,840</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares outstanding — diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,518</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,248</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — basic</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.11</p></td><td style="vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.09</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.10</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.08</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 5041000 3949000 47520000 46408000 1998000 1840000 49518000 48248000 0.11 0.09 0.10 0.08 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 5. Segment Reporting </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company’s business is the development, manufacture, and marketing of pharmaceutical products. The Company has identified two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">280, Segment Reporting. The Company’s performance is assessed and resources are allocated by the CODM based on the following two reportable segments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Finished pharmaceutical products</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">API</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selected financial information by reporting segment is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net revenues:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Finished pharmaceutical products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">API</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,138</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total net revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Gross profit (loss):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Finished pharmaceutical products</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,286</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,810</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">API</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (340)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,987)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total gross profit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,946</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,823</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,640</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,343</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,306</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,480</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-operating expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,192)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,675)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. The Company does not identify total assets by segment for internal purposes, as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The amount of net revenues in the finished pharmaceutical product segment is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Finished pharmaceutical products net revenues:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Primatene Mist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Epinephrine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,578</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,990</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Enoxaparin </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Phytonadione</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,565</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,029</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lidocaine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Glucagon</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,984</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Naloxone </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other finished pharmaceutical products</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,302</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,702</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total finished pharmaceutical products net revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The amount of depreciation and amortization expense included in cost of revenues, by reporting segments is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Depreciation and amortization expense </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finished pharmaceutical products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">API</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,048</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 582</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total depreciation and amortization expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net revenues and carrying values of long-lived assets by geographic regions are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Lived Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 99,170</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,065</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,861</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 129,401</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">France</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,729</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,395</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,431</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,770</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 273,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:14pt;visibility:hidden;">​</span></p> 2 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net revenues:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Finished pharmaceutical products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">API</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,138</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total net revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Gross profit (loss):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Finished pharmaceutical products</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,286</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,810</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">API</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (340)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,987)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total gross profit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,946</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,823</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,640</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,343</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,306</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,480</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-operating expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,192)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,675)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 97882000 81298000 5138000 3390000 103020000 84688000 45286000 38810000 -340000 -1987000 44946000 36823000 34640000 29343000 10306000 7480000 -5192000 -1675000 5114000 5805000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Finished pharmaceutical products net revenues:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Primatene Mist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Epinephrine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,578</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,990</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Enoxaparin </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Phytonadione</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,565</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,029</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lidocaine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Glucagon</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,984</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Naloxone </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other finished pharmaceutical products</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,302</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,702</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total finished pharmaceutical products net revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 18383000 12877000 15578000 3990000 10658000 9168000 9565000 11029000 9071000 10657000 7984000 6341000 8875000 20302000 24702000 97882000 81298000 <p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Depreciation and amortization expense </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finished pharmaceutical products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">API</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,048</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 582</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total depreciation and amortization expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 1435000 1464000 1048000 582000 2483000 2046000 <p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Lived Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 99,170</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,065</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,861</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 129,401</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 98,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">France</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,729</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,395</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,431</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,770</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 273,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 99170000 81065000 125861000 129401000 1121000 228000 97847000 98538000 2729000 3395000 49431000 52770000 103020000 84688000 273139000 280709000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 6. Customer and Supplier Concentration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Customer Concentrations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Three large wholesale drug distributors, AmerisourceBergen Corporation, or AmerisourceBergen, Cardinal Health, Inc., or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. The Company considers these three customers to be its major customers, as each individually, and these customers collectively, represented a significant percentage of the Company’s net revenue for the three months ended March 31, 2021 and 2020 and accounts receivable as of March 31, 2021 and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 31, 2020, respectively. The following table provides accounts receivable and net revenue information for these major customers:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:10.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:26.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total Accounts</b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Net</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:26.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Receivable</b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:26.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:16.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AmerisourceBergen</p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">McKesson</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cardinal Health</p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Supplier Concentrations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company depends on suppliers for raw materials, APIs, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Company’s business, financial condition, and results of operations.</p> 3 3 3 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:10.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:26.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Total Accounts</b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% of Net</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:26.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Receivable</b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:26.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:16.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:normal;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AmerisourceBergen</p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">McKesson</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cardinal Health</p></td><td style="vertical-align:bottom;white-space:normal;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:normal;width:4.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:normal;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 0.14 0.09 0.25 0.24 0.21 0.24 0.20 0.22 0.16 0.17 0.15 0.19 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 7. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:14pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Level 1</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> – Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-bottom:14pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Level 2 – </i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Inputs to measure fair value are based on the following: a) quoted prices in active markets on similar assets or liabilities, b) quoted prices for identical or similar instruments in inactive markets, or c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; and </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-bottom:14pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Level 3</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> – Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on best information available in the circumstances.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-bottom:14pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of March 31, 2021, cash equivalents include money market accounts. Short-term investments consist of certificates of deposit as well as investment-grade corporate and municipal bonds with original expiration dates within 12 months. The certificates of deposit are carried at amortized cost in the Company’s condensed consolidated balance sheet, which approximates their fair value determined based on Level 2 inputs. The corporate and municipal bonds are classified as held-to-maturity and are carried at amortized cost net of allowance for credit losses, which approximates their fair value determined based on Level 2 inputs. The restrictions on restricted cash and short-term investments have a negligible effect on the fair value of these financial assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The fair value of the Company’s financial assets and liabilities measured on a recurring basis as of March 31, 2021 and December 31, 2020, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents - money market</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - money market </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments - certificates of deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,284</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,284</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted short-term investments - certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate and municipal bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,199</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,199</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest rate swap liabilities related to variable rate loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (723)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (723)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value measurement as of March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,731</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,771</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,960</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents - money market</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - money market </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments - certificates of deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,089</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,089</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted short-term investments - certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate and municipal bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,855</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,855</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest rate swap liabilities related to variable rate loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (902)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (902)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value measurement as of December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,817</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,575</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,242</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company does not hold any Level 3 instruments that are measured at fair value on a recurring basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nonfinancial assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include long-lived assets, goodwill, and intangible assets for which the fair value of assets is determined as part of the related impairment test. As of March 31, 2021 and December 31, 2020, there were no significant adjustments to fair value for nonfinancial assets or liabilities.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents - money market</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - money market </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments - certificates of deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,284</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,284</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted short-term investments - certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate and municipal bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,199</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,199</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest rate swap liabilities related to variable rate loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (723)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (723)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value measurement as of March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,731</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,771</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,960</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents - money market</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - money market </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments - certificates of deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,089</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,089</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted short-term investments - certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate and municipal bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,855</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,855</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest rate swap liabilities related to variable rate loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (902)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (902)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value measurement as of December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,817</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,575</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,242</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 76536000 76536000 235000 235000 9284000 9284000 2200000 2200000 4199000 4199000 723000 723000 91731000 76771000 14960000 58710000 58710000 1865000 1865000 9089000 9089000 2200000 2200000 3855000 3855000 902000 902000 74817000 60575000 14242000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note</b><b style="font-weight:bold;white-space:pre-wrap;"> 8. Investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A summary of the Company’s investments that are classified as held-to-maturity are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,053</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,052</p></td></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Municipal bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,147</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total investments as of March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,201</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,199</p></td></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,560</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,559</p></td></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Municipal bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,296</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total investments as of December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,857</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,855</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting neither a significant deterioration since purchase nor any other factors that would indicate a material credit loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures expected credit losses on held-to-maturity investments on a collective basis. All the Company’s held-to-maturity investments were considered to be one pool. The estimate for credit losses considers historical loss </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">information that is adjusted for current conditions and reasonable and supportable forecasts. Expected credit losses on held-to-maturity investments were not material to the condensed consolidated financial statements<b style="font-weight:bold;">.</b></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,053</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,052</p></td></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Municipal bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,147</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total investments as of March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,201</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,199</p></td></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,560</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,559</p></td></tr><tr><td style="vertical-align:bottom;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Municipal bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,296</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total investments as of December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,857</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,855</p></td></tr></table> 1053000 1000 1052000 3148000 1000 3147000 4201000 2000 4199000 1560000 1000 1559000 2297000 1000 2296000 3857000 2000 3855000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note</b><b style="font-weight:bold;white-space:pre-wrap;"> 9. Goodwill and Intangible Assets </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Original Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Book Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Definite-lived intangible assets</i></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">IMS (UK) international product rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Patents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Land-use rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,666</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,441</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Indefinite-lived intangible assets</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Trademark</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Goodwill - Finished pharmaceutical products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"> As of March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Original Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Book Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Definite-lived intangible assets</i></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">IMS (UK) international product rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Patents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 297</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 189</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Land-use rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,587</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,137</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,450</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Indefinite-lived intangible assets</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Trademark</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Goodwill - Finished pharmaceutical products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,165</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,165</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"> As of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">*</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Intangible assets with indefinite lives have an indeterminable average life.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Goodwill</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The changes in the carrying amounts of goodwill were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,940</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,634</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,793</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,940</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Primatene</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">®</sup><i style="font-style:italic;"> Trademark</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In January 2009, the Company acquired the exclusive rights to the trademark, domain name, website and domestic marketing, distribution and selling rights related to Primatene Mist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, an over-the-counter bronchodilator product, recorded at the allocated fair value of $29.2 million, which is its carrying value as of March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The trademark was determined to have an indefinite life. In determining its indefinite life, the Company considered the following: the expected use of the intangible; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Original Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Book Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Definite-lived intangible assets</i></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">IMS (UK) international product rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Patents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Land-use rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,666</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,441</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Indefinite-lived intangible assets</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Trademark</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Goodwill - Finished pharmaceutical products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"> As of March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Original Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Book Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:48.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Definite-lived intangible assets</i></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">IMS (UK) international product rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Patents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 297</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 189</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Land-use rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,587</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,137</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,450</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Indefinite-lived intangible assets</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Trademark</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Goodwill - Finished pharmaceutical products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,165</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,165</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"> As of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">*</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Intangible assets with indefinite lives have an indeterminable average life.</span></p></td></tr></table> P10Y 9640000 4499000 5141000 P12Y 486000 308000 178000 P39Y 2540000 634000 1906000 P12Y 12666000 5441000 7225000 29225000 29225000 3793000 3793000 33018000 33018000 45684000 5441000 40243000 P10Y 9561000 4223000 5338000 P12Y 486000 297000 189000 P39Y 2540000 617000 1923000 P12Y 12587000 5137000 7450000 29225000 29225000 3940000 3940000 33165000 33165000 45752000 5137000 40615000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,940</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,634</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,793</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,940</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 3940000 3634000 -147000 306000 3793000 3940000 29200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 10. Inventories</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials and supplies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,258</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,051</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,771</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,523</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Charges of $9.5 million and $2.1 million were included in the cost of revenues in the Company’s condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020, respectively, to adjust the Company’s inventory and related firm purchase commitments to their net realizable value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Losses on firm purchase commitments related to raw materials on order were $8.6 million and $2.1 million as of March 31, 2021 and 2020, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials and supplies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,258</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,051</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,771</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,523</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 43258000 47051000 35081000 37257000 18771000 12523000 97110000 96831000 9500000 2100000 8600000 2100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 11. Property, Plant, and Equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant, and equipment consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:79.99%;"><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Buildings</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,952</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,326</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,093</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,028</p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Land</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,659</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,719</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210,776</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,666</p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Furniture, fixtures, and automobiles</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,862</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,482</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,165</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,981</p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total property, plant, and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 442,507</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.77%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 444,202</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (189,242)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (184,147)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total property, plant, and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.72%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 253,265</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.77%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 260,055</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:79.99%;"><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Buildings</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,952</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,326</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,093</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,028</p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Land</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,659</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,719</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210,776</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,666</p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Furniture, fixtures, and automobiles</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,862</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,482</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,165</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,981</p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total property, plant, and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 442,507</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.77%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 444,202</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (189,242)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (184,147)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total property, plant, and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.72%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 253,265</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.77%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 260,055</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 124952000 124326000 30093000 30028000 7659000 7719000 210776000 211666000 26862000 26482000 42165000 43981000 442507000 444202000 189242000 184147000 253265000 260055000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 12. Accounts Payable and Accrued Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable and accrued liabilities consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued customer fees and rebates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,466</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,029</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,597</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued product returns, current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,676</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,190</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued loss on firm purchase commitments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,223</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued litigation and settlements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,449</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,780</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,328</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,558</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,147</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,357</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accounts payable and accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,545</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95,504</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued customer fees and rebates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,466</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,029</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,597</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued product returns, current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,676</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,190</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued loss on firm purchase commitments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,223</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued litigation and settlements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,449</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,780</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,328</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,558</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,147</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,357</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accounts payable and accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,545</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95,504</p></td></tr></table> 10466000 9029000 26742000 24597000 10676000 10190000 8625000 1223000 19449000 13780000 9600000 12328000 85558000 71147000 22987000 24357000 108545000 95504000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note</b><b style="font-weight:bold;white-space:pre-wrap;"> 13. Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:22.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Line of Credit Facilities</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Line of credit facility with China Everbright Bank due June 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 763</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 764</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Line of credit facility with China Merchant Bank due August 2021</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 382</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Line of credit facility with Bank of Nanjing due October 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Line of credit facility with Cathay Bank due May 2022</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Line of credit facility with East West Bank due December 2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment line of credit facility with East West Bank due September 2025</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,216</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,216</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Mortgage Loans</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mortgage payable with East West Bank due May 2021</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,282</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,306</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mortgage payable with East West Bank due October 2026</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,317</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mortgage payable with East West Bank due June 2027</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,472</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,510</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mortgage payable with Cathay Bank due August 2027</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,220</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,268</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Equipment Loans</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment loan with East West Bank due June 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 306</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 612</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment loan with East West Bank due December 2022</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,500</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,000</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment loan with East West Bank due February 2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,839</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,254</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Loans and Payment Obligations</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition loan with Cathay Bank due June 2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,137</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">French government loan due July 2021</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">64</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">French government loans due December 2026</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 338</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">350</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Equipment under Finance Leases</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 519</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 526</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total debt</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,507</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,449</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Less current portion of long-term debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,173</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,263</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt, net of current portion</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,334</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,186</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of March 31, 2021, the fair value of the loans listed above approximated their carrying amount. The interest rate used in the fair value estimation was determined to be a Level 2 input. For certain loans with East West Bank, the Company has entered into fixed interest rate swap contracts to exchange the variable interest rates for fixed interest rates over the life of certain debt instruments without the exchange of the underlying notional debt amount. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Covenants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At March 31, 2021 and December 31, 2020, the Company was in compliance with its debt covenants.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:22.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Line of Credit Facilities</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Line of credit facility with China Everbright Bank due June 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 763</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 764</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Line of credit facility with China Merchant Bank due August 2021</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 382</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Line of credit facility with Bank of Nanjing due October 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Line of credit facility with Cathay Bank due May 2022</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Line of credit facility with East West Bank due December 2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment line of credit facility with East West Bank due September 2025</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,216</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,216</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Mortgage Loans</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mortgage payable with East West Bank due May 2021</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,282</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,306</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mortgage payable with East West Bank due October 2026</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,317</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mortgage payable with East West Bank due June 2027</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,472</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,510</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mortgage payable with Cathay Bank due August 2027</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,220</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,268</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Equipment Loans</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment loan with East West Bank due June 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 306</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 612</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment loan with East West Bank due December 2022</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,500</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,000</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment loan with East West Bank due February 2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,839</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,254</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Loans and Payment Obligations</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition loan with Cathay Bank due June 2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,137</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">French government loan due July 2021</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">64</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">French government loans due December 2026</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 338</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">350</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Equipment under Finance Leases</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 519</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 526</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total debt</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,507</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,449</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Less current portion of long-term debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,173</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,263</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt, net of current portion</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,334</p></td><td style="vertical-align:bottom;white-space:normal;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,186</p></td><td style="vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 763000 764000 381000 382000 153000 153000 3216000 3216000 3282000 3306000 3317000 3334000 8472000 8510000 7220000 7268000 306000 612000 3500000 4000000 4839000 5254000 8137000 8710000 64000 64000 338000 350000 519000 526000 44507000 46449000 12173000 12263000 32334000 34186000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 14. Income Taxes </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table sets forth the Company’s income tax provision for the periods indicated:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:19.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income before taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,114</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,805</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,155</p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,280</p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,959</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,525</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax provision as a percentage of income before income taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39.3</p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company’s effective tax rate for the three months ended March 31, 2021 decreased in comparison to the three months ended March 31, 2020, primarily due to differences in pre-tax income positions and timing of discrete tax items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Valuation Allowance</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will be realized. Ultimately, realization depends on the existence of future taxable income. Management considers sources of taxable income such as income in prior carryback periods, future reversal of existing deferred taxable temporary differences, tax-planning strategies, and projected future taxable income. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company continues to record a full valuation allowance on the net deferred income tax assets of its subsidiaries AFP and Hanxin and will continue to do so until the subsidiaries generate sufficient taxable income to realize their respective deferred income tax assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For purposes of computing its annual effective tax rate, the Company did not benefit from its losses in the states where it files separately. This increased the Company’s income tax expense by $0.1 million and $0.2 million during the three months ended March 31, 2021 and 2020, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:19.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:19.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income before taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,114</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,805</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,155</p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,280</p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,959</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,525</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax provision as a percentage of income before income taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:normal;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39.3</p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 5114000 5805000 1155000 2280000 3959000 3525000 0.226 0.393 100000 200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note</b><b style="font-weight:bold;"> 15. Stockholders' Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Share Buyback Program</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the Company’s existing share buyback program, the Company purchased 204,698 and 646,715 shares of its common stock during the three months ended March 31, 2021 and 2020, totaling $3.8 million and $10.9 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August 2020, the Company’s Board of Directors authorized an increase of $20.0 million to the Company’s share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Purchases are made through open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the SEC and applicable laws. The timing and actual number of treasury share purchases will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. These treasury share purchases are accounted for under the cost method and are included as a component of treasury stock in the Company’s condensed consolidated balance sheets. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Amended and Restated 2015 Equity Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of March 31, 2021, the Company reserved an aggregate of 6,181,926 shares of common stock for future issuance under the Amended and Restated 2015 Equity Incentive Plan, or the 2015 Plan, including 1,187,386 shares, which were reserved in January 2021 pursuant to the evergreen provision in the 2015 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">2014 Employee Stock Purchase Plan </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of March 31, 2021, the Company has issued 807,550 shares of common stock under the ESPP and 1,192,450 shares of its common stock remains available for issuance under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the three months ended March 31, 2021 and 2020, the Company recorded ESPP expense of $0.1 million and $0.1 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Share-Based Award Activity and Balances (excluding the ANP Equity Plan)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company accounts for share-based compensation payments in accordance with ASC 718, which requires measurement and recognition of compensation expense at fair value for all share-based payment awards made to employees and directors. Under these standards, the fair value of option awards and the option components of the Employee Stock Purchase Plan awards are estimated at the grant date using the Black-Scholes option-pricing model. The fair value of RSUs is estimated at the grant date using the Company’s common share price. The portion that is ultimately expected to vest is amortized and recognized in compensation expense on a straight-line basis over the requisite service period, generally from the grant date to the vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The weighted-averages for key assumptions used in determining the fair value of options granted during the three months ended March 31, 2021 and 2020, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average expected life in years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A summary of option activity for the three months ended March 31, 2021, is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Outstanding as of December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,580,475</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,166,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (173,436)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.64</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Options cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51,506)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,854)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Outstanding as of March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,490,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercisable as of March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,588,157</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.83</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.28</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,310</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s common stock for those awards that have an exercise price below the estimated fair value at March 31, 2021.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the three months ended March 31, 2021 and 2020, the Company recorded an expense of $2.4 million and $2.6<span style="white-space:pre-wrap;"> million, respectively, related to stock options granted under all plans. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Information relating to option grants and exercises is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average grant date fair value per option share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intrinsic value of options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash received from options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,169</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,251</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total fair value of the options vested during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A summary of the status of the Company’s non-vested options as of March 31, 2021, and changes during the three months ended March 31, 2021, is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-vested as of December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,825,652</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,166,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,038,624)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.52</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51,506)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-vested as of March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,902,224</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.96</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of March 31, 2021, there was $16.3 million of total unrecognized compensation cost, net of forfeitures, related to non-vested stock option based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 3.0<span style="white-space:pre-wrap;"> years and will be adjusted for future changes in estimated forfeitures. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Restricted Stock Units</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company grants restricted stock units, or RSUs, to certain employees and members of the Board of Directors with a vesting period of up to five years. The grantee receives one share of common stock at a specified future date for each RSU awarded. The RSUs may not be sold or otherwise transferred until certificates of common stock have been issued, recorded, and delivered to the participant. The RSUs do not have any voting or dividend rights prior to the issuance of certificates of the underlying common stock. The share-based expense associated with these grants was based on the Company’s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period using the straight-line method. During the three months ended March 31, 2021 and 2020, the Company recorded expenses of $2.2 million and $2.4 million, respectively, related to RSU awards granted under all plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">As of March 31, 2021, there was </span><span style="font-size:10pt;">$17.6</span><span style="font-size:10pt;"> million of total unrecognized compensation cost, net of forfeitures, related to non-vested RSU-based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;">3.0</span><span style="font-size:10pt;"> years and will be adjusted for future changes in estimated forfeitures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Information relating to RSU grants and deliveries is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Fair Market</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value of RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">as</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,156,518</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 496,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">RSUs forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,627)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">RSUs vested<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (416,973)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs outstanding at March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,213,660</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">Of the vested RSUs, </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">161,147</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;"> shares of common stock were surrendered to fulfill tax withholding obligations.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">The 2018 ANP Equity Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2018, ANP’s board of directors approved the 2018 Plan, which is set to expire in December 2023. The 2018 Plan permits the grant of stock options and other equity awards in ANP shares to ANP employees. As of March 31, 2021, ANP granted 6,082,377 stock options to its employees under the 2018 Plan. The number of stock options outstanding as of March 31, 2021 was 5,037,280. The options vest over a period of approximately <span style="white-space:pre-wrap;">four years</span><span style="white-space:pre-wrap;"> and have up to a </span><span style="white-space:pre-wrap;">10 year</span><span style="white-space:pre-wrap;"> contractual term. For the three months ended March 31, 2021 and 2020, the Company recorded expense of $0.1 million and $0.1 million related to stock options issued by ANP under the 2018 Plan, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Share-based Compensation Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recorded share-based compensation expense, which is included in the Company’s condensed consolidated statement of operations as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,146</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,359</p></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Selling, distribution, and marketing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 127</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107</p></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,968</p></td><td style="vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,219</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 593</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 597</p></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,834</p></td><td style="vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,282</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">​</span></p> 204698 646715 3800000 10900000 20000000.0 6181926 1187386 807550 1192450 100000 100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average expected life in years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 0.422 0.430 0.013 0.008 P6Y3M18D P5Y9M18D 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Outstanding as of December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,580,475</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,166,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (173,436)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.64</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Options cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51,506)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Options expired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,854)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Outstanding as of March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,490,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercisable as of March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,588,157</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.83</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.28</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,310</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s common stock for those awards that have an exercise price below the estimated fair value at March 31, 2021.</span></td></tr></table> 8580475 15.00 1166702 17.99 173436 12.64 51506 15.67 31854 11.66 9490381 15.42 P5Y7M17D 32322000 6588157 14.83 P4Y3M10D 26310000 2400000 2600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average grant date fair value per option share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intrinsic value of options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash received from options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,169</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,251</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total fair value of the options vested during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 7.66 5.33 1029000 488000 2169000 1251000 6772000 7432000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-vested as of December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,825,652</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,166,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,038,624)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.52</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51,506)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-vested as of March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,902,224</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.96</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 2825652 6.50 1166702 7.66 1038624 6.52 51506 6.77 2902224 6.96 16300000 P3Y P5Y 1 2200000 2400000 17600000 P3Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Fair Market</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value of RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">as</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,156,518</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 496,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">RSUs forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,627)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">RSUs vested<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (416,973)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs outstanding at March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,213,660</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">Of the vested RSUs, </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">161,147</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;"> shares of common stock were surrendered to fulfill tax withholding obligations.</span></td></tr></table> 1156518 496742 8936000 22627 416973 1213660 161147 6082377 5037280 P4Y P10Y 100000 100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,146</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,359</p></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Selling, distribution, and marketing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 127</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107</p></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,968</p></td><td style="vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:normal;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,219</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 593</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 597</p></td></tr><tr><td style="vertical-align:bottom;width:78.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,834</p></td><td style="vertical-align:bottom;white-space:normal;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,282</p></td></tr></table> 1146000 1359000 127000 107000 2968000 3219000 593000 597000 4834000 5282000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note</b><b style="font-weight:bold;white-space:pre-wrap;"> 16. Employee Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">401(k) Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has a defined contribution 401(k) plan, or the Plan, whereby eligible employees voluntarily contribute up to a defined percentage of their annual compensation. The Company matches contributions at a rate of 50% on the first 6% of employee contributions, and pays the administrative costs of the Plan. Total employer contributions for the three months ended March 31, 2021 and 2020, were approximately $0.5 million and $0.5 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Defined Benefit Pension Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company’s subsidiary, AFP, has an obligation associated with a defined-benefit plan for its eligible employees. This plan provides benefits to the employees from the date of retirement and is based on the employee’s length of time employed by the Company. The calculation is based on a statistical calculation combining a number of factors that include the employee’s age, length of service, and AFP employee turnover rate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The liability under the plan is based on a discount rate of 0.30%<span style="white-space:pre-wrap;"> as of March 31, 2021 and December 31, 2020. The liability is included in accrued liabilities in the accompanying condensed consolidated balance sheets. The plan is currently unfunded, and the benefit obligation under the plan was $2.9 million and $3.0</span><span style="white-space:pre-wrap;"> million at March 31, 2021 and December 31, 2020. The Company recorded an immaterial amount of expense under the plan for the three months ended March 31, 2021 and 2020. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Deferred Compensation Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2019, the Company established a non-qualified deferred compensation plan. The deferred compensation plan allows certain eligible participants to defer a portion of their cash compensation and provides a matching contribution at the discretion of the Company. The plan obligations are payable upon retirement, termination of employment and/or certain other times in a lump-sum distribution or in installments, as elected by the participant in accordance with the plan. Participants can allocate their deferred compensation amongst various investment options with earnings accruing to the participant. The Company has established a Rabbi Trust to fund the plan obligations and to hold the plan assets. Eligible participants began contributing to the plan in January 2020. As of March 31, 2021, the plan assets and liabilities were valued at approximately $2.0 million and $2.1 million, respectively. As of December 31, 2020, the plan assets and liabilities were valued at approximately $1.6 million and $1.7 million, respectively.</p> 0.50 0.06 500000 500000 0.0030 0.0030 2900000 3000000.0 2000000.0 2100000 1600000 1700000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note</b><b style="font-weight:bold;white-space:pre-wrap;"> 17. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Purchase Commitments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of March 31, 2021, the Company has entered into commitments to purchase equipment and raw materials for an aggregate amount of approximately $52.4 million. The Company anticipates that most of these commitments with a remaining term in excess of one year will be fulfilled by 2022. </p> 52400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note</b><b style="font-weight:bold;"> 18.   Litigation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Amphastar Pharmaceuticals, Inc. v. Aventis Pharma, SA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In January 2009, the Company filed a <i style="font-style:italic;">qui tam</i> complaint in the U.S. District Court for the Central District of California, alleging that Aventis Pharma S.A., or Aventis, through its acquisition of a patent through false and misleading statements to the U.S. Patent and Trademark Office, as well as through false and misleading statements to the FDA, overcharged the federal and state governments for its Lovenox<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May 11, 2017, the Company’s lawsuit against Aventis was dismissed for lack of jurisdiction. On July 14, 2017, Aventis filed an application with the District Court for entitlement to attorneys’ fees and expenses. On November 20, 2017, the District Court issued its order granting Aventis’ application for fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On November 13, 2020, the Court issued an Order (“November Order”) awarding Aventis $12.1 million in attorneys’ fees and $0.7 million in costs and expenses, and ordered Aventis to submit updated calculations on accrued interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May 3, 2021, the Court issued a further Order based upon supplemental application to the Court seeking fees, expenses, and interest for the period after, and not covered by, the November Order. The Court awarded Aventis an additional $4.4 million bringing the total awarded Aventis to $17.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company had previously accrued $12.8 million as of December 31, 2020, based upon the November Order. As a result of the most recent ruling, the Company recorded an additional charge of $4.4 million for the three months ended March 31, 2021, in other income (expenses), in the condensed consolidated statement of operations. This amount represents management’s best estimate of the probable loss at this time. There is a reasonable possibility that the final fee award could change; however, at this time, the range of loss cannot be estimated. The Company intends to continue to vigorously defend against any imposition of attorneys’ fees and expenses in this case.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Regadenoson (0.4 mg/5 mL, 0.08 mg/mL) Patent Litigation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On February 25, 2020, Astellas US LLC, Astellas Pharma US, Inc., and Gilead Sciences, Inc. (collectively, “Astellas-Gilead”) filed a Complaint in the United States District Court for the District of Delaware against IMS for infringement of U.S. Patent Nos. 8,106,183 (the “‘183 patent”), RE47,301 (the “‘301 patent”), and 8,524,883 (the “‘883 patent”) (collectively, “Astellas-Gilead Patents”) with regard to IMS’s ANDA No. 214,252 for approval to manufacture and sell 0.4 mg/5 mL (0.08 mg/mL) intravenous solution of Regadenoson. On March 4, 2020, IMS filed its Answer and Counterclaims. On March 30, 2020, the Court issued an Order allowing the Company to join pending consolidated litigation with five other generic Regadenoson ANDA filers involving similar claims. Trial is currently scheduled for June 14, 2021. The Company’s 30-month FDA stay expires August 10, 2022. The Company intends to vigorously defend this patent lawsuit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Employee Litigation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Brenes v. International Medication Systems, Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On September 11, 2019, a former employee, Raquel Brenes, (“Brenes”), initiated an employment litigation against IMS et al. by filing a Complaint in the Superior Court of California, Los Angeles County alleging individual and class action claims for alleged violations of various California labor laws pertaining to wage and hour, and other state laws. On September 18, 2019, Brenes filed a First Amended Complaint maintaining the individual and class action claims. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On January 21, 2020, Brenes filed a Second Amended Complaint that alleges only Private Attorney General Act, or PAGA, claims and omitted the individual and class action claims. On February 9, 2021, the parties reached a settlement for $1.0 million. The settlement was approved by the Court on April 7, 2021. The Company accrued the amount of $1.0 million for this litigation as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Navarrette v. International Medication Systems, Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">On January 30, 2020, a former employee, Robert Navarrette (“Navarrette”), provided written notice, through his counsel to IMS that he intends to file a PAGA lawsuit for alleged violation of various California labor laws pertaining to wage and hour. On April 7, 2020, Navarrette filed his PAGA lawsuit against IMS and Amphastar Pharmaceuticals, Inc. in the Superior Court of California, Los Angeles County, Central District. As to IMS, the </span><i style="font-style:italic;">Brenes</i> settlement subsumes the claims of Navarrette.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><i style="font-style:italic;">Ramirez v. Amphastar Pharmaceuticals, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May 29, 2020, Priscilla Ramirez, (“Ramirez”), a former employee filed a PAGA lawsuit for alleged violations of various California labor laws pertaining to wage and hour against the Company. On April 5, 2021, the parties reached a settlement for $1.0 million. The agreement is still subject to approval by the Court. The Company accrued the amount of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">$1.0 million for this litigation as of March 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Other Litigation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company is also subject to various other claims, arbitrations, and lawsuits from time to time arising in the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In the opinion of management, the ultimate resolution of any such matters is not expected to have a material adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable and the Company’s view of these matters may change in the future. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.</p> 12100000 700000 4400000 17200000 12800000 4400000 1000000.0 1000000.0 1000000.0 1000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note</b><b style="font-weight:bold;"> 19.   Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In May 2021, the board of directors approved a plan for the restructuring of the equity ownership of ANP, whereby the Company will purchase an additional ownership interest in ANP from certain equity holders of ANP (the “Sellers”), and spin-off of certain subsidiaries of ANP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company entered into three agreements relating to the restructuring of the equity ownership of ANP and its subsidiaries and the spin-off of certain subsidiaries of ANP:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:49.5pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The Company entered into a Share Purchase Agreement, or SPA, to acquire an additional approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> of ownership interest in ANP for approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$29.4</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million from the Sellers, who had initially acquired shares in the previously disclosed July 2018 private placement, or the ANP Private Placement. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:49.5pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">ANP entered into a Share Repurchase Agreement, or SRA, with the Sellers and Nanjing Qianqia Enterprise Management Consulting LLP, or Qianqia, to issue shares in Hanxin, including Hanxin’s existing subsidiaries, Baixin and Letop, both of which will be included in the spin-off of Hanxin, in exchange for an additional approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">9%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> of ownership interest in ANP.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:49.5pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">ANP entered into a Separation Agreement with Hanxin which sets forth certain assets to be held by each entity, as well as certain responsibilities and obligations of ANP and Hanxin following completion of the spin-off.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upon completion of the restructuring, the Company will own approximately 85% of ANP, and ANP will retain approximately 20% of ownership interest in Hanxin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certain of the Sellers are the Company’s executive officers, directors and other related parties. The Sellers who are participating in the SPA include William J. Peters, Rong Zhou, Jacob Liawatidewi, Howard Lee, Richard Koo, Stephen Shohet, Henry Zhang, Qingqing Chen, Chongqing Zhang, Lu Zhang, and James Luo. Neither Dr. Mary Luo nor Dr. Jack Zhang are participating in the SPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Sellers who are participating in the SRA include Dr. Mary Luo, Dr Jack Zhang, Henry Zhang, Qingqing Chen, Chongqing Zhang, Bill Zhang, and Lu Zhang.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:14pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As part of the restructuring, the Company will terminate the 2018 ANP Equity Incentive Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 0.18 29400000 0.09 0.85 0.20 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2021
May 03, 2021
Document and Entity Information [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 001-36509  
Entity Registrant Name Amphastar Pharmaceuticals, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 33-0702205  
Entity Address, Address Line One 11570 6th Street  
Entity Address, City or Town Rancho Cucamonga  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 91730  
City Area Code 909  
Local Phone Number 980-9484  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol AMPH  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   47,635,351
Entity Central Index Key 0001297184  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current Assets:    
Cash and cash equivalents $ 101,601 $ 92,642
Restricted cash 235 1,865
Short-term investments 13,531 12,977
Restricted short-term investments 2,200 2,200
Accounts receivable, net 77,938 66,005
Inventories 97,110 96,831
Income tax refunds and deposits 800 385
Prepaid expenses and other assets 6,749 6,777
Total current assets 300,164 279,682
Property, plant, and equipment, net 253,265 260,055
Finance lease right-of-use assets 594 612
Operating lease right-of-use assets 19,280 20,042
Goodwill and intangible assets, net 40,243 40,615
Other assets 7,212 5,250
Deferred tax assets 24,980 24,980
Total assets 645,738 631,236
Current Liabilities:    
Accounts payable and accrued liabilities 108,545 95,504
Income taxes payable 2,676 1,077
Current portion of long-term debt 12,173 12,263
Current portion of operating lease liabilities 3,702 3,357
Total current liabilities 127,096 112,201
Long-term reserve for income tax liabilities 4,709 4,709
Long-term debt, net of current portion 32,334 34,186
Long-term operating lease liabilities, net of current portion 16,464 17,464
Deferred tax liabilities 755 741
Other long-term liabilities 13,420 13,212
Total liabilities 194,778 182,513
Stockholders' equity:    
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding
Common stock: par value $0.0001; 300,000,000 shares authorized; 55,184,000 and 47,718,003 shares issued and outstanding as of March 31, 2021 and 54,760,922 and 47,495,439 shares issued and outstanding as of December 31, 2020, respectively 6 5
Additional paid-in capital 413,926 410,061
Retained earnings 122,814 117,773
Accumulated other comprehensive loss (5,642) (3,721)
Treasury stock (125,546) (121,812)
Total Amphastar Pharmaceuticals, Inc. stockholders' equity 405,558 402,306
Non-controlling Interests 45,402 46,417
Total equity 450,960 448,723
Total liabilities and stockholders' equity $ 645,738 $ 631,236
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2021
Dec. 31, 2020
CONSOLIDATED BALANCE SHEETS    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock; shares authorized 300,000,000 300,000,000
Common stock; shares issued 55,184,000 54,760,922
Common stock; shares outstanding 47,718,003 47,495,439
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS    
Net revenues $ 103,020 $ 84,688
Cost of revenues 58,074 47,865
Gross profit 44,946 36,823
Operating (income) expenses:    
Selling, distribution, and marketing 4,537 3,294
General and administrative 15,338 10,746
Research and development 14,765 15,303
Total operating expenses 34,640 29,343
Income (loss) from operations 10,306 7,480
Non-operating (expenses) income:    
Interest income 161 153
Interest expense (104) (76)
Other income (expenses), net (5,249) (1,752)
Total non-operating (expenses) income, net (5,192) (1,675)
Income (loss) before income taxes 5,114 5,805
Income tax provision (benefit) 1,155 2,280
Net income (loss) 3,959 3,525
Net income (loss) attributable to non-controlling interests (1,082) (424)
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc. $ 5,041 $ 3,949
Net income (loss) per share attributable to Amphastar Pharmaceuticals, Inc. stockholders:    
Basic (in Dollars per share) $ 0.11 $ 0.09
Diluted (in Dollars per share) $ 0.10 $ 0.08
Weighted-average shares used to compute net income (loss) per share attributable to Amphastar Pharmaceuticals, Inc. stockholders:    
Basic (in Shares) 47,520 46,408
Diluted (in Shares) 49,518 48,248
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)    
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc. $ 5,041 $ 3,949
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc., net of income taxes    
Foreign currency translation adjustment (1,921) (774)
Total other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc. (1,921) (774)
Total comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc. $ 3,120 $ 3,175
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common stock
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Treasury Stock [Member]
Total Amphastar Stockholders' Equity [Member]
Non-controlling Interest [Member]
Total
Balance at Dec. 31, 2019 $ 5 $ 367,305 $ 116,370 $ (4,687) $ (97,627) $ 381,366 $ 46,162  
Balance at Dec. 31, 2019               $ 427,528
Balance at Dec. 31, 2019 52,495,483       (5,918,515)      
Changes in Stockholders' Equity                
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.     3,949     3,949   3,949
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.       (774)   (774)   (774)
Net loss attributable to non-controlling interest             (424) (424)
Treasury stock acquired         $ (10,950) (10,950)   (10,950)
Treasury stock acquired (in Shares)         (647,246)      
Issuance of treasury stock in connection with the Company's equity plans   (84)     $ 84      
Issuance of treasury stock in connection with the Company's equity plans (in Shares)         6,873      
Issuance of common stock in connection with the Company's equity plans   (1,238)       (1,238)   (1,238)
Issuance of common stock in connection with the Company's equity plans (in Shares) 369,508              
Share-based compensation expense   5,161       5,161 121 5,282
Balance at Mar. 31, 2020 $ 5 371,144 120,319 (5,461) $ (108,493) 377,514 45,859  
Balance at Mar. 31, 2020               423,373
Balance at Mar. 31, 2020 52,864,991       (6,558,888)      
Balance at Dec. 31, 2020 $ 5 410,061 117,773 (3,721) $ (121,812) 402,306 46,417 402,306
Balance at Dec. 31, 2020               $ 448,723
Balance at Dec. 31, 2020 54,760,922       (7,265,483)     47,495,439
Changes in Stockholders' Equity                
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.     5,041     5,041   $ 5,041
Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.       (1,921)   (1,921)   (1,921)
Net loss attributable to non-controlling interest             (1,082) (1,082)
Treasury stock acquired         $ (3,783) (3,783)   (3,783)
Treasury stock acquired (in Shares)         (204,698)      
Issuance of treasury stock in connection with the Company's equity plans   (49)     $ 49      
Issuance of treasury stock in connection with the Company's equity plans (in Shares)         4,184      
Issuance of common stock in connection with the Company's equity plans $ 1 (853)       (852)   (852)
Issuance of common stock in connection with the Company's equity plans (in Shares) 423,078              
Share-based compensation expense   4,767       4,767 67 4,834
Balance at Mar. 31, 2021 $ 6 $ 413,926 $ 122,814 $ (5,642) $ (125,546) $ 405,558 $ 45,402 405,558
Balance at Mar. 31, 2021               $ 450,960
Balance at Mar. 31, 2021 55,184,000       (7,465,997)     47,718,003
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash Flows From Operating Activities:    
Net income (loss) $ 3,959 $ 3,525
Reconciliation to net cash provided by operating activities:    
Loss (gain) on impairment and disposal of assets 6 14
Depreciation of property, plant, and equipment 5,686 4,716
Amortization of product rights, trademarks, and patents 276 258
Operating lease right-of-use asset amortization 863 848
Share-based compensation 4,834 5,282
Changes in deferred taxes, net   1,638
Changes in operating assets and liabilities:    
Accounts receivable, net (12,078) (12,487)
Inventories (1,144) 2,241
Prepaid expenses and other assets 1,119 1,494
Income tax refunds, deposits, and payables, net 1,182 451
Operating lease liabilities (754) (824)
Accounts payable and accrued liabilities 18,876 (5,679)
Net cash provided by operating activities 22,825 1,477
Cash Flows From Investing Activities:    
Purchases and construction of property, plant, and equipment (7,618) (8,006)
Sales of short-term investments, net   21
Purchase of short-term investments (4,501) (4,561)
Maturity of short-term investments 3,944 4,030
Payment of deposits and other assets (520) (206)
Net cash used in investing activities (8,695) (8,722)
Cash Flows From Financing Activities:    
Proceeds from equity plans, net of withholding tax payments (854) (1,238)
Purchase of treasury stock (3,783) (10,950)
Proceeds from issuance of long-term debt   3,067
Principal payments on long-term debt (2,002) (2,328)
Net cash provided by (used in) financing activities (6,639) (11,449)
Effect of exchange rate changes on cash (162) (146)
Net increase (decrease) in cash, cash equivalents and restricted cash 7,329 (18,840)
Cash, cash equivalents, and restricted cash at beginning of period 94,507 75,550
Cash, cash equivalents, and restricted cash at end of period 101,836 56,710
Noncash Investing and Financing Activities:    
Capital expenditure included in accounts payable 6,238 5,840
Operating lease right-of-use assets 103  
Equipment acquired under finance leases 74  
Supplemental Disclosures of Cash Flow Information:    
Interest paid, net of capitalized interest 508 559
Income taxes paid $ 30 $ 209
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.1
General
3 Months Ended
Mar. 31, 2021
General  
General

Note 1. General

Amphastar Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, hereinafter referred to as the “Company”) is a bio-pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products, including products with high technical barriers to market entry. Additionally, the Company sells insulin active pharmaceutical ingredient, or API, products. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company’s insulin API products are sold to other pharmaceutical companies for use in their own products and are being used by the Company in the development of injectable finished pharmaceutical products. The Company’s inhalation product, Primatene Mist® is primarily distributed through drug retailers.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2020 and the notes thereto as filed with the Securities and Exchange Commission, or SEC, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles, or GAAP, have been condensed or omitted from the accompanying condensed consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from the audited financial statements. The accompanying interim financial statements are unaudited, but reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the Company’s consolidated financial position, results of operations, comprehensive income (loss), stockholders’ equity, and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. The Company’s results of operations, comprehensive income (loss) and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2021
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with United States generally accepted accounting principles, or GAAP. Certain prior period amounts have been reclassified within the investing activities of the statement of cash flows to conform to the current period presentation. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.

The Company’s subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals, Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Nanjing Letop Biological Technology Co., Ltd., or Letop, (5) Nanjing Hanxin Pharmaceutical Technology Co., Ltd., or Hanxin, (6) Nanjing Hanxin Biomedical Testing Service Co., Ltd., or Hanxin Biomedical, (7) Nanjing Baixin Trading Co., Ltd., or Baixin, (8) Amphastar France Pharmaceuticals, S.A.S., or AFP, (9) Amphastar UK Ltd., or AUK, and (10) International Medication Systems (UK) Limited, or IMS UK.

In July 2018, the Company’s Chinese subsidiary, ANP, completed a private placement of its common equity interest to accredited investors and received approximately $56.3 million of cash proceeds, a portion of which was received in 2019. The Company has retained approximately 58% of the equity interest in ANP following the private placement and continues to consolidate the financial results of ANP with the Company’s results of operations. ANP’s net income after July 2, 2018, was attributed to the Company in accordance with the Company’s equity interest of approximately 58% in ANP.

COVID-19 Pandemic

The Company is subject to risks and uncertainties as a result of the ongoing novel coronavirus pandemic, or COVID-19. The complete extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the information is constantly evolving. The Company considered the impact of COVID-19 on the assumptions and estimates used to determine the results reported and asset valuations as of March 31, 2021.

All of the Company’s production facilities continued to operate during the quarter as they had prior to the COVID-19 pandemic with very little change, other than for enhanced safety measures intended to prevent the spread of the virus.

It is not possible at this time to estimate the complete impact that COVID-19 could have on the Company’s business, including its customers and suppliers, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. The Company will continue to monitor the impact of COVID-19 on all aspects of its business.

Use of Estimates

The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for credit losses, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to their net realizable values, impairment of long-lived and intangible assets and goodwill, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.

Foreign Currency

The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the US Dollar. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company’s condensed consolidated statements of operations.

The Company’s French subsidiary, AFP, maintains its book of record in euros. ANP’s subsidiaries maintain their books of record in Chinese yuan. AUK’s subsidiary, IMS UK, maintains its book of record in British pounds. These local currencies have been determined to be the subsidiaries’ respective functional currencies. These books of record are translated into USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other accumulated comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature for the three months ended March 31, 2021 and 2020 were $1.5 million loss and $0.6 million loss, respectively.

Comprehensive Income (Loss)

For the three months ended March 31, 2021 and 2020, the Company included its foreign currency translation gain or loss as part of its comprehensive income (loss). No income tax expense (benefit) was allocated to other comprehensive income (loss) for the three months ended March 31, 2021 and 2020.

Advertising Expense

Advertising expenses, primarily associated with Primatene Mist®, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Company’s condensed consolidated statement of operations. For the three months ended March 31, 2021 and 2020, advertising expense was $2.2 million and $1.0 million, respectively.

Financial Instruments

The carrying amounts of cash and cash equivalents, short-term investments, restricted cash and short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. The majority of the Company’s long-term obligations consist of variable rate debt, and their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. The Company at times enters into fixed interest rate swap contracts to exchange the variable interest rates for fixed interest rates without the exchange of the underlying notional debt amounts. Such interest rate swap contracts are recorded at their fair values.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments purchased with original maturities of three months or less.

Short-Term Investments

Short-term investments as of March 31, 2021 and December 31, 2020 consisted of certificates of deposit and investment grade debt securities with original expiration dates within 12 months.

Restricted Cash

Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of March 31, 2021 and December 31, 2020, the restricted cash balance was $0.2 million and $1.9 million, respectively.

Restricted Short-Term Investments

Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workers’ compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of March 31, 2021 and December 31, 2020, the balance of restricted short-term investments was $2.2 million.

Deferred Income Taxes

The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized.

Recent Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU,

No. 2019-12 Simplifying the Accounting for Income Taxes (Topic 740). The amendment removes certain exceptions for performing intra-period tax allocations, recognizing deferred taxes for investment, and calculating income taxes in interim periods. The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods. The guidance is effective for the Company’s interim and annual reporting periods during the year ended December 31, 2021. The adoption of this accounting guidance did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition
3 Months Ended
Mar. 31, 2021
Revenue Recognition  
Revenue Recognition

Note 3. Revenue Recognition

In accordance with Accounting Standard Codification, or ASC, 606 Revenue from Contracts with Customers, revenue is recognized at the time that the Company’s customers obtain control of the promised goods.

Generally, revenue is recognized at the time of product delivery to the Company’s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements.

The consideration the Company receives in exchange for its goods or services is only recognized when it is probable that a significant reversal will not occur. The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration. The Company makes significant estimates for related variable consideration at the point of sale, including chargebacks, rebates, product returns, other discounts and allowances.

The Company’s payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customers, but payment is generally required in a term ranging from 30 to 75 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.

Provisions for estimated chargebacks, rebates, discounts, product returns and credit losses are made at the time of sale and are analyzed and adjusted, if necessary, at each balance sheet date.

Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers, and after the customer has accepted test samples of the products to be shipped.

The Company’s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. The Company does not have any revenue arrangements with multiple performance obligations.

Provision for Chargebacks and Rebates

The provision for chargebacks and rebates is a significant estimate used in the recognition of revenue. Wholesaler chargebacks relate to sales terms under which the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products that wholesalers resell under the Company’s various contractual arrangements with third parties such as hospitals and group purchasing organizations in the United States. Rebates include primarily amounts paid to retailers, payers, and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements. The Company estimates chargebacks and rebates using the expected value method at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback and rebate rates, and current contract pricing.

The provision for chargebacks and rebates is reflected as a component of net revenues. The following table is an analysis of the chargeback and rebate provision:

Three Months Ended

 

March 31, 

2021

2020

 

(in thousands)

 

Beginning balance

    

$

20,380

    

$

21,644

Provision for chargebacks and rebates

 

47,031

 

35,987

Credits and payments issued to third parties

 

(46,881)

 

(39,353)

Ending balance

$

20,530

$

18,278

Changes in the chargeback provision from period to period are primarily dependent on the Company’s sales to its wholesalers, the level of inventory held by wholesalers, and the wholesalers’ customer mix. Changes in the rebate provision from period to period are primarily dependent on retailer’s and other indirect customers’ purchases. The approach that the Company uses to estimate chargebacks has been consistently applied for all periods presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and rebates and makes adjustments when it believes that the actual chargebacks and rebates may differ from the estimates. The settlement of chargebacks and rebates generally occurs within 30 days to 60 days after the sale to wholesalers. Accounts receivable and/or accounts payable and accrued liabilities are reduced and/or increased by the chargebacks and rebate amounts depending on whether the Company has the right to offset with the customer. Of the provision for chargebacks and rebates as of March 31, 2021 and December 31, 2020, $16.4 million and $16.4 million were included in accounts receivable, net, on the condensed consolidated balance sheets, respectively. The remaining provision as of March 31, 2021 and December 31, 2020 of $4.1 million and $4.0 million, respectively, were included in accounts payable and accrued liabilities.

Accrual for Product Returns

The Company offers most customers the right to return qualified excess or expired inventory for partial credit; however, API product sales are generally non-returnable. The Company’s product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for product returns estimated using the expected value method. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and the introduction of new competition. Although these factors do not normally give the Company’s customers the right to return products outside of the regular return policy, the Company realizes that such factors could ultimately lead to increased returns. The Company analyzes these situations on a case-by-case basis and makes adjustments to the product return reserve as appropriate.

The provision for product returns is reflected as a component of net revenues. The following table is an analysis of the product return liability:

Three Months Ended

 

March 31, 

2021

2020

 

(in thousands)

 

Beginning balance

    

$

14,204

    

$

10,339

Provision for product returns

 

3,233

 

3,099

Credits issued to third parties

 

(2,517)

 

(2,239)

Ending balance

$

14,920

$

11,199

Of the provision for product returns as of March 31, 2021 and December 31, 2020, $10.7 million and $10.2 million, were included in accounts payable and accrued liabilities on the condensed consolidated balance sheets, respectively. The remaining provision as of March 31, 2021 and December 31, 2020 of $4.2 million and $4.0 million, respectively, were included in other long-term liabilities. For the three months ended March 31, 2021 and 2020, the Company’s aggregate product return rate was 1.4% and 1.1% of qualified sales, respectively.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders
3 Months Ended
Mar. 31, 2021
Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders  
Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders

Note 4. Income per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders

Basic net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders gives effect to all potential dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Company’s Employee Stock Purchase Plan, or ESPP and the reallocation of net income attributable to non-controlling interest from the assumed dilutive effect of stock options issued under the 2018 ANP Equity Incentive Plan, or the 2018 Plan.

For the three months ended March 31, 2021, options to purchase 1,899,833 shares of stock with a weighted-average exercise price of $20.85 per share, and the reallocation of net income attributable to non-controlling interests were excluded in the computation of diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders because the effect would be anti-dilutive.

For the three months ended March 31, 2020, options to purchase 1,999,083 shares of stock with a weighted-average exercise price of $20.81 per share, and the reallocation of net income attributable to non-controlling interest were excluded in the computation of diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders because the effect would be anti-dilutive.

The following table provides the calculation of basic and diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders for each of the periods presented:

Three Months Ended

March 31, 

2021

2020

(in thousands, except per share data)

Basic and dilutive numerator:

    

    

    

    

 

Net income attributable to Amphastar Pharmaceuticals, Inc.

$

5,041

$

3,949

Denominator:

Weighted-average shares outstanding — basic

 

47,520

 

46,408

Net effect of dilutive securities:

Incremental shares from equity awards

 

1,998

 

1,840

Weighted-average shares outstanding — diluted

 

49,518

 

48,248

Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — basic

$

0.11

$

0.09

Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — diluted

$

0.10

$

0.08

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting
3 Months Ended
Mar. 31, 2021
Segment Reporting  
Segment Reporting

Note 5. Segment Reporting

The Company’s business is the development, manufacture, and marketing of pharmaceutical products. The Company has identified two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC

280, Segment Reporting. The Company’s performance is assessed and resources are allocated by the CODM based on the following two reportable segments:

Finished pharmaceutical products
API

The finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.

Selected financial information by reporting segment is presented below:

Three Months Ended

March 31, 

2021

2020

(in thousands)

Net revenues:

    

    

    

    

 

Finished pharmaceutical products

$

97,882

$

81,298

API

 

5,138

3,390

Total net revenues

 

103,020

 

84,688

Gross profit (loss):

Finished pharmaceutical products

 

45,286

 

38,810

API

 

(340)

(1,987)

Total gross profit

 

44,946

 

36,823

Operating expenses

 

34,640

 

29,343

Income from operations

 

10,306

 

7,480

Non-operating expense

 

(5,192)

 

(1,675)

Income before income taxes

$

5,114

$

5,805

The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. The Company does not identify total assets by segment for internal purposes, as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

The amount of net revenues in the finished pharmaceutical product segment is presented below:

Three Months Ended

March 31, 

2021

2020

(in thousands)

Finished pharmaceutical products net revenues:

    

    

    

    

 

Primatene Mist®

$

18,383

$

12,877

Epinephrine

15,578

3,990

Enoxaparin

10,658

9,168

Phytonadione

 

9,565

 

11,029

Lidocaine

9,071

10,657

Glucagon

7,984

Naloxone

6,341

8,875

Other finished pharmaceutical products

 

20,302

 

24,702

Total finished pharmaceutical products net revenues

$

97,882

$

81,298

The amount of depreciation and amortization expense included in cost of revenues, by reporting segments is presented below:

Three Months Ended

March 31, 

2021

2020

(in thousands)

Depreciation and amortization expense

    

    

    

    

 

Finished pharmaceutical products

$

1,435

$

1,464

API

 

1,048

 

582

Total depreciation and amortization expense

$

2,483

$

2,046

Net revenues and carrying values of long-lived assets by geographic regions are as follows:

Net Revenue

Long-Lived Assets

 

Three Months Ended

 

March 31, 

March 31, 

December 31, 

2021

2020

2021

2020

 

(in thousands)

 

United States

    

$

99,170

    

$

81,065

    

$

125,861

    

$

129,401

China

 

1,121

228

 

97,847

 

98,538

France

 

2,729

3,395

 

49,431

 

52,770

Total

$

103,020

$

84,688

$

273,139

$

280,709

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Customer and Supplier Concentration
3 Months Ended
Mar. 31, 2021
Customer and Supplier Concentration  
Customer and Supplier Concentration

Note 6. Customer and Supplier Concentration

Customer Concentrations

Three large wholesale drug distributors, AmerisourceBergen Corporation, or AmerisourceBergen, Cardinal Health, Inc., or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. The Company considers these three customers to be its major customers, as each individually, and these customers collectively, represented a significant percentage of the Company’s net revenue for the three months ended March 31, 2021 and 2020 and accounts receivable as of March 31, 2021 and

December 31, 2020, respectively. The following table provides accounts receivable and net revenue information for these major customers:

% of Total Accounts

% of Net

Receivable

Revenue

Three Months Ended

March 31, 

December 31, 

March 31, 

    

2021

    

2020

    

2021

    

2020

    

AmerisourceBergen

 

14

%

9

%

25

%

24

%

McKesson

 

21

%

24

%

20

%

22

%

Cardinal Health

 

16

%

17

%

15

%

19

%

Supplier Concentrations

The Company depends on suppliers for raw materials, APIs, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Company’s business, financial condition, and results of operations.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2021
Fair Value Measurements  
Fair Value Measurements

Note 7. Fair Value Measurements

GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below:

Level 1 – Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities;

Level 2 – Inputs to measure fair value are based on the following: a) quoted prices in active markets on similar assets or liabilities, b) quoted prices for identical or similar instruments in inactive markets, or c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; and

Level 3 – Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on best information available in the circumstances.

As of March 31, 2021, cash equivalents include money market accounts. Short-term investments consist of certificates of deposit as well as investment-grade corporate and municipal bonds with original expiration dates within 12 months. The certificates of deposit are carried at amortized cost in the Company’s condensed consolidated balance sheet, which approximates their fair value determined based on Level 2 inputs. The corporate and municipal bonds are classified as held-to-maturity and are carried at amortized cost net of allowance for credit losses, which approximates their fair value determined based on Level 2 inputs. The restrictions on restricted cash and short-term investments have a negligible effect on the fair value of these financial assets.

The fair value of the Company’s financial assets and liabilities measured on a recurring basis as of March 31, 2021 and December 31, 2020, are as follows:

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

 

(in thousands)

 

Cash equivalents - money market

$

76,536

$

76,536

$

$

Restricted cash - money market

235

235

Short-term investments - certificates of deposit

9,284

9,284

Restricted short-term investments - certificates of deposit

 

2,200

 

 

2,200

 

Corporate and municipal bonds

4,199

4,199

Interest rate swap liabilities related to variable rate loans

(723)

(723)

Fair value measurement as of March 31, 2021

$

91,731

$

76,771

$

14,960

$

Cash equivalents - money market

$

58,710

$

58,710

$

$

Restricted cash - money market

1,865

1,865

Short-term investments - certificates of deposit

9,089

9,089

Restricted short-term investments - certificates of deposit

 

2,200

 

 

2,200

 

Corporate and municipal bonds

3,855

3,855

Interest rate swap liabilities related to variable rate loans

(902)

(902)

Fair value measurement as of December 31, 2020

$

74,817

$

60,575

$

14,242

$

The Company does not hold any Level 3 instruments that are measured at fair value on a recurring basis.

Nonfinancial assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include long-lived assets, goodwill, and intangible assets for which the fair value of assets is determined as part of the related impairment test. As of March 31, 2021 and December 31, 2020, there were no significant adjustments to fair value for nonfinancial assets or liabilities.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Investments
3 Months Ended
Mar. 31, 2021
Investments  
Investments

Note 8. Investments

A summary of the Company’s investments that are classified as held-to-maturity are as follows:

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

    

Cost

    

Gains

    

Losses

    

Value

(in thousands)

Corporate bonds

$

1,053

$

$

(1)

$

1,052

Municipal bonds

3,148

(1)

3,147

Total investments as of March 31, 2021

$

4,201

$

$

(2)

$

4,199

Corporate bonds

$

1,560

$

$

(1)

$

1,559

Municipal bonds

2,297

(1)

2,296

Total investments as of December 31, 2020

$

3,857

$

$

(2)

$

3,855

At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting neither a significant deterioration since purchase nor any other factors that would indicate a material credit loss.

The Company measures expected credit losses on held-to-maturity investments on a collective basis. All the Company’s held-to-maturity investments were considered to be one pool. The estimate for credit losses considers historical loss

information that is adjusted for current conditions and reasonable and supportable forecasts. Expected credit losses on held-to-maturity investments were not material to the condensed consolidated financial statements.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Intangible Assets
3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets  
Goodwill and Intangible Assets

Note 9. Goodwill and Intangible Assets

The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification:

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

IMS (UK) international product rights

10

$

9,640

$

4,499

$

5,141

Patents

 

12

 

486

308

 

178

Land-use rights

 

39

 

2,540

634

 

1,906

Subtotal

 

12

 

12,666

 

5,441

 

7,225

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,793

 

 

3,793

Subtotal

 

*

 

33,018

 

 

33,018

As of March 31, 2021

 

*

$

45,684

$

5,441

$

40,243

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

IMS (UK) international product rights

10

$

9,561

$

4,223

$

5,338

Patents

 

12

 

486

297

 

189

Land-use rights

 

39

 

2,540

617

 

1,923

Subtotal

 

12

 

12,587

 

5,137

 

7,450

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,940

 

 

3,940

Subtotal

 

*

 

33,165

 

 

33,165

As of December 31, 2020

 

*

$

45,752

$

5,137

$

40,615

*

Intangible assets with indefinite lives have an indeterminable average life.

Goodwill

The changes in the carrying amounts of goodwill were as follows:

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Beginning balance

    

$

3,940

    

$

3,634

Currency translation

 

(147)

 

306

Ending balance

$

3,793

$

3,940

Primatene® Trademark

In January 2009, the Company acquired the exclusive rights to the trademark, domain name, website and domestic marketing, distribution and selling rights related to Primatene Mist®, an over-the-counter bronchodilator product, recorded at the allocated fair value of $29.2 million, which is its carrying value as of March 31, 2021.

The trademark was determined to have an indefinite life. In determining its indefinite life, the Company considered the following: the expected use of the intangible; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Inventories
3 Months Ended
Mar. 31, 2021
Inventories  
Inventories

Note 10. Inventories

Inventories consist of the following:

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Raw materials and supplies

    

$

43,258

    

$

47,051

Work in process

 

35,081

 

37,257

Finished goods

 

18,771

 

12,523

Total inventories

$

97,110

$

96,831

Charges of $9.5 million and $2.1 million were included in the cost of revenues in the Company’s condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020, respectively, to adjust the Company’s inventory and related firm purchase commitments to their net realizable value.

Losses on firm purchase commitments related to raw materials on order were $8.6 million and $2.1 million as of March 31, 2021 and 2020, respectively.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant, and Equipment
3 Months Ended
Mar. 31, 2021
Property, Plant, and Equipment  
Property, Plant, and Equipment

Note 11. Property, Plant, and Equipment

Property, plant, and equipment consist of the following:

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Buildings

    

$

124,952

    

$

124,326

Leasehold improvements

 

30,093

 

30,028

Land

 

7,659

 

7,719

Machinery and equipment

 

210,776

 

211,666

Furniture, fixtures, and automobiles

 

26,862

 

26,482

Construction in progress

 

42,165

 

43,981

Total property, plant, and equipment

 

442,507

 

444,202

Less accumulated depreciation

 

(189,242)

 

(184,147)

Total property, plant, and equipment, net

$

253,265

$

260,055

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Accounts Payable and Accrued Liabilities
3 Months Ended
Mar. 31, 2021
Accounts Payable and Accrued Liabilities.  
Accounts Payable and Accrued Liabilities

Note 12. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following:

March 31, 

December 31, 

2021

2020

(in thousands)

Accrued customer fees and rebates

$

10,466

$

9,029

Accrued payroll and related benefits

26,742

24,597

Accrued product returns, current portion

10,676

10,190

Accrued loss on firm purchase commitments

8,625

1,223

Accrued litigation and settlements

19,449

13,780

Other accrued liabilities

9,600

12,328

Total accrued liabilities

 

85,558

 

71,147

Accounts payable

 

22,987

 

24,357

Total accounts payable and accrued liabilities

$

108,545

$

95,504

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Debt
3 Months Ended
Mar. 31, 2021
Debt  
Debt

Note 13. Debt

Debt consists of the following:

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Line of Credit Facilities

    

    

    

    

Line of credit facility with China Everbright Bank due June 2021

$

763

$

764

Line of credit facility with China Merchant Bank due August 2021

381

382

Line of credit facility with Bank of Nanjing due October 2021

153

153

Line of credit facility with Cathay Bank due May 2022

 

 

Line of credit facility with East West Bank due December 2022

Equipment line of credit facility with East West Bank due September 2025

3,216

3,216

Mortgage Loans

Mortgage payable with East West Bank due May 2021

3,282

3,306

Mortgage payable with East West Bank due October 2026

3,317

3,334

Mortgage payable with East West Bank due June 2027

8,472

8,510

Mortgage payable with Cathay Bank due August 2027

 

7,220

 

7,268

Equipment Loans

Equipment loan with East West Bank due June 2021

306

612

Equipment loan with East West Bank due December 2022

3,500

4,000

Equipment loan with East West Bank due February 2024

4,839

5,254

Other Loans and Payment Obligations

Acquisition loan with Cathay Bank due June 2024

 

8,137

 

8,710

French government loan due July 2021

64

64

French government loans due December 2026

338

350

Equipment under Finance Leases

 

519

 

526

Total debt

 

44,507

 

46,449

Less current portion of long-term debt

 

12,173

 

12,263

Long-term debt, net of current portion

$

32,334

$

34,186

As of March 31, 2021, the fair value of the loans listed above approximated their carrying amount. The interest rate used in the fair value estimation was determined to be a Level 2 input. For certain loans with East West Bank, the Company has entered into fixed interest rate swap contracts to exchange the variable interest rates for fixed interest rates over the life of certain debt instruments without the exchange of the underlying notional debt amount.

Covenants

At March 31, 2021 and December 31, 2020, the Company was in compliance with its debt covenants.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes
3 Months Ended
Mar. 31, 2021
Income Taxes  
Income Taxes

Note 14. Income Taxes

The following table sets forth the Company’s income tax provision for the periods indicated:

Three Months Ended

March 31, 

    

2021

    

2020

    

(in thousands)

Income before taxes

$

5,114

$

5,805

Income tax provision

1,155

 

2,280

Net income

$

3,959

$

3,525

Income tax provision as a percentage of income before income taxes

22.6

%

 

39.3

%

The Company’s effective tax rate for the three months ended March 31, 2021 decreased in comparison to the three months ended March 31, 2020, primarily due to differences in pre-tax income positions and timing of discrete tax items.

Valuation Allowance

In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will be realized. Ultimately, realization depends on the existence of future taxable income. Management considers sources of taxable income such as income in prior carryback periods, future reversal of existing deferred taxable temporary differences, tax-planning strategies, and projected future taxable income.

The Company continues to record a full valuation allowance on the net deferred income tax assets of its subsidiaries AFP and Hanxin and will continue to do so until the subsidiaries generate sufficient taxable income to realize their respective deferred income tax assets.

For purposes of computing its annual effective tax rate, the Company did not benefit from its losses in the states where it files separately. This increased the Company’s income tax expense by $0.1 million and $0.2 million during the three months ended March 31, 2021 and 2020, respectively.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2021
Stockholders' Equity  
Stockholders' Equity

Note 15. Stockholders' Equity

Share Buyback Program

Pursuant to the Company’s existing share buyback program, the Company purchased 204,698 and 646,715 shares of its common stock during the three months ended March 31, 2021 and 2020, totaling $3.8 million and $10.9 million, respectively.

In August 2020, the Company’s Board of Directors authorized an increase of $20.0 million to the Company’s share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs.

Purchases are made through open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the SEC and applicable laws. The timing and actual number of treasury share purchases will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. These treasury share purchases are accounted for under the cost method and are included as a component of treasury stock in the Company’s condensed consolidated balance sheets.

Amended and Restated 2015 Equity Incentive Plan

As of March 31, 2021, the Company reserved an aggregate of 6,181,926 shares of common stock for future issuance under the Amended and Restated 2015 Equity Incentive Plan, or the 2015 Plan, including 1,187,386 shares, which were reserved in January 2021 pursuant to the evergreen provision in the 2015 Plan.

2014 Employee Stock Purchase Plan

As of March 31, 2021, the Company has issued 807,550 shares of common stock under the ESPP and 1,192,450 shares of its common stock remains available for issuance under the ESPP.

For the three months ended March 31, 2021 and 2020, the Company recorded ESPP expense of $0.1 million and $0.1 million, respectively.

Share-Based Award Activity and Balances (excluding the ANP Equity Plan)

The Company accounts for share-based compensation payments in accordance with ASC 718, which requires measurement and recognition of compensation expense at fair value for all share-based payment awards made to employees and directors. Under these standards, the fair value of option awards and the option components of the Employee Stock Purchase Plan awards are estimated at the grant date using the Black-Scholes option-pricing model. The fair value of RSUs is estimated at the grant date using the Company’s common share price. The portion that is ultimately expected to vest is amortized and recognized in compensation expense on a straight-line basis over the requisite service period, generally from the grant date to the vesting date.

The weighted-averages for key assumptions used in determining the fair value of options granted during the three months ended March 31, 2021 and 2020, are as follows:

Three Months Ended

March 31, 

    

2021

    

2020

    

Average volatility

 

42.2

%  

43.0

%  

Average risk-free interest rate

 

1.3

%  

0.8

%  

Weighted-average expected life in years

 

6.3

5.8

Dividend yield rate

 

%  

%  

A summary of option activity for the three months ended March 31, 2021, is presented below:

Weighted-Average

 

Weighted-Average

Remaining

Aggregate

 

Exercise

Contractual

Intrinsic

 

Options

Price

Term (Years)

Value(1)

 

(in thousands)

 

Outstanding as of December 31, 2020

    

8,580,475

    

$

15.00

    

    

    

    

Options granted

 

1,166,702

 

17.99

Options exercised

 

(173,436)

 

12.64

Options cancelled

 

(51,506)

 

15.67

Options expired

 

(31,854)

 

11.66

Outstanding as of March 31, 2021

 

9,490,381

$

15.42

 

5.63

$

32,322

Exercisable as of March 31, 2021

 

6,588,157

$

14.83

 

4.28

$

26,310

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s common stock for those awards that have an exercise price below the estimated fair value at March 31, 2021.

For the three months ended March 31, 2021 and 2020, the Company recorded an expense of $2.4 million and $2.6 million, respectively, related to stock options granted under all plans.

Information relating to option grants and exercises is as follows:

Three Months Ended

 

March 31, 

    

2021

    

2020

 

(in thousands, except per share data)

 

Weighted-average grant date fair value per option share

$

7.66

$

5.33

Intrinsic value of options exercised

 

1,029

 

488

Cash received from options exercised

 

2,169

 

1,251

Total fair value of the options vested during the year

 

6,772

 

7,432

A summary of the status of the Company’s non-vested options as of March 31, 2021, and changes during the three months ended March 31, 2021, is presented below:

    

    

Weighted-Average

 

Grant Date

 

Options

Fair Value

 

Non-vested as of December 31, 2020

2,825,652

$

6.50

Options granted

 

1,166,702

7.66

Options vested

 

(1,038,624)

6.52

Options forfeited

 

(51,506)

6.77

Non-vested as of March 31, 2021

 

2,902,224

 

6.96

As of March 31, 2021, there was $16.3 million of total unrecognized compensation cost, net of forfeitures, related to non-vested stock option based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 3.0 years and will be adjusted for future changes in estimated forfeitures.

Restricted Stock Units

The Company grants restricted stock units, or RSUs, to certain employees and members of the Board of Directors with a vesting period of up to five years. The grantee receives one share of common stock at a specified future date for each RSU awarded. The RSUs may not be sold or otherwise transferred until certificates of common stock have been issued, recorded, and delivered to the participant. The RSUs do not have any voting or dividend rights prior to the issuance of certificates of the underlying common stock. The share-based expense associated with these grants was based on the Company’s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period using the straight-line method. During the three months ended March 31, 2021 and 2020, the Company recorded expenses of $2.2 million and $2.4 million, respectively, related to RSU awards granted under all plans.

As of March 31, 2021, there was $17.6 million of total unrecognized compensation cost, net of forfeitures, related to non-vested RSU-based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 3.0 years and will be adjusted for future changes in estimated forfeitures.

Information relating to RSU grants and deliveries is as follows:

Total Fair Market

 

Value of RSUs

 

Issued

 

Total RSUs

as

 

    

Issued

    

Compensation(1)

 

(in thousands)

 

RSUs outstanding at December 31, 2020

 

1,156,518

RSUs granted

 

496,742

$

8,936

RSUs forfeited

 

(22,627)

RSUs vested(2)

 

(416,973)

RSUs outstanding at March 31, 2021

 

1,213,660

(1)The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.
(2)Of the vested RSUs, 161,147 shares of common stock were surrendered to fulfill tax withholding obligations.

The 2018 ANP Equity Incentive Plan

In December 2018, ANP’s board of directors approved the 2018 Plan, which is set to expire in December 2023. The 2018 Plan permits the grant of stock options and other equity awards in ANP shares to ANP employees. As of March 31, 2021, ANP granted 6,082,377 stock options to its employees under the 2018 Plan. The number of stock options outstanding as of March 31, 2021 was 5,037,280. The options vest over a period of approximately four years and have up to a 10 year contractual term. For the three months ended March 31, 2021 and 2020, the Company recorded expense of $0.1 million and $0.1 million related to stock options issued by ANP under the 2018 Plan, respectively.

Share-based Compensation Expense

The Company recorded share-based compensation expense, which is included in the Company’s condensed consolidated statement of operations as follows:

Three Months Ended

March 31, 

2021

2020

(in thousands)

Cost of revenues

    

$

1,146

    

$

1,359

Operating expenses:

Selling, distribution, and marketing

 

127

 

107

General and administrative

 

2,968

 

3,219

Research and development

 

593

 

597

Total share-based compensation

$

4,834

$

5,282

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Employee Benefits
3 Months Ended
Mar. 31, 2021
Employee Benefits  
Employee Benefits

Note 16. Employee Benefits

401(k) Plan

The Company has a defined contribution 401(k) plan, or the Plan, whereby eligible employees voluntarily contribute up to a defined percentage of their annual compensation. The Company matches contributions at a rate of 50% on the first 6% of employee contributions, and pays the administrative costs of the Plan. Total employer contributions for the three months ended March 31, 2021 and 2020, were approximately $0.5 million and $0.5 million, respectively.

Defined Benefit Pension Plan

The Company’s subsidiary, AFP, has an obligation associated with a defined-benefit plan for its eligible employees. This plan provides benefits to the employees from the date of retirement and is based on the employee’s length of time employed by the Company. The calculation is based on a statistical calculation combining a number of factors that include the employee’s age, length of service, and AFP employee turnover rate.

The liability under the plan is based on a discount rate of 0.30% as of March 31, 2021 and December 31, 2020. The liability is included in accrued liabilities in the accompanying condensed consolidated balance sheets. The plan is currently unfunded, and the benefit obligation under the plan was $2.9 million and $3.0 million at March 31, 2021 and December 31, 2020. The Company recorded an immaterial amount of expense under the plan for the three months ended March 31, 2021 and 2020.

Deferred Compensation Plan

In December 2019, the Company established a non-qualified deferred compensation plan. The deferred compensation plan allows certain eligible participants to defer a portion of their cash compensation and provides a matching contribution at the discretion of the Company. The plan obligations are payable upon retirement, termination of employment and/or certain other times in a lump-sum distribution or in installments, as elected by the participant in accordance with the plan. Participants can allocate their deferred compensation amongst various investment options with earnings accruing to the participant. The Company has established a Rabbi Trust to fund the plan obligations and to hold the plan assets. Eligible participants began contributing to the plan in January 2020. As of March 31, 2021, the plan assets and liabilities were valued at approximately $2.0 million and $2.1 million, respectively. As of December 31, 2020, the plan assets and liabilities were valued at approximately $1.6 million and $1.7 million, respectively.

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2021
Commitments and Contingencies  
Commitments and Contingencies

Note 17. Commitments and Contingencies

Purchase Commitments

As of March 31, 2021, the Company has entered into commitments to purchase equipment and raw materials for an aggregate amount of approximately $52.4 million. The Company anticipates that most of these commitments with a remaining term in excess of one year will be fulfilled by 2022.

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Litigation
3 Months Ended
Mar. 31, 2021
Litigation  
Litigation

Note 18.   Litigation

Amphastar Pharmaceuticals, Inc. v. Aventis Pharma, SA

In January 2009, the Company filed a qui tam complaint in the U.S. District Court for the Central District of California, alleging that Aventis Pharma S.A., or Aventis, through its acquisition of a patent through false and misleading statements to the U.S. Patent and Trademark Office, as well as through false and misleading statements to the FDA, overcharged the federal and state governments for its Lovenox® product.

On May 11, 2017, the Company’s lawsuit against Aventis was dismissed for lack of jurisdiction. On July 14, 2017, Aventis filed an application with the District Court for entitlement to attorneys’ fees and expenses. On November 20, 2017, the District Court issued its order granting Aventis’ application for fees.

On November 13, 2020, the Court issued an Order (“November Order”) awarding Aventis $12.1 million in attorneys’ fees and $0.7 million in costs and expenses, and ordered Aventis to submit updated calculations on accrued interest.

On May 3, 2021, the Court issued a further Order based upon supplemental application to the Court seeking fees, expenses, and interest for the period after, and not covered by, the November Order. The Court awarded Aventis an additional $4.4 million bringing the total awarded Aventis to $17.2 million.

The Company had previously accrued $12.8 million as of December 31, 2020, based upon the November Order. As a result of the most recent ruling, the Company recorded an additional charge of $4.4 million for the three months ended March 31, 2021, in other income (expenses), in the condensed consolidated statement of operations. This amount represents management’s best estimate of the probable loss at this time. There is a reasonable possibility that the final fee award could change; however, at this time, the range of loss cannot be estimated. The Company intends to continue to vigorously defend against any imposition of attorneys’ fees and expenses in this case.

Regadenoson (0.4 mg/5 mL, 0.08 mg/mL) Patent Litigation

On February 25, 2020, Astellas US LLC, Astellas Pharma US, Inc., and Gilead Sciences, Inc. (collectively, “Astellas-Gilead”) filed a Complaint in the United States District Court for the District of Delaware against IMS for infringement of U.S. Patent Nos. 8,106,183 (the “‘183 patent”), RE47,301 (the “‘301 patent”), and 8,524,883 (the “‘883 patent”) (collectively, “Astellas-Gilead Patents”) with regard to IMS’s ANDA No. 214,252 for approval to manufacture and sell 0.4 mg/5 mL (0.08 mg/mL) intravenous solution of Regadenoson. On March 4, 2020, IMS filed its Answer and Counterclaims. On March 30, 2020, the Court issued an Order allowing the Company to join pending consolidated litigation with five other generic Regadenoson ANDA filers involving similar claims. Trial is currently scheduled for June 14, 2021. The Company’s 30-month FDA stay expires August 10, 2022. The Company intends to vigorously defend this patent lawsuit.

Employee Litigation

Brenes v. International Medication Systems, Limited

On September 11, 2019, a former employee, Raquel Brenes, (“Brenes”), initiated an employment litigation against IMS et al. by filing a Complaint in the Superior Court of California, Los Angeles County alleging individual and class action claims for alleged violations of various California labor laws pertaining to wage and hour, and other state laws. On September 18, 2019, Brenes filed a First Amended Complaint maintaining the individual and class action claims.

On January 21, 2020, Brenes filed a Second Amended Complaint that alleges only Private Attorney General Act, or PAGA, claims and omitted the individual and class action claims. On February 9, 2021, the parties reached a settlement for $1.0 million. The settlement was approved by the Court on April 7, 2021. The Company accrued the amount of $1.0 million for this litigation as of December 31, 2020.

Navarrette v. International Medication Systems, Limited

On January 30, 2020, a former employee, Robert Navarrette (“Navarrette”), provided written notice, through his counsel to IMS that he intends to file a PAGA lawsuit for alleged violation of various California labor laws pertaining to wage and hour. On April 7, 2020, Navarrette filed his PAGA lawsuit against IMS and Amphastar Pharmaceuticals, Inc. in the Superior Court of California, Los Angeles County, Central District. As to IMS, the Brenes settlement subsumes the claims of Navarrette.

Ramirez v. Amphastar Pharmaceuticals, Inc.

On May 29, 2020, Priscilla Ramirez, (“Ramirez”), a former employee filed a PAGA lawsuit for alleged violations of various California labor laws pertaining to wage and hour against the Company. On April 5, 2021, the parties reached a settlement for $1.0 million. The agreement is still subject to approval by the Court. The Company accrued the amount of

$1.0 million for this litigation as of March 31, 2021.

Other Litigation

The Company is also subject to various other claims, arbitrations, and lawsuits from time to time arising in the ordinary course of business.

The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In the opinion of management, the ultimate resolution of any such matters is not expected to have a material adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable and the Company’s view of these matters may change in the future. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events
3 Months Ended
Mar. 31, 2021
Subsequent Events  
Subsequent Events

Note 19.   Subsequent Events

In May 2021, the board of directors approved a plan for the restructuring of the equity ownership of ANP, whereby the Company will purchase an additional ownership interest in ANP from certain equity holders of ANP (the “Sellers”), and spin-off of certain subsidiaries of ANP.

The Company entered into three agreements relating to the restructuring of the equity ownership of ANP and its subsidiaries and the spin-off of certain subsidiaries of ANP:

The Company entered into a Share Purchase Agreement, or SPA, to acquire an additional approximately 18% of ownership interest in ANP for approximately $29.4 million from the Sellers, who had initially acquired shares in the previously disclosed July 2018 private placement, or the ANP Private Placement.
ANP entered into a Share Repurchase Agreement, or SRA, with the Sellers and Nanjing Qianqia Enterprise Management Consulting LLP, or Qianqia, to issue shares in Hanxin, including Hanxin’s existing subsidiaries, Baixin and Letop, both of which will be included in the spin-off of Hanxin, in exchange for an additional approximately 9% of ownership interest in ANP.
ANP entered into a Separation Agreement with Hanxin which sets forth certain assets to be held by each entity, as well as certain responsibilities and obligations of ANP and Hanxin following completion of the spin-off.

Upon completion of the restructuring, the Company will own approximately 85% of ANP, and ANP will retain approximately 20% of ownership interest in Hanxin.

Certain of the Sellers are the Company’s executive officers, directors and other related parties. The Sellers who are participating in the SPA include William J. Peters, Rong Zhou, Jacob Liawatidewi, Howard Lee, Richard Koo, Stephen Shohet, Henry Zhang, Qingqing Chen, Chongqing Zhang, Lu Zhang, and James Luo. Neither Dr. Mary Luo nor Dr. Jack Zhang are participating in the SPA.

The Sellers who are participating in the SRA include Dr. Mary Luo, Dr Jack Zhang, Henry Zhang, Qingqing Chen, Chongqing Zhang, Bill Zhang, and Lu Zhang.

As part of the restructuring, the Company will terminate the 2018 ANP Equity Incentive Plan.

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2021
Summary of Significant Accounting Policies  
Basis of Presentation

Basis of Presentation

The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with United States generally accepted accounting principles, or GAAP. Certain prior period amounts have been reclassified within the investing activities of the statement of cash flows to conform to the current period presentation. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.

The Company’s subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals, Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Nanjing Letop Biological Technology Co., Ltd., or Letop, (5) Nanjing Hanxin Pharmaceutical Technology Co., Ltd., or Hanxin, (6) Nanjing Hanxin Biomedical Testing Service Co., Ltd., or Hanxin Biomedical, (7) Nanjing Baixin Trading Co., Ltd., or Baixin, (8) Amphastar France Pharmaceuticals, S.A.S., or AFP, (9) Amphastar UK Ltd., or AUK, and (10) International Medication Systems (UK) Limited, or IMS UK.

In July 2018, the Company’s Chinese subsidiary, ANP, completed a private placement of its common equity interest to accredited investors and received approximately $56.3 million of cash proceeds, a portion of which was received in 2019. The Company has retained approximately 58% of the equity interest in ANP following the private placement and continues to consolidate the financial results of ANP with the Company’s results of operations. ANP’s net income after July 2, 2018, was attributed to the Company in accordance with the Company’s equity interest of approximately 58% in ANP.

COVID-19 Pandemic

COVID-19 Pandemic

The Company is subject to risks and uncertainties as a result of the ongoing novel coronavirus pandemic, or COVID-19. The complete extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the information is constantly evolving. The Company considered the impact of COVID-19 on the assumptions and estimates used to determine the results reported and asset valuations as of March 31, 2021.

All of the Company’s production facilities continued to operate during the quarter as they had prior to the COVID-19 pandemic with very little change, other than for enhanced safety measures intended to prevent the spread of the virus.

It is not possible at this time to estimate the complete impact that COVID-19 could have on the Company’s business, including its customers and suppliers, as the impact will depend on future developments, which are highly uncertain and cannot be predicted. The Company will continue to monitor the impact of COVID-19 on all aspects of its business.

Use of Estimates

Use of Estimates

The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for credit losses, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to their net realizable values, impairment of long-lived and intangible assets and goodwill, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.

Foreign Currency

Foreign Currency

The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the US Dollar. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company’s condensed consolidated statements of operations.

The Company’s French subsidiary, AFP, maintains its book of record in euros. ANP’s subsidiaries maintain their books of record in Chinese yuan. AUK’s subsidiary, IMS UK, maintains its book of record in British pounds. These local currencies have been determined to be the subsidiaries’ respective functional currencies. These books of record are translated into USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other accumulated comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss). The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature for the three months ended March 31, 2021 and 2020 were $1.5 million loss and $0.6 million loss, respectively.

Comprehensive Income (Loss)

Comprehensive Income (Loss)

For the three months ended March 31, 2021 and 2020, the Company included its foreign currency translation gain or loss as part of its comprehensive income (loss). No income tax expense (benefit) was allocated to other comprehensive income (loss) for the three months ended March 31, 2021 and 2020.

Advertising Expense

Advertising Expense

Advertising expenses, primarily associated with Primatene Mist®, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Company’s condensed consolidated statement of operations. For the three months ended March 31, 2021 and 2020, advertising expense was $2.2 million and $1.0 million, respectively.

Financial Instruments

Financial Instruments

The carrying amounts of cash and cash equivalents, short-term investments, restricted cash and short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. The majority of the Company’s long-term obligations consist of variable rate debt, and their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. The Company at times enters into fixed interest rate swap contracts to exchange the variable interest rates for fixed interest rates without the exchange of the underlying notional debt amounts. Such interest rate swap contracts are recorded at their fair values.

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments purchased with original maturities of three months or less.

Short-Term Investments

Short-Term Investments

Short-term investments as of March 31, 2021 and December 31, 2020 consisted of certificates of deposit and investment grade debt securities with original expiration dates within 12 months.

Restricted Cash

Restricted Cash

Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of March 31, 2021 and December 31, 2020, the restricted cash balance was $0.2 million and $1.9 million, respectively.

Restricted Short-Term Investments

Restricted Short-Term Investments

Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workers’ compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of March 31, 2021 and December 31, 2020, the balance of restricted short-term investments was $2.2 million.

Deferred Income Taxes

Deferred Income Taxes

The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU,

No. 2019-12 Simplifying the Accounting for Income Taxes (Topic 740). The amendment removes certain exceptions for performing intra-period tax allocations, recognizing deferred taxes for investment, and calculating income taxes in interim periods. The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods. The guidance is effective for the Company’s interim and annual reporting periods during the year ended December 31, 2021. The adoption of this accounting guidance did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2021
Revenue Recognition  
Schedule of chargeback and rebates provision analysis

Three Months Ended

 

March 31, 

2021

2020

 

(in thousands)

 

Beginning balance

    

$

20,380

    

$

21,644

Provision for chargebacks and rebates

 

47,031

 

35,987

Credits and payments issued to third parties

 

(46,881)

 

(39,353)

Ending balance

$

20,530

$

18,278

Schedule of product return liability analysis

Three Months Ended

 

March 31, 

2021

2020

 

(in thousands)

 

Beginning balance

    

$

14,204

    

$

10,339

Provision for product returns

 

3,233

 

3,099

Credits issued to third parties

 

(2,517)

 

(2,239)

Ending balance

$

14,920

$

11,199

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Tables)
3 Months Ended
Mar. 31, 2021
Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders  
Schedule of basic and diluted net income (loss) per share calculation

Three Months Ended

March 31, 

2021

2020

(in thousands, except per share data)

Basic and dilutive numerator:

    

    

    

    

 

Net income attributable to Amphastar Pharmaceuticals, Inc.

$

5,041

$

3,949

Denominator:

Weighted-average shares outstanding — basic

 

47,520

 

46,408

Net effect of dilutive securities:

Incremental shares from equity awards

 

1,998

 

1,840

Weighted-average shares outstanding — diluted

 

49,518

 

48,248

Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — basic

$

0.11

$

0.09

Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — diluted

$

0.10

$

0.08

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting  
Schedule of financial information by reporting segment

Three Months Ended

March 31, 

2021

2020

(in thousands)

Net revenues:

    

    

    

    

 

Finished pharmaceutical products

$

97,882

$

81,298

API

 

5,138

3,390

Total net revenues

 

103,020

 

84,688

Gross profit (loss):

Finished pharmaceutical products

 

45,286

 

38,810

API

 

(340)

(1,987)

Total gross profit

 

44,946

 

36,823

Operating expenses

 

34,640

 

29,343

Income from operations

 

10,306

 

7,480

Non-operating expense

 

(5,192)

 

(1,675)

Income before income taxes

$

5,114

$

5,805

Schedule of net revenues in the finished pharmaceutical products segment

Three Months Ended

March 31, 

2021

2020

(in thousands)

Finished pharmaceutical products net revenues:

    

    

    

    

 

Primatene Mist®

$

18,383

$

12,877

Epinephrine

15,578

3,990

Enoxaparin

10,658

9,168

Phytonadione

 

9,565

 

11,029

Lidocaine

9,071

10,657

Glucagon

7,984

Naloxone

6,341

8,875

Other finished pharmaceutical products

 

20,302

 

24,702

Total finished pharmaceutical products net revenues

$

97,882

$

81,298

Schedule of depreciation and amortization expense by reporting segment

Three Months Ended

March 31, 

2021

2020

(in thousands)

Depreciation and amortization expense

    

    

    

    

 

Finished pharmaceutical products

$

1,435

$

1,464

API

 

1,048

 

582

Total depreciation and amortization expense

$

2,483

$

2,046

Schedule of net revenues and carrying values of long-lived assets by geographic region

Net Revenue

Long-Lived Assets

 

Three Months Ended

 

March 31, 

March 31, 

December 31, 

2021

2020

2021

2020

 

(in thousands)

 

United States

    

$

99,170

    

$

81,065

    

$

125,861

    

$

129,401

China

 

1,121

228

 

97,847

 

98,538

France

 

2,729

3,395

 

49,431

 

52,770

Total

$

103,020

$

84,688

$

273,139

$

280,709

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Customer and Supplier Concentration (Tables)
3 Months Ended
Mar. 31, 2021
Customer and Supplier Concentration  
Schedule of accounts receivable and net revenues by major customer

% of Total Accounts

% of Net

Receivable

Revenue

Three Months Ended

March 31, 

December 31, 

March 31, 

    

2021

    

2020

    

2021

    

2020

    

AmerisourceBergen

 

14

%

9

%

25

%

24

%

McKesson

 

21

%

24

%

20

%

22

%

Cardinal Health

 

16

%

17

%

15

%

19

%

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Measurements  
Schedule of financial assets and liabilities measured on a recurring basis

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

 

(in thousands)

 

Cash equivalents - money market

$

76,536

$

76,536

$

$

Restricted cash - money market

235

235

Short-term investments - certificates of deposit

9,284

9,284

Restricted short-term investments - certificates of deposit

 

2,200

 

 

2,200

 

Corporate and municipal bonds

4,199

4,199

Interest rate swap liabilities related to variable rate loans

(723)

(723)

Fair value measurement as of March 31, 2021

$

91,731

$

76,771

$

14,960

$

Cash equivalents - money market

$

58,710

$

58,710

$

$

Restricted cash - money market

1,865

1,865

Short-term investments - certificates of deposit

9,089

9,089

Restricted short-term investments - certificates of deposit

 

2,200

 

 

2,200

 

Corporate and municipal bonds

3,855

3,855

Interest rate swap liabilities related to variable rate loans

(902)

(902)

Fair value measurement as of December 31, 2020

$

74,817

$

60,575

$

14,242

$

XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Investments (Tables)
3 Months Ended
Mar. 31, 2021
Investments  
Schedule of securities classified as held-to-maturity

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

    

Cost

    

Gains

    

Losses

    

Value

(in thousands)

Corporate bonds

$

1,053

$

$

(1)

$

1,052

Municipal bonds

3,148

(1)

3,147

Total investments as of March 31, 2021

$

4,201

$

$

(2)

$

4,199

Corporate bonds

$

1,560

$

$

(1)

$

1,559

Municipal bonds

2,297

(1)

2,296

Total investments as of December 31, 2020

$

3,857

$

$

(2)

$

3,855

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets  
Schedule of weighted-average life, original cost, accumulated amortization and net book value by major class

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

IMS (UK) international product rights

10

$

9,640

$

4,499

$

5,141

Patents

 

12

 

486

308

 

178

Land-use rights

 

39

 

2,540

634

 

1,906

Subtotal

 

12

 

12,666

 

5,441

 

7,225

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,793

 

 

3,793

Subtotal

 

*

 

33,018

 

 

33,018

As of March 31, 2021

 

*

$

45,684

$

5,441

$

40,243

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

IMS (UK) international product rights

10

$

9,561

$

4,223

$

5,338

Patents

 

12

 

486

297

 

189

Land-use rights

 

39

 

2,540

617

 

1,923

Subtotal

 

12

 

12,587

 

5,137

 

7,450

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,940

 

 

3,940

Subtotal

 

*

 

33,165

 

 

33,165

As of December 31, 2020

 

*

$

45,752

$

5,137

$

40,615

*

Intangible assets with indefinite lives have an indeterminable average life.

Schedule of changes in carrying amounts of goodwill

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Beginning balance

    

$

3,940

    

$

3,634

Currency translation

 

(147)

 

306

Ending balance

$

3,793

$

3,940

XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Inventories (Tables)
3 Months Ended
Mar. 31, 2021
Inventories  
Schedule of inventories

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Raw materials and supplies

    

$

43,258

    

$

47,051

Work in process

 

35,081

 

37,257

Finished goods

 

18,771

 

12,523

Total inventories

$

97,110

$

96,831

XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant, and Equipment (Tables)
3 Months Ended
Mar. 31, 2021
Property, Plant, and Equipment  
Schedule of property, plant, and equipment

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Buildings

    

$

124,952

    

$

124,326

Leasehold improvements

 

30,093

 

30,028

Land

 

7,659

 

7,719

Machinery and equipment

 

210,776

 

211,666

Furniture, fixtures, and automobiles

 

26,862

 

26,482

Construction in progress

 

42,165

 

43,981

Total property, plant, and equipment

 

442,507

 

444,202

Less accumulated depreciation

 

(189,242)

 

(184,147)

Total property, plant, and equipment, net

$

253,265

$

260,055

XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Accounts Payable and Accrued Liabilities (Tables)
3 Months Ended
Mar. 31, 2021
Accounts Payable and Accrued Liabilities.  
Schedule of accounts payable and accrued liabilities

March 31, 

December 31, 

2021

2020

(in thousands)

Accrued customer fees and rebates

$

10,466

$

9,029

Accrued payroll and related benefits

26,742

24,597

Accrued product returns, current portion

10,676

10,190

Accrued loss on firm purchase commitments

8,625

1,223

Accrued litigation and settlements

19,449

13,780

Other accrued liabilities

9,600

12,328

Total accrued liabilities

 

85,558

 

71,147

Accounts payable

 

22,987

 

24,357

Total accounts payable and accrued liabilities

$

108,545

$

95,504

XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Debt (Tables)
3 Months Ended
Mar. 31, 2021
Debt  
Schedule of debt

March 31, 

December 31, 

 

2021

2020

 

(in thousands)

 

Line of Credit Facilities

    

    

    

    

Line of credit facility with China Everbright Bank due June 2021

$

763

$

764

Line of credit facility with China Merchant Bank due August 2021

381

382

Line of credit facility with Bank of Nanjing due October 2021

153

153

Line of credit facility with Cathay Bank due May 2022

 

 

Line of credit facility with East West Bank due December 2022

Equipment line of credit facility with East West Bank due September 2025

3,216

3,216

Mortgage Loans

Mortgage payable with East West Bank due May 2021

3,282

3,306

Mortgage payable with East West Bank due October 2026

3,317

3,334

Mortgage payable with East West Bank due June 2027

8,472

8,510

Mortgage payable with Cathay Bank due August 2027

 

7,220

 

7,268

Equipment Loans

Equipment loan with East West Bank due June 2021

306

612

Equipment loan with East West Bank due December 2022

3,500

4,000

Equipment loan with East West Bank due February 2024

4,839

5,254

Other Loans and Payment Obligations

Acquisition loan with Cathay Bank due June 2024

 

8,137

 

8,710

French government loan due July 2021

64

64

French government loans due December 2026

338

350

Equipment under Finance Leases

 

519

 

526

Total debt

 

44,507

 

46,449

Less current portion of long-term debt

 

12,173

 

12,263

Long-term debt, net of current portion

$

32,334

$

34,186

XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2021
Income Taxes  
Schedule of reconciliation of the statutory federal income tax rate

Three Months Ended

March 31, 

    

2021

    

2020

    

(in thousands)

Income before taxes

$

5,114

$

5,805

Income tax provision

1,155

 

2,280

Net income

$

3,959

$

3,525

Income tax provision as a percentage of income before income taxes

22.6

%

 

39.3

%

XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2021
Stockholders' Equity  
Schedule of key assumptions to determine fair value of options

Three Months Ended

March 31, 

    

2021

    

2020

    

Average volatility

 

42.2

%  

43.0

%  

Average risk-free interest rate

 

1.3

%  

0.8

%  

Weighted-average expected life in years

 

6.3

5.8

Dividend yield rate

 

%  

%  

Schedule of the summary of option activity under all plans

Weighted-Average

 

Weighted-Average

Remaining

Aggregate

 

Exercise

Contractual

Intrinsic

 

Options

Price

Term (Years)

Value(1)

 

(in thousands)

 

Outstanding as of December 31, 2020

    

8,580,475

    

$

15.00

    

    

    

    

Options granted

 

1,166,702

 

17.99

Options exercised

 

(173,436)

 

12.64

Options cancelled

 

(51,506)

 

15.67

Options expired

 

(31,854)

 

11.66

Outstanding as of March 31, 2021

 

9,490,381

$

15.42

 

5.63

$

32,322

Exercisable as of March 31, 2021

 

6,588,157

$

14.83

 

4.28

$

26,310

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s common stock for those awards that have an exercise price below the estimated fair value at March 31, 2021.
Schedule of information relating to options grants

Three Months Ended

 

March 31, 

    

2021

    

2020

 

(in thousands, except per share data)

 

Weighted-average grant date fair value per option share

$

7.66

$

5.33

Intrinsic value of options exercised

 

1,029

 

488

Cash received from options exercised

 

2,169

 

1,251

Total fair value of the options vested during the year

 

6,772

 

7,432

Schedule of the summary of nonvested options status

    

    

Weighted-Average

 

Grant Date

 

Options

Fair Value

 

Non-vested as of December 31, 2020

2,825,652

$

6.50

Options granted

 

1,166,702

7.66

Options vested

 

(1,038,624)

6.52

Options forfeited

 

(51,506)

6.77

Non-vested as of March 31, 2021

 

2,902,224

 

6.96

Schedule of information relating to RSU grants and deliveries

Total Fair Market

 

Value of RSUs

 

Issued

 

Total RSUs

as

 

    

Issued

    

Compensation(1)

 

(in thousands)

 

RSUs outstanding at December 31, 2020

 

1,156,518

RSUs granted

 

496,742

$

8,936

RSUs forfeited

 

(22,627)

RSUs vested(2)

 

(416,973)

RSUs outstanding at March 31, 2021

 

1,213,660

(1)The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.
(2)Of the vested RSUs, 161,147 shares of common stock were surrendered to fulfill tax withholding obligations.
Schedule of recorded share-based compensation expense under all plans

Three Months Ended

March 31, 

2021

2020

(in thousands)

Cost of revenues

    

$

1,146

    

$

1,359

Operating expenses:

Selling, distribution, and marketing

 

127

 

107

General and administrative

 

2,968

 

3,219

Research and development

 

593

 

597

Total share-based compensation

$

4,834

$

5,282

XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jul. 31, 2018
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Gains and (losses) of intercompany foreign currency transactions   $ (1,500) $ (600)  
Income tax expense allocated to other comprehensive income   0 0  
Selling, distribution, and marketing expense   4,537 3,294  
Restricted cash   235   $ 1,865
Certificates of deposit   2,200   $ 2,200
ANP        
Proceeds from private placement $ 56,300      
Equity interest retained post private placement 58.00%      
Finished Pharmaceutical Products | Primatene Mist        
Advertising expense   $ 2,200 $ 1,000  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition (Analysis of the Chargeback Provision) (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Beginning balance $ 20,380 $ 21,644 $ 21,644
Provision for chargebacks and rebates 47,031 35,987  
Credits and payments issued to third parties (46,881) (39,353)  
Ending balance 20,530 $ 18,278 20,380
Accounts Receivable, Net      
Provision for chargebacks and rebates 16,400   16,400
Accounts Payable and Accrued Liabilities      
Provision for chargebacks and rebates $ 4,100   $ 4,000
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition (Analysis of Product Return Liability) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Aggregate product return rate 1.40% 1.10%  
Return accrual included in accounts payable and accrued liabilities $ 10,676   $ 10,190
Return accrual included in other long-term liabilities 4,200   $ 4,000
Product returns      
Beginning balance 14,204 $ 10,339  
Provision for product returns 3,233 3,099  
Credits issued to third parties (2,517) (2,239)  
Ending balance $ 14,920 $ 11,199  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Narrative) (Details) - Stock Options - $ / shares
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Shares 1,899,833 1,999,083
Antidilutive Securities Excluded from Computation of Earnings Per Share, Exercise Price of Excluded Securities $ 20.85 $ 20.81
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Basic and dilutive numerator:    
Net Income (Loss) Attributable to Parent $ 5,041 $ 3,949
Denominator:    
Weighted-average shares outstanding-basic 47,520 46,408
Net effect of dilutive securities:    
Incremental shares from equity awards 1,998 1,840
Weighted-average shares outstanding - diluted 49,518 48,248
Net income (loss) per share - basic $ 0.11 $ 0.09
Net income (loss) per share - diluted $ 0.10 $ 0.08
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Selected Financial Information by Reporting Segment) (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
segment
Mar. 31, 2020
USD ($)
Segment Reporting Information [Line Items]    
Number of Reportable Segments | segment 2  
Net revenues:    
Net Revenue $ 103,020 $ 84,688
Gross profit (loss):    
Gross Profit 44,946 36,823
Operating expenses 34,640 29,343
Income (loss) from operations 10,306 7,480
Non-operating income (expenses) (5,192) (1,675)
Income (loss) before income taxes 5,114 5,805
Finished Pharmaceutical Products    
Net revenues:    
Net Revenue 97,882 81,298
Gross profit (loss):    
Gross Profit 45,286 38,810
API    
Net revenues:    
Net Revenue 5,138 3,390
Gross profit (loss):    
Gross Profit $ (340) $ (1,987)
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Summary of Net Revenues by Product Segment) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Net Revenue $ 103,020 $ 84,688
Finished Pharmaceutical Products    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Net Revenue 97,882 81,298
Finished Pharmaceutical Products | Enoxaparin    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Net Revenue 10,658 9,168
Finished Pharmaceutical Products | Lidocaine    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Net Revenue 9,071 10,657
Finished Pharmaceutical Products | Phytonadione    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Net Revenue 9,565 11,029
Finished Pharmaceutical Products | Naloxone    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Net Revenue 6,341 8,875
Finished Pharmaceutical Products | Epinephrine    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Net Revenue 15,578 3,990
Finished Pharmaceutical Products | Primatene Mist    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Net Revenue 18,383 12,877
Finished Pharmaceutical Products | Glucagon    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Net Revenue 7,984  
Finished Pharmaceutical Products | Other Finished Pharmaceutical Products    
Segment Reporting Information, Revenue for Reportable Segment [Abstract]    
Net Revenue $ 20,302 $ 24,702
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Segment Reporting Information [Line Items]    
Depreciation and amortization expense $ 2,483 $ 2,046
Finished Pharmaceutical Products    
Segment Reporting Information [Line Items]    
Depreciation and amortization expense 1,435 1,464
API    
Segment Reporting Information [Line Items]    
Depreciation and amortization expense $ 1,048 $ 582
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Revenue $ 103,020 $ 84,688  
Long-Lived Assets 273,139   $ 280,709
UNITED STATES      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Revenue 99,170 81,065  
Long-Lived Assets 125,861   129,401
CHINA      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Revenue 1,121 228  
Long-Lived Assets 97,847   98,538
FRANCE      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Revenue 2,729 $ 3,395  
Long-Lived Assets $ 49,431   $ 52,770
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Customer and Supplier Concentration (Details) - Customer Concentration Risk [Member] - item
3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Revenue, Major Customer [Line Items]      
Number of major customers that are wholesale distributors 3    
Accounts Receivable, Net      
Revenue, Major Customer [Line Items]      
Number of major customers 3   3
Net Revenues      
Revenue, Major Customer [Line Items]      
Number of major customers 3 3  
AmerisourceBergen | Accounts Receivable, Net      
Revenue, Major Customer [Line Items]      
Major Customers 14.00%   9.00%
AmerisourceBergen | Net Revenues      
Revenue, Major Customer [Line Items]      
Major Customers 25.00% 24.00%  
Cardinal Health | Accounts Receivable, Net      
Revenue, Major Customer [Line Items]      
Major Customers 16.00%   17.00%
Cardinal Health | Net Revenues      
Revenue, Major Customer [Line Items]      
Major Customers 15.00% 19.00%  
McKesson | Accounts Receivable, Net      
Revenue, Major Customer [Line Items]      
Major Customers 21.00%   24.00%
McKesson | Net Revenues      
Revenue, Major Customer [Line Items]      
Major Customers 20.00% 22.00%  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value measurement $ 91,731 $ 74,817
Recurring Basis | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest rate swaps related to variable rate loans (723) (902)
Recurring Basis | Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Corporate and municipal bonds 4,199 3,855
Recurring Basis | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 9,284 9,089
Restricted short-term investments 2,200 2,200
Recurring Basis | Money market    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 76,536 58,710
Restricted cash 235 1,865
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value measurement 76,771 60,575
Level 1 | Money market    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 76,536 58,710
Restricted cash 235 1,865
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value measurement 14,960 14,242
Level 2 | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest rate swaps related to variable rate loans (723) (902)
Level 2 | Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Corporate and municipal bonds 4,199 3,855
Level 2 | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term investments 9,284 9,089
Restricted short-term investments $ 2,200 $ 2,200
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Investments (Held-to_Maturity) (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Schedule of Held-to-maturity Securities [Line Items]    
Amortized Cost $ 4,201 $ 3,857
Gross Unrealized Losses (2) (2)
Fair Value 4,199 3,855
Corporate bonds    
Schedule of Held-to-maturity Securities [Line Items]    
Amortized Cost 1,053 1,560
Gross Unrealized Losses (1) (1)
Fair Value 1,052 1,559
Municipal Bonds [Member]    
Schedule of Held-to-maturity Securities [Line Items]    
Amortized Cost 3,148 2,297
Gross Unrealized Losses (1) (1)
Fair Value $ 3,147 $ 2,296
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Intangible Assets (Summary of Intangible Assets) (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Definite-lived intangible assets      
Weighted-Average Life (Years) 12 years 12 years  
Finite-Lived Intangible Assets, Gross $ 12,666 $ 12,587  
Accumulated Amortization 5,441 5,137  
Finite-Lived Intangible Assets, Net 7,225 7,450  
Indefinite-lived intangible assets      
Goodwill recognized 3,793 3,940 $ 3,634
Subtotal, Original Cost 33,018 33,165  
Subtotal, Net Book Value 33,018 33,165  
Balance, Original Cost 45,684 45,752  
Balance, Net Book Value 40,243 40,615  
Finished Pharmaceutical Products      
Indefinite-lived intangible assets      
Goodwill recognized 3,793 3,940  
Trademarks      
Indefinite-lived intangible assets      
Indefinite-lived intangible assets $ 29,225 $ 29,225  
Patents      
Definite-lived intangible assets      
Weighted-Average Life (Years) 12 years 12 years  
Finite-Lived Intangible Assets, Gross $ 486 $ 486  
Accumulated Amortization 308 297  
Finite-Lived Intangible Assets, Net $ 178 $ 189  
Land-use rights      
Definite-lived intangible assets      
Weighted-Average Life (Years) 39 years 39 years  
Finite-Lived Intangible Assets, Gross $ 2,540 $ 2,540  
Accumulated Amortization 634 617  
Finite-Lived Intangible Assets, Net $ 1,906 $ 1,923  
International Medication Systems (UK) Limited | Acquired international product rights      
Definite-lived intangible assets      
Weighted-Average Life (Years) 10 years 10 years  
Finite-Lived Intangible Assets, Gross $ 9,640 $ 9,561  
Accumulated Amortization 4,499 4,223  
Finite-Lived Intangible Assets, Net $ 5,141 $ 5,338  
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Goodwill and Intangible Assets    
Beginning balance $ 3,940 $ 3,634
Currency translation and other adjustments (147) 306
Ending balance $ 3,793 $ 3,940
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Inventories (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Raw materials and supplies $ 43,258   $ 47,051
Work in process 35,081   37,257
Finished goods 18,771   12,523
Total inventory, net 97,110   $ 96,831
Inventory adjustment to reflect net realizable value 9,500 $ 2,100  
Enoxaparin      
Inventory, Firm Purchase Commitment, Loss $ 8,600 $ 2,100  
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Total property, plant, and equipment $ 442,507 $ 444,202
Less accumulated depreciation and amortization (189,242) (184,147)
Total property, plant, and equipment, net 253,265 260,055
Buildings    
Property, Plant and Equipment [Line Items]    
Total property, plant, and equipment 124,952 124,326
Leasehold improvement    
Property, Plant and Equipment [Line Items]    
Total property, plant, and equipment 30,093 30,028
Land    
Property, Plant and Equipment [Line Items]    
Total property, plant, and equipment 7,659 7,719
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Total property, plant, and equipment 210,776 211,666
Furniture, fixtures, and automobiles    
Property, Plant and Equipment [Line Items]    
Total property, plant, and equipment 26,862 26,482
Construction in progress    
Property, Plant and Equipment [Line Items]    
Total property, plant, and equipment $ 42,165 $ 43,981
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Accounts Payable and Accrued Liabilities.    
Accrued customer fees and rebates $ 10,466 $ 9,029
Accrued payroll and related benefits 26,742 24,597
Accrued product returns, current portion 10,676 10,190
Accrued loss on firm purchase commitments 8,625 1,223
Accrued litigation settlement 19,449 13,780
Other accrued liabilities 9,600 12,328
Total accrued liabilities 85,558 71,147
Accounts payable 22,987 24,357
Total accounts payable and accrued liabilities $ 108,545 $ 95,504
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Debt (Schedule of Debt) (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Debt Instrument    
Equipment under Finance Leases $ 519 $ 526
Total debt 44,507 46,449
Less current portion of long-term debt and finance leases 12,173 12,263
Long-term debt and finance leases, net of current portion 32,334 34,186
Mortgage Payable - Due May 2021 | East West Bank    
Debt Instrument    
Long Term Debt 3,282 3,306
Equipment Loan - Due June 2021 | East West Bank    
Debt Instrument    
Long Term Debt 306 612
Equipment Loan - Due December 2022 | East West Bank    
Debt Instrument    
Long Term Debt 3,500 4,000
Equipment Loan - Due February 2024 | East West Bank    
Debt Instrument    
Long Term Debt 4,839 5,254
Mortgage Payable - Due October 2026 | East West Bank    
Debt Instrument    
Long Term Debt 3,317 3,334
Mortgage Payable - Due June 2027 | East West Bank    
Debt Instrument    
Long Term Debt 8,472 8,510
Mortgage Payable - Due August 2027 | Cathay Bank    
Debt Instrument    
Long Term Debt 7,220 7,268
Acquisition Loan - Due June 2024 | Cathay Bank    
Debt Instrument    
Long Term Debt 8,137 8,710
Line of credit - Due June 2021 | China Everbright Bank    
Debt Instrument    
Long Term Debt 763 764
Line of Credit - Due August 2021 | China Merchant Bank    
Debt Instrument    
Long Term Debt 381 382
Line of Credit - Due October 2021 | Bank of Nanjing    
Debt Instrument    
Long Term Debt 153 153
Equipment Line of Credit - Due September 2025 | East West Bank    
Debt Instrument    
Long Term Debt 3,216 3,216
French Government Loan - Due July 2021 | Seine-Normandie Water Agency    
Debt Instrument    
Long Term Debt 64 64
French Government Loan 4 - Due December 2026 | Seine-Normandie Water Agency    
Debt Instrument    
Long Term Debt $ 338 $ 350
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes (Summary of Income Before Taxes) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income (loss) before income taxes:    
Income (loss) before income taxes $ 5,114 $ 5,805
Income tax provision (benefit) 1,155 2,280
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ 3,959 $ 3,525
Income tax provision as a percentage of income before income taxes 22.60% 39.30%
Other Effective Tax Rate Provision (Benefit) $ 100 $ 200
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Share Buyback Program) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Aug. 04, 2020
Equity, Class of Treasury Stock [Line Items]      
Treasury Stock, Value, Acquired, Cost Method $ 3,783 $ 10,950  
November 2014 Share Repurchase Plan      
Equity, Class of Treasury Stock [Line Items]      
Increase authorized for share buyback program     $ 20,000
Treasury Stock, Shares, Acquired (in Shares) 204,698 646,715  
Treasury Stock, Value, Acquired, Cost Method $ 3,800 $ 10,900  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (The 2015 Equity Incentive Plan) (Details) - The 2015 Equity Incentive Plan - shares
1 Months Ended
Jan. 31, 2021
Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)   6,181,926
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 1,187,386  
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Allocated share based compensation $ 4,834 $ 5,282
2014 Employee Stock Purchase Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares) 807,550  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares) 1,192,450  
Allocated share based compensation $ 100 $ 100
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Stockholders' Equity    
Average volatility 42.20% 43.00%
Risk-free interest rate 1.30% 0.80%
Weighted-average expected life in years 6 years 3 months 18 days 5 years 9 months 18 days
Dividend yield rate 0.00% 0.00%
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Summary of Option Activity) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Options    
Outstanding Options, Beginning of period 8,580,475  
Options granted 1,166,702  
Options exercised (173,436)  
Options cancelled (51,506)  
Options expired (31,854)  
Outstanding Options, End of period 9,490,381  
Exercisable at the end of period 6,588,157  
Weighted-Average Exercise Price    
Outstanding Exercise Price (in dollars per share) $ 15.00  
Options granted (in dollars per share) 17.99  
Options exercised (in dollars per share) 12.64  
Options cancelled (in dollars per share) 15.67  
Options expired (in dollars per share) 11.66  
Outstanding Exercise Price (in dollars per share) 15.42  
Exercisable at the end of period (in dollars per share) $ 14.83  
Additional Disclosures    
Outstanding Intrinsic Value $ 32,322  
Exercisable aggregate intrinsic value 26,310  
Allocated share based compensation $ 4,834 $ 5,282
Employee Stock Option    
Additional Disclosures    
Outstanding Contractual Term (in Years) 5 years 7 months 17 days  
Exercisable remaining contractual term (in Years) 4 years 3 months 10 days  
Allocated share based compensation $ 2,400 $ 2,600
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Stockholders' Equity    
Weighted-average grant date fair value (in Dollars per share) $ 7.66 $ 5.33
Intrinsic value of options exercised $ 1,029 $ 488
Cash received 2,169 1,251
Total fair value of the options vested during the year $ 6,772 $ 7,432
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Summary of Nonvested Options) (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Options    
Nonvested at beginning of period 2,825,652  
Options granted 1,166,702  
Options vested (1,038,624)  
Options forfeited (51,506)  
Nonvested at end of period 2,902,224  
Weighted-Average Grant Date Fair Value    
Nonvested at beginning of period (in dollars per share) $ 6.50  
Options granted (in dollars per share) 7.66 $ 5.33
Options vested (in dollars per share) 6.52  
Options forfeited (in dollars per share) 6.77  
Nonvested at end of period (in dollars per share) $ 6.96  
Employee Consultant And Directors Stock Options    
Weighted-Average Grant Date Fair Value    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options $ 16.3  
Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 3 years  
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Restricted Stock Units) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Allocated share based compensation $ 4,834 $ 5,282
Restricted Stock Units (RSUs)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 5 years  
Allocated share based compensation $ 2,200 $ 2,400
Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 3 years  
Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Number of Shares of Common Stock Per Award (in Shares) 1  
Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options $ 17,600  
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
shares
Restricted Stock Units (RSUs)  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Total RSUs outstanding at the beginning of the period 1,156,518
RSUs granted 496,742
RSUs forfeited (22,627)
RSUs vested (416,973)
Total RSUs outstanding at the end of the period 1,213,660
Stock surrendered to fulfill tax withholding obligations 161,147
Restricted Stock Units Issued as Compensation  
Total Fair Market Value of RSUs Issued  
RSUs granted (in Dollars) | $ $ 8,936
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (The 2018 ANP Equity Incentive Plan) (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jun. 30, 2019
Mar. 31, 2021
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Options granted   1,166,702  
Outstanding Options, End of period   9,490,381  
Allocated share based compensation   $ 4,834 $ 5,282
The 2018 ANP Equity Incentive Plan | Employees      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Options granted   6,082,377  
Outstanding Options, End of period   5,037,280  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 4 years    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 10 years    
Allocated share based compensation   $ 100 $ 100
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Allocated share based compensation $ 4,834 $ 5,282
Cost of revenues    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Allocated share based compensation 1,146 1,359
Selling, distribution and marketing    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Allocated share based compensation 127 107
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Allocated share based compensation 2,968 3,219
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Allocated share based compensation $ 593 $ 597
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.21.1
Employee Benefits (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Employee Benefits      
Defined Contribution Plan, Employer Matching Contribution, Percent of Match 50.00%    
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay 6.00%    
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 0.5 $ 0.5  
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate 0.30%   0.30%
Defined Benefit Plan, Benefit Obligation $ 2.9   $ 3.0
Pension Cost 0.0 $ 0.0  
Deferred compensation plan assets 2.0   1.6
Deferred compensation plan liabilities $ 2.1   $ 1.7
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Purchase Commitments) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Purchase Commitment, Excluding Long-term Commitment [Line Items]    
Contractual Obligation $ 44,507 $ 46,449
Commitments to Purchase Equipment and Raw Materials    
Purchase Commitment, Excluding Long-term Commitment [Line Items]    
Long-term Purchase Commitment, Amount $ 52,400  
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.21.1
Litigation (Details) - USD ($)
$ in Thousands
1 Months Ended
May 03, 2021
Apr. 05, 2021
Feb. 09, 2021
Nov. 13, 2020
May 31, 2021
Mar. 31, 2021
Dec. 31, 2020
Loss Contingencies [Line Items]              
Estimated Litigation Liability           $ 19,449 $ 13,780
Brenes vs International Medication Systems, Limited              
Loss Contingencies [Line Items]              
Litigation Settlement, Amount     $ 1,000        
Estimated Litigation Liability             1,000
Amphastar Pharmaceuticals, Inc. Vs Aventis Pharma, SA              
Loss Contingencies [Line Items]              
Estimated Litigation Liability           4,400 $ 12,800
Amphastar Pharmaceuticals, Inc. Vs Aventis Pharma, SA | Subsequent Event              
Loss Contingencies [Line Items]              
Litigation Settlement, Amount $ 4,400       $ 17,200    
Settled Litigation [Member] | Ramirez vs Amphastar Pharmaceuticals, Inc              
Loss Contingencies [Line Items]              
Estimated Litigation Liability           $ 1,000  
Settled Litigation [Member] | Ramirez vs Amphastar Pharmaceuticals, Inc | Subsequent Event              
Loss Contingencies [Line Items]              
Litigation Settlement, Amount   $ 1,000          
Settled Litigation [Member] | Amphastar Pharmaceuticals, Inc. Vs Aventis Pharma, SA              
Loss Contingencies [Line Items]              
Litigation Settlement, Amount       $ 12,100      
Costs and expenses       $ 700      
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events (Details) - Subsequent Event
$ in Millions
1 Months Ended
May 31, 2021
USD ($)
Hanxin  
Subsequent Event  
Ownership after transaction 20.00%
ANP  
Subsequent Event  
Percentage of ownership interest acquired 18.00%
Payments for additional ownership interest $ 29.4
Percentage of additional ownership interest from shares repurchase 9.00%
Ownership percentage 85.00%
EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

F"6L&LH$TTP"78 M F'&M-YSN89)J;;2NH@#V06+_FOL^Q(T&\2]'V"_CL)IKCF4KHS7S+! M9(9MAUA1I)[">KF32" M539!K5!T736P_"=]3F1 IZVH9%?<@R-%E[W^]8GLMT%)E+:K3AO5::=JNHO_ M:&CZME?7-\F)LI:@XZY7TL(CGRA1K[U]&LC<]UM91K/:./3$&U/X)[RR=[KZ M=!<,"%P1-+JZIJ;HRC*KB54;[SI+9(2-/^M\6]0 M2P,$% @ 38.G4JAA73@, P N@@ !D !X;"]W;W)K&ULC5;;;N(P$/T5*]J'5NHV-W*A J0"K;;25D*];)]-,A!O'3MK M&VCWZ]=.0A9(B/I";&?.\3EC/)/1CHMWF0$H])%3)L=6IE1Q8]LRR2#'\IH7 MP/2;%1 ;U6BR$GMD-2TIR8))PA@2LQM:M>S,?FO@R MX!>!G3P8(^-DR?F[F3RD8\LQ@H!"H@P#UH\MS(!20Z1E_*DYK69+ SP<[]GO M2^_:RQ)+F''Z1E*5C:W80BFL\(:J)[[[ ;6?P/ EG,KR%^VJV,"W4+*1BN^*/.PP% \W0#O!K@G0(&9P!^#?"_"AC4@$&9F@EXQN)62I'MM)[&J2=U/S3BM\[P^^C1\Y4)M$=2R$]QMM::R/8VPN> M>KV$CUA<(]^]0I[CN1UZ9E^'.QWP>3]\#LDY^)$;OTF_7_(-SO ]X9T^306" M8"J13K&^?T5!]6ETI;KB"DLNJ.N(BKP@ZE87-.J"7G7WA!%]!U*TYKS[ M7QJTMG7C*#H5UQ'E!9[?+2YLQ(6]XEZXPE3GKKIHGU>(@>J2&+8V'T:NZYQ( M#%NG.PQC_\SI1HW$J%?BO@I\(IS^UD5'UW6%%#=UW11HHUB/,25_\9("VF*Z M@2X+4=M"X)PXF$4M!YY[$'1D(&X,Q+T&[AC_P 46A/5@F8\STF9G"OTDW??@F'+71RV4M .ZDB!?5#5_03GI@, M "&PO=V]R:W-H965TUG-;N5Z*4J<\9UN)5)EE5/ZX9:DXK QL/$]\XOM$ M5Q/F>EG0/;MG^DNQE3 RNR@QSUBNN,B19+N5\1:_V1"[!]O#*L"A%+6:2K$!3^'MF&I6D5"7!\;X,:W9J5X_#Y.?J[.GE(YH$J MMA'IWSS6R ME?%>2WC+P4^OMQ)VA-0_%FB;TEPO$,UC],?WDA=0*XVN[IOR(K%#\Z;7Z.J. M:HR_W=^CJU35ZA7B./B>B5&"LEJ8&R-7"9M3"NVW@D3/P/E)Y@VR\ M0,0B>,)],^]^QZ+.W3IV-X&HCBW2L47J>/;/L34BZY\/8([>:Y:IKS.+V=UB M=KV8/:<8AK^4OS</<%$7)MX[@CZA)EG6:X[C=SKD'NS MR&]+GL8\WZN9O>=WL?S+;_2@6RRXR$8/3FC$Q G=\4:9-(.J3+,==J##_]GH M\/%(1!HCG@'T1W:*\B@NMGI%MB[//1Y\ /!%V&_##GFU+2NT1^Q/FY%@FGW< M*S$F\_P#P+G\>Y7%]@O0W>LCGA?(7Z;[5.]\SPW';$]8^3@\0W:OB7A>%#_2 M*($IZ -FR_ ?R]LV+\,__ZI:&/+][UQ!:;LL.>=D1O5\EW MI7'O;#A\/(%(;W<$>LB!6G#'G]% V^L M_I-F3G"FS2&];))YV=R(7&E9-I<1:'(A@3V49*X$9-!FOD"?27H)))?I-,E$ M#TGP2;LS96:' 1Z5P!S<8JHK)/3^>YXKE+(=^%DW/M10-K>R9J!%45]L'H2& M$U _)G"39;(R@/<[(?3SH+HK=7?C]7]02P,$% @ 38.G4IMGU/(M P M% H !D !X;"]W;W)K&ULI99M;],P$,>_BA7Q M8DBP),XS:BO!)@02B(DQ>.TFU\;"B8/MK.S;8SM9Z!)W5.)-:SOWO_O=63Y[ M=>#BIZP!%/K=L%:NO5JI[HWOR[*&ALA+WD&KO^RX:(C24['W92> 5%;4,!\' M0>HWA+;>9F77;L1FQ7O%: LW LF^:8AX> >,']9>Z#TN?*7[6ID%?[/JR!YN M0=UU-T+/_,E+11MH)>4M$K!;>V_#-U>A%5B+[Q0.\FB,3"I;SG^:R<=J[06& M"!B4RK@@^N\>KH QXTES_!J=>E-,(SP>/WI_;Y/7R6R)A"O.?M!*U6LO]U % M.](S]94?/L"84&+\E9Q)^XL.@VV6>JCLI>+-*-8$#6V'?_)[+,21((Q/"/ H MP.<*HE$0V40',IO6-5%DLQ+\@(2QUM[,P-;&JG4VM#7;>*N$_DJU3FW>EB7O M6R71#7D@6P:(M!72BZ*'"GVB9$L9510DNK@&12B3+]%K='=[C2Y>O$0O$&W1 MMYKW4JODRE<:R+CURS'XNR$X/A'\,Q&7* I?(1S@T"&_>EY^#>4D#Y[*?5V& MJ19XJ@6V_J+_K,7E,[&B*59D8\6G8UFWPQ:#0#O0138!!6R) FI=6G. MY_TF#.(T7?GWQT5;6A4!+B:C)[CQA!N?A=N1!\$9&T&9!JW0%EK84>4D'KPF M1RPXS6(\(W98Q4F1N9&3"3DY#UGPJB^5QE6]:.4K77(AH%6HX\)T$A=VL@ * M@S2;%]IE%1:!&SN=L-.SL!F7$ND^MZ.B05TOREHW*U3RIJ%*MU%WN=,%49[B M9(:]- HQCMS4V42=G4>M#\B>V 8M02D&!M5%FBTABC@N9J@.JRC+3U0XGUCS M9UF_J%J?-S(13^?:Q9DO"(HT"&:82Z,01SAW8Q839O$LYC>N"#L7LUAN?)(D M^8QS:96%87SBG(7!WRLD^-?F#WVS&_JF\R((EF<<%WDV(W29Q5%R"O'HE@O/ M*^834-O&SJSP&.!I\\V3>'ZZ''9%D@3Q+ /_Z,HV[R5]%>YI*Q&#G=8%EYDN M@1B>(,-$\<[>XENN](5AA[5^MH$P!OK[CG/U.#$/@^DAN/D#4$L#!!0 ( M $V#IU)%,N[>6P4 'L: 9 >&PO=V]R:W-H965T:N-TTOT[37U[(MVUQ!779_B#^[,'T4\F>Z8TR!WTG,TZO13JG]^_$X7>U80M-W M8L^X_F(\\+Q@F-^&@VS??=R=E49"J..+N3(,V2 MA,JG#RP6CU\37:[I39,9Y-]W3+[IGZOK^3>FM<1EE'">-I)#B0;',U MNH;OYR0T#KG%/Q%[3"N_@2EE*<1/L_%I?37R3$8L9BME0E#]]<#F+(Y-))W' MKR+HJ#RF<:S^?HY^DQ>OBUG2E,U%_"-:J]W5*!R!-=O0+%9?Q>.?K"C(-_%6 M(D[S3_!XL)T$([#*4B62PEEGD$3\\$U_%R J#I"T.*#" 9WJ@ L'G!=ZR"PO M:T$5G4VE> 326.MHYD?.)O?6U43) M^9V)?69IJI>]E ;B7LC\4M>+,A9\>Z&83/*D@5Y_8%/ C5OA^HT,(8(37*O# M984"[*XC*.L(NNOHR_:*O"#Z8\/E/_LN(C"\I#A0)?E M91GQLO=D@&_F9"Q:5ORE@W"(:H =1MAKX0L]J[_>B9KQ65!>\/TKX^S%@&%% M\^% B*$54XC.A%P$. )8X5?< II& 40MD*TNPU.%N0)9WT]8LM0RK4&C%X&V M,@O)4*"M0L(>B>P'W90T['M>G733BG@5J^/TK/#!;N5SHKYA2YGI+M&@)B]" M;84*3H9";94(AN>B#IL00UR_@SNL?.23%M16UF"WKK6(\]\K)8IE';R$-;*: MA;R!6".K20B>R;H(<"S L-Z6.*UP"VM4Z16[Y:V%];-03UX$VNH6PD.!MIJ$ MNGN_$T W6[N03.JW0Y>5#UOT UEY0]WRU@+Z.MOJ8>@9]9RJG6Y!^CA;T4+! M4)RM(*'NUND$SI,&P0E"=9UV6@5A"V>K;:A;VZY76JC3*&^P'9T'.9VRU2MT M.=3 9:4(=[=/_92+ $?K%.*Z;+BL)FVK&5M5PSVJIK?S+E^R=:0!;>@:FR^4_QOQ;1<4JUIXJ.$06UG"YXZ'N#GZ0;^QJ+N-CI_36'TC)X^' M+N3W;*_*(<9_21-"K(:1H:9%8L6)G#LM$L>TB&!]7.RS.D[/ZASIUKD;R?AJ M!_X06I=YJ+ )4'_EB M'-;Y.XS\>L,RKKP9,*]E;JG<1CP%,=MH+^_=1)\^>7C3<=A08I^_+%@*I422 M_]PQNF;2&.C_-T*HYPWS_J%\WS3['U!+ P04 " !-@Z=2XKQWD_L" !D M" &0 'AL+W=O5XZ%8:T8Y3B6H=5$0^6>"3&Q'7NCM)A[H,M=VPA\/5V2),]1/ MJZDT([]F26F!7%'!06(V\B[#BZN!C78$5A P7 MVC(0\[?!*V3,$AD9ORM.K][2 O>?=^Q?G7?C94X47@GVBZ8Z'WD##U+,R)KI M![']AI6?Q/(M!%/N%[95;.#!8JVT*"JP45!07OZ3ERH/>P##TPR(*D!T".B] M X@K0.R,ELJ)8@,JH4)FIM2K9] YQHUH84"9O\S*?M)S4-JT7+9OTZDUZ;I/>_V[2="XE M9=]1VK=],T["L#?T-_O):@@:!$D=]$9M4JM-/J+6"(.5%!OJ2D)GCAPSJD^: MI)9\R9Z*,$R2 ZG'05$T")JE]FNI_5:I]Z:0[I+[W2;WU [9.J5\"5,A72VZ MU%K2^5J3.3.N!-P+@^!:"L9LV"W7*%'I)F/]H_3&Y\GY@;&&H"1ZYPS.:F-G M_WX&1 &!%Z-Z4%M>M!* M]$/G*.$FR]!U#UO6X(%HA.GK-9RT7,/!T4&$07!P6,K5OEI>L0!_,3TT++CO=*4_9?4\:6E"M@F!G*H'MFW@M9]K1R MH,7*M86YT*;)N,?&PO=V]R:W-H965TJ#XL]8 O;2W;7$/KUW5T;!X)!Z4/[ M KOK.6?.S(YGW-M2MN(AHH#7)$YYWPB%6-^8)O=#3 AOT#6F\LF"LH0(N65+ MDZ\9DD"#DMAT+*ME)B1*C4%/GTW9H$XY0=K4)', M*5VIS5W0-RPE"&/TA6(@\F^#8XQC121EO!2<1NE2 0_7>_8O.G89RYQP'-/X M1Q2(L&]T# AP0;)8/-#M5RSB:2H^G\9<_\*VL+4,\#,N:%* I8(D2O-_\EKD MX0 @>:H!3@%PW@.\,P"W +@?!7@%P-.9R4/1>9@0008]1K? E+5D4PN=3(V6 MX4>INO:98/)I)'%B,!/47X4T#I#Q3W#[DD5B![592!C"*-O-B;^"*:-+1I(Z MU"8H2!3S.GR&I]D$:E=UN((HA<>09IRD >^90HI2U*9?"!CE IPS ERXIZD( M.=RF 0;'>%,&4T;D[",:.1<)[PEK@&M?@V,Y=H6>\X\ M[29SA-0Q]*8-A('50+N >14B#JKO.V5N:776N3F\ M@%,CV^HVK=+J2'FS5-Z\J/P[W6 R1R83;WN0%_ #KC/FA[(MP#0FZ87\M$HO MK?]Q'>W27?MB4'>IK_@12"8SSJ+?&(!L]//B_5SG[V=5L;9/4BWG@74F MU9U25>>OBD0GF[]5"=1D2\@/ZU5%DK,WCT1YK6[G79FD"F#.3S M!:5BOU$.RN^1P1]02P,$% @ 38.G4F"D#QB @ 7 8 !D !X;"]W M;W)K&ULO55=3]LP%/TK5WD92$":I(4.I9%*81K3 MF"K8Q\.T!S>Y;2S\46RGH?OULYTT*]#V;7M)[.MSKL^YL6_26JI'72(:>.9, MZ%%0&K.\#$.=E\B)/I-+%'9E+A4GQD[5(M1+A:3P),["N-<[#SFA(LA2'YNJ M+)65853@5(&N."=J?85,UJ,@"C:!>[HHC0N$6;HD"WQ \VTY5786=ED*RE%H M*@4HG(^"<70Y&3B\!WRG6.NM,3@G,RD?W>2V& 4])P@9YL9E(/:UP@DRYA)9 M&4]MSJ#;TA&WQYOL'[QWZV5&-$XD^T$+4XZ"80 %SDG%S+VL/V+KQPO,)=/^ M"76+[0605]I(WI*M DY%\R;/;1VV"#;/;D+<$N+7A/X>0M(2$F^T4>9M71-# MLE3)&I1#VVQNX&OCV=8-%>XK/AAE5ZGEF>S!R/RQE*Q I=_!S5-%S1J.OI8( M<2\:; *W(D?AZ@U31L0Q'%VC(93I8SB%PU@+T"51J-/06+ENTS!OI5TUTN(] MTB*XD\*4&FY$@<5+?FAM=E[CC=>K^&#"3T2<01*=6+EQM$//Y##]CJA]]!=R MDJ[TB<^7["N]J\NI.X,%3"2W]U(3?[3'2A&Q0'M7#,S6L(V;DK4/CVNB"OCY MV::$6X-<_SH@J-\)ZGM!_7\EZ 2^5'R&"N2\ 6D85Z:4BOZVT",JVNCQKN(W MV@9>F^L]J^P\&D;OX_,T7.TP->A,#?Z?J7%14$:H%KZO:NJZ($,Z9.Q0IS^K(0,F.: MIG+IJI5$%ENGC+N!YW7=C*6Y,QK8M9D<#42A>9KC3((JLHS)[02YV P=WWE: MN$F7B38+[FBP8DN\17VWFDF:N35*G&:8JU3D('$Q=,;^^;1O[*W!MQ0W:F<, M1LE*DRG#FD<=\=/Z!^L=M(R9PJG M@G]/8YT,G9X#,2Y8P?6-V'S"2D_'X$6"*_N$367K.1 52HNLM>"=Y#F\#41A6)YK :N)H(FC!M59"8EF> F1"N M1:X3!9=YC/%S?Y>$U>J")W63H!'PFLE3"/UC"+S W\-G^N?N7@.=L$YV:/'" M0\E.F,03<^IBF(J,*E$Q>YC'4K)\B50=&N9;V+6;L:U='F^8C.''9X*$*XV9 M^ME J%T3:EM"[0.$QIR+B&D*HTQ(*$-&.]3V;6*)V;68YI98C]J]L#UPU[N9 M?6W4"7I!;?2,;J>FVVFD^^:Q;$A)MX[1_3_VZ*PF=-8HNI1YI51!D2X*F>9+ MF*%,17QCO5JW6G'ML&\6)]0!RX;YF^8LGW3U;=, MZ>QP7!"D=WI&*91E2RPG6JQL5YD+33W*#A/ZBT!I#.C[0@C]-#$!ZO^2T2]0 M2P,$% @ 38.G4H7?"TFW @ V0< !D !X;"]W;W)K&ULE95M3]LP$,>_RBG2-)!&DR9]8*BMU!;8I@D-@8#7IKXT5AT[ MV.[3MY_MI%F!-H,WK>WX_\O]S\[=8"W50F>(!C8Y%WH89,84%V&H9QGF1+=D M@<(^2:7*B;%3-0]UH9!0+\IY&$=1+\P)$\%HX-=NU6@@EX8S@;<*]#+/B=I. MD,OU,&@'NX4[-L^,6PA'@X+,\1[-0W&K["RL*93E*#23 A2FPV#28:IY(_,6JR87 > ,64++FYD^N?6/GI.MY,26V M$>1,E/]D4^5A3Q!WCPCB2A!_5)!4@L0;+2/SMBZ)(:.!DFM0;K>EN8'/C5=; M-TRX4[PWRCYE5F=&]T;.%IGD%)7^"EPGC^G00&ANG>ULXJV*:E#'% M1V)*X$8*DVFX$A3I:WUH_=4FXYW)2=P(O"&J!4G[&\11W#X0S_3C\J@AG*3. M>>)YR2=RWH#MU-B.QW:.8,Z*-7^^@U M-E4VDG)B M9.%K\;,TMK+[869[+RJWP3Y/I32[B7M!W?! K1$ !D !X;"]W;W)K&ULK5C;;MLX M$/T5PBBP"=!8(G5UX!APG"RV#\4&3=-B'QF)MHA2HDO2$,>B7K:/@A]Y]1>4IJ30E)> $'6-Y,EO%ZAR!C8&=\HV_;? Z MF&OU4*T#% P8( J W1@ /T! Z\R\&R@)3,;UAU6>#$7? ^$F:V]F0N[ M-M9:1T,+D\9')?13JNW4XE'QY$?&64J$_ O<_]Q1]08N'LND KX&_V[MI MG#M*TS6@3E)1NRVIH0%J'OC,"Y5)<%^D)/W=WM%AUK&B]UAOT:C#SUA,@0<_ M N0BV,-G=;JY.T+'JY?>L_Z\ 7_ERLH13W[MR;>>_"%/.R657F1:;*I\Z>6_ M)1M:%&9(9W%+!.5I7PY*SX'U;/;\RR(.8M>/@KGSTD,IJ"D%XY1*&F C<*$. MLU#W \]JX-GYQ:>W['C9S3I<9O[, M]6+83P:ZC9ZYHW3NR[3C9T8 5D!E!)!C9"J7;39A$,:SF8#C!JAA$>4\E $1:?TC51[U M+9<_\,:!C?;" [ FS$%$VG/Y[O/WW?GG$=KI5],CFCAK1#2C(/!_PF^/:M&QP2IZ5>G&+FVP<=!TA%)A:A\#H;X53%,(!$8W7&C-H MCG2);7N#_MUK)RW/S.!4B2>>V7P1, MHP$NX5%R:T[(2?9#KDI#"&846M+AV(1IS?FRXAQ]PCF&6R5M;N!:9IA]S ]) M?U.$:%.$R^@@X"W3'8A[)Q!UH]X>/M-_3^\>H!,W/8D]7OP?/3D VV]@^QZV M_PGLD[_2F)VR%6KZ0F'AV@@9LPASQC6LF"@1CJ@Y5TH(I@TL45?M.][7I>JX M,W^Y#ME)J>1ER)-K+W$JO1!Z\RH M-]PFMAO4BP:]_D0L_/K?\E_2^5,_! M7YCJ<:(O=D$7" 3.";+;2:BJNAKXU<*JI9^9S\K2!/9F3F\D:A= ^W.E[&;A M#FA>W&PO=V]R:W-H M965T7#& UL5G;P'9__8V3D&1+DBMWVA>P'<\WW\S87R;C@U0O>@-@R(\T$7KB M;(S9?G1=O=Q RG1/;D'@DY54*3,X56M7;Q6P.#-*$]?WO,A-&1?.=)RM/:CI M6.Y,P@4\**)W:.3KC;$+[G2\96M8@'G:/BBSC""!I;$0#/_V,(TFY^:W< O(O11FH\F=B"'^U=[% M.,M@_6.P-WXGX#U3/1+0*^)[/FW@,W^_N==!)RAS'V1X00M>D= .I'Z)U,^0 M^BU(59&8(<^PYD)PL;;EVX+B,F[*?8X89HCVLN^G_M /H] ?N_L&*F%))>RD M4@1%UHH)\[9JN>?PQ#.E433P6CQ'I>?H79[S3#0YCDX<7U,O&$9^O]GSH/0\ M>)=G5-45\!;G@U/G(0V]J-GUL'0]?'_E0<3=-1^>UGSD^7Y;_*.2Q*CS('_+ MQ!+BZ]D>%(H_^6R+3U"0@'QB7)&O+-E!QSFG7B57WO\ZZ>0")2>62<*4MDNY M*%TVBD_N:5C+1M0+FS-!:WI*SSG_Y_#)@45)V/7***777682\(6FC[ M%6W_C,MS#FO_A#5FL>4JTTH::7#>E3J'4M! :3!HH51I+#U#9'^Y:N=PZS<< MNE&+"-!*=&FWZMZEVT2^ I Y)@T[&'O]9DCQEBOLER32RE[TY-]?.;226QK] MYEM?Z2OM%M@RO 6H/5_BOTWPM>W?8@PYQ:96,QO95:U?F1V8BK$+J3_'QX:\ M8G?\"$NY%OPGQ%==J2F*EK.S@E&]LJ)>VZ6KM)MVB_=_CF(NM6D,Y2$_CWAK MCLMV?V-,W=0"A,;3W%0]M]9MIJ#661.NR5+NA,E[L7*U;/1G67O[9OW&?@!D M76P%DW\]8*>%RJY) BN$]'H#//TJ;\CSB9';K*=]E@8[Y&RXP8\84'8#/E]) M:8X3ZZ#\+)K^ U!+ P04 " !-@Z=2P9*]KY M-4O*"Q2:2P$*5V-O&KZ:A0[@+#YQW.O&&JPK2RGO[>9-.O8"JPAS3(RE8/2W MPQGFN64B'5\K4J^^TP*;ZR/[7\YY',9&%D!&G\/9#1K&7VDTK!=:D@.J$@AG=2F$S#:Y%B^A#ODS>U2]'1I>NHD_ =4Y<0AQ<0 M!5'8HF?V\_"@0TY<1SAV?/&I"&=,X0M;:BG,9$'OGV:N@J=*,;%&>B<,+ _0 MM)NS@SN>[IE*X9^W1 EO#!;Z2X>@7BVHYP3U3@B:YKE,F,VMME=">672D-:6 MQ))SX#CMMV$WZ0WCWLC?-2/[U*@?#:/:Z('J%G35Z?#_%G11Z?I$D>-B#7-47*9M2>T6TH<#,J4[7!K6+@U_0\D- MGU131-WI4REV%%4Z=R'6%P\S-)/:D(VAP!FX MQ42N!?\7*2%E"H#:[O'XE-/=RN(?IB0,OG_Y@]]=9^WO)H5I6RQ1@5R58&U7 M=$5!Y*4=Q:,JTC/J'J71>6OO*'WH-_(;MB(/QRFMLRW"0K M0?#!9.2FR9B #QL+;.^.X9,*#J\&3TK8;_3X M7:C3Z:WJ&M,&5OK$_K\6KJ MAHI'Y]=V['*SPW>:AB=_ =02P,$% @ 38.G4@TS!TV; P EPD !D M !X;"]W;W)K&ULI59;;QH[$/XKHU6D0Z0T>P$6 MJ I";WDH6T$3?MPU ?##JP5KTUM;TBD_O@S]L*&%MA(/2^[OLU\WUSMX4;I M!Y,C6G@JA#2C(+=V_38,S2+'@IE+M49).TNE"V9IJE>A66MDF1Y=0OA>+AF*YRAO5_? M:9J%M9:,%R@-5Q(T+D?!5?SV.FX[ 7_B&\>-V1N#,V6NU(.;W&:C('*,4.#" M.A6,?H]X@T(X3<3CYU9I4&,ZP?WQ3OM[;SP9,V<&;Y3XSC.;CX)^ !DN62GL M5&T^XM:@KM.W4,+X+VRV9Z, %J6QJM@*$X."R^K/GK:.V!-(>B<$DJU XGE7 M0)[EA%DV'FJU >U.DS8W\*9Z:2+'I8O*S&K:Y21GQS.K%@^Y$AEJ\P^\^UER M^PRM6UG%V_EMBH(&<@56P71V#Q\TD]8 DQE,4)!+-4=S#JT)6L8%C!C>JH&HT55RN- 5BA50A%N;/L'_NCCW[Y:L- MT]G%+JJWDIB6;L/ %YNC!ILS"5_63IVY@,]*/I(Q2!*?RV).^VI9J37P[U0) M 50'3N./!K.ZM5G=1K=]598)ET\&J%<82ZGBPIBQ3 MV;%.X_1JW_SIN%?QCH/U#T$Z<#GKMXZB# M&G7P/W( J<&\&OW!8?23N)VFT7%F\^X!NJJ#_1J^,9$B2Y0/HX5=!/42U^-7VFL>Q4(+;I2)M2" MF*8+YA><'75SI2_=H31D0N"31Z+)'$=;5*Z":6+7V-^]<6;K'_3"GEQ-J=X#VETK9W<0! MU&^Q\7]02P,$% @ 38.G4M1TS2E_ P O L !D !X;"]W;W)K&ULS59M:]LZ%/XK!S-8"UTMOR1Q1A)(DX[U%MML^ M7.X'U3Z)36TID^1F@?OCKR0[KFD==S *^Y)(LI[G/.=%TIGLN+B7*:*"GT7. MY-1)E=J^=UT9IUA0>$ZVZ3*++BSR99N\ ;5U^U*Z)G;L"19 M@4QFG(' ]=29>^^77F =L>W#'>R-0;CRAWG]V9RE4P=8A1ACK$R%%3_/> " M\]PP:1T_:E*GL6F [?&!_8-U7CMS1R4N>/X]2U0Z=2('$ES3,E?7?/<1:X<& MAB_FN;2_L*OW$@?B4BI>U&"MH,A8]4]_UH%H 31/-\"O ?ZO H(:$#P%A$< M80T(;60J5VP3FY3!)]X$/"),Y5*N&0))AWX13\^Z,&[ M.C)->/Q#>"[\7L*_2G8. 3DST1AWZ>F'?Z)"PST#][T.^/+7X:3'FZ!)=F#Y M@F/)3JG =^:8)+#@A;X[)+6G;RX$91O4YUG!W1[:^U9T;Y?G.RH2^.=O30E7 M"@OY;X^@L!$46D'A$4%?ML:\A(TVK[H37A$,+(&YQ!YFGC<\4,W@F9AR.21!YW6*&C9AAKYAYGO.8 MZ@" -)&'*O)Q*T-=8BK.84M,& 5AHZ0JL.>;!GYT)':C1NZH5^[+MP/\!Y?% M-N=[1-E3)E%C,/HSZG;<"!K_;MV.GY7*D$1^,!IUQ]XCCQ87*K4G;>@8D M&/D1.:*G]8!XO7I^.SEG=8Z^H53&J=4Q)RY>4!+"'JGH*SC/?_3*?VVOFN2T M,G8&WVTGHG?/'U#HS@JNT;1GQO&%?KN$;H1*FL,MBJ(S!/VR/?)R#!Y?"R]X MA6NI)FU?.1XA3ZZE%S95@MU66U.@V-CV4&H!)5/5$]ZL-BWHW#9>3]87IC6U M[=(C3=77ZA=VD^F#G.-:4Y+SD3X@HFH5JXGB6]L\W7&E6S$[3'5[C<)LT-_7 MG*O#Q!AH&O;9_U!+ P04 " !-@Z=2 Q0R,UT# 5# &0 'AL+W=O MA+@+Q8O,PN+-PL^+,+$.SN(?!CO=&A,;RDK*>SNYR29>8!D!A]18"(J/ M!U@ YQ8)>?RN0;WF3.O8'C^C?W'!8S KJF$A^2^6F7SB#3V2P9J6W-S)W3>H M ^I;O%1R[7[)KK8-/)*6VLBB=D8&!1/5DS[6B6@Y(,YIAZAVB X=>F<6,T3%@9ET;A+D,_,UT:F=[GDF>@]'MR M_;MDYHE<+'.JX-,DS"/.@&_4W5)XO CB8(H/,%G\>?N00>= MN-$D=GCQ.4U<]E?'V9\I1<6FRO/JB;3M;NF36Y[MJ,K(OW\A)+E!2?1_'81Z M#:&>(]0[0VC&N4Q1X(QH>R2ICDQ;U$Z)6&$F#M-6DX=I;QCWQOY#.[/'1OUH M&+^CV&[K]3KH+J=U[J. !1 FZ(P-) YF\#4D&#:'!*TA28?9;V0[#7G(@ MR0FCN#\Z+,WH9* M8; OK\$KZ%2#OM @&ASH=,HH&)S6*6S=!V$GX:\@L'ISIPW-\,:Q@E%[UW;E M(]K#1V]$HGVU#>/7D"@^RGXT2H:'&AU;Q5%XYF,*]_4X["[(=Z"!JC1W*F58 MYKCL[-1(H MA:G:C&:UZ6UGKJ,[6)_;GMZOI33/$WM \T]@^C]02P,$% @ 38.G4@3W7T)& M P Y0H !D !X;"]W;W)K&ULO59;;]HP%/XK M5M1IG=0E3L*U B0NW>4!#;7J]FR2$[#JQ)EM2OOO9SLA#310UDE[ 5_.=\[W MG6/'9[#EXD&N 11Z2EDFA\Y:J?S:\V2TAI1(E^>0Z9V$BY0H/14K3^8"2&Q! M*?,"C#M>2FCFC 9V;2%& [Y1C&:P$$ANTI2(YPDPOATZOK-;N*6KM3(+WFB0 MDQ7<@;K/%T+/O,I+3%/().49$I ,G;%_/?,MP%K\I+"5M3$R4I:"A&C.,[66Z":+(=['>YIPQ3K8L9X$)QW.B7!1Z%^A =^ M Y_I^7#< )^=AL\@.@;?4Q-6-0BMO_#<&ISPV:I\MJS/UE&.B5Z)T50G7M#E MQEZR!2/9%2K#"30G*EK3;+5G=(46("+(%.))8=%4[]/!V]C%^,,)%>U*1?L_ MJ-CE5WY$7P67$BW(WU+,6.JW)#><);J71C!AT881 M96JU,_VQ9'1%BHH9T48;NB4*F@2>9H'=\+ ^Q67^:]A>$GI5$GKO2,)KG4W" M>J^+$KC]_8QXJGL;:7.& M;6P[E(/UB7\]+3JN%S=% ZB?S!75-YE!HEUBMZN3+8J>JI@HGMLN8\F5[EGL M<*W[4!#&0.\GG*O=Q 2H.MO1'U!+ P04 " !-@Z=2-6=RS)D" "_!@ M&0 'AL+W=O]Y+X[/N^^^XNOJ2- MTH^FI-3"B^#23(/2VNH\#$U64D',F:JHQ).UTH)8-'41FDI3DGN0X&$<1>-0 M$":#6>KWEGJ6JMIR)NE2@ZF%(/KW)>6JF0:#8+-QQXK2NHUPEE:DH/?4/E1+ MC5;8L^1,4&F8DJ#I>AI<#,[G$^?O';XSVIBM-;A,5DH].N,ZGP:1$T0YS:QC M(/AZIG/*N2-"&4\=9]"'=,#M]8;]L\\=*_V"Y+:?!QP!RNB8UMW>J M^4*[?$:.+U/<^"T"R!S#L M $.?:*O,I[4@ELQ2K1K0SAO9W,+7QJ,Q&R9=%^^MQE.&.#N;*R&8Q;98 T3F M,%?2,EE0F3%JX'A9ZZS$*L&6WPD<+Z@EC./J SS<+^#XZ 2.@$GX5JK:((U) M0XOB7(@PZX1+,*)@UPND9H=#;!CNIV7+:&596?."ME<7[Y M98E_&*J= YZOE;(;PP7H_UFS/U!+ P04 " !-@Z=2XROA&M$# "J$ M&0 'AL+W=O$-""TA7?&:P4Y5G9%.9"O'=#F[G M/2^P$4$,,VU-4/.UA2'$L;5DXOB1&_4*GQ98?7ZQ?ITF;Y*94@5#$7]A<[WJ M>6T/S6%!-[%^%+L;R!-J6'LS$:OT$^WRM8&'9ANE19*#300)X]DW?U)B_I\\H""\0"0@^ M@!ZZT8.UO$1!HQ8^HAKG?_].[1) MW0&_<<-',"O@O\3NFPXIVH04;4)2>V%=FPBET%!PS?@2^(R!0E_OS!ITJR%1 MWQP>PL)#F'J(:CR,E69&BF".*BUYQ^B4Q4P_'RI@9J^9VK,2O>WC3A1UNOZV M6J<#J\)6.RA6O0HV*H*-G,%>2>"F!%N%;KD&R=-H:8SN8B39V5+4OD"#1&RX/K0!F_O5#8*:XK:* M(%JG[82;S%[CJ"C:111M9Q2#9+VB2E.)'E;4')(SV&C#;6P8O>5F00,7TS@>CO?T[_;P^C K+.&:T]\D5^4D& 4HAP(W5#WP[1WL#M0W MO(Q3:9]HV^X=# .4-5+Q:N>L%52$M6_\LDO$@4,2G7!(=@Z)U=T&LBIOL,+3 M5/ M$F:WIIF!/:KUUN((,U]EJ81>)=I/39?-2L)S TRAVXU^2G1^ PH3*B_0 M-_1^%9TAPM"<4*HS*M-0:06&$V:[:+,V6G(B6HSFG*E2HEN60_ZW?ZB5._G) M7OXL\0+G^!5UXZ\HB9+X<7F#SL\N/-2N2TK74GLGJ'>8O1#F ?4&Y(>+]S]@FSX^.1Q\D M;^PTCOT:\6MEKYXNL@CG.3$?$],C:H^);-EQ9.&F"&^FR;C32\/-$4EQ]%87 MHG](G%<5*@2OD"RQ-G2EKAN1E;I0'BT/_J#C#S(:'Y2U^)/7I'8'.2K(CQGU M3RD*#VIN!6)M.XM$&6^8:LNOFW7=ZZJMV6_;V]8WQV)-F$04"NT:=8;ZTHJV MF[2&XK6MX"NN=#^PPU)W8!!F@UXO.%=[PP1P/7WZ!U!+ P04 " !-@Z=2 MIQ2M.RD# .$P #0 'AL+W-T>6QES[?-]]]EVP MQ; T:\'N%XR98)4+68[(PICB4QB6LP7+:7FI"B8MDBF=4V.[>AZ6A68T+<$I M%V&OTXG#G'))QD.YS&]R4P8SM91F1/J-*7"/K^F(=../)'!T$Y6R$7D\?_]S MJ+Z[W[><5<$%"+VG_"-++CKU0Y@K%Z./CZ ^18]171U$? M8,:(![O$+=&.8U@G;3S,E&QS%Q%GL,PT9\$3%2,RH8)/-0>OC.9Q703W/:V'[P&;'@CD0C0">\09QL." M&L.TO+&=:G!E? $%=?MA75B%& KLRFG589K M[KU!S7]WG>=,,DW%MFA;^Z>\RJ]6'%W]*\G5K\J^8*_&>@<]=9']MR R/GV1 M47+Z&NM3S*F+')RDR+#>O[<."3M'A,8:P%%L1+[#H4ZT08/ID@O#9=U;\#1E M\L5)P=(;.K6'_1U^.SYE&5T*\]" (]*V;UG*EWG2C+J#A:A'M>UO,+UNW)P# M;2PN4[9BZ:3NZOFT:@:V8:/6%SCL(S?5Y4 ^C@O'S*I;BR.WR>QEW^F21)%<8RMZ&3B53#!UBV.X>-G MP[2!!Q8'(OW96N/9QBOD!MQ!%, &C DBJI]<&\_"C?[5-C^ S;^#5!+ P04 " !-@Z=2EXJ[ M', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6 M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(= MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( M $V#IU+-U>-YH@4 )XP / >&PO=V]R:V)O;VLN>&ULQ9O?;^(X$(#_ M%8N7:Z7= _*+;E4JT4*WZ&A!!/5U91(#5A.;M9UVV;_^G+!IY*>4S^95G0O=;&V.VE^VV3C8LI_ION67"[EE)E5-C-]6Z MK;>*T51O&#-YUO8ZG:B=4RY:UU>'<\U4V]V0AB6&2V$'RX$GSE[UV_YRD[QP MS9<\XV;7;U4_9ZQ%R-=[J?AO*0S-XD3)+.NWNOL=3TP9 MGGP8CDO(!5WJ:L30Y9Q:D'XKZM@3KKC2ICJB.C^UC"_,'KS?*HR\XYEA:D@- M^ZYDL>5B79[&7D7;N8PJ#H?/?1 OU?\)HURM>,*&,BER)LP^CHIE):#0&[[5 M+2)HSOJMPR%D(%(R$L8&B8S%_E3VV/)*[:\>I_NK-A;7B:&ZY':'&J<5.![D M[?0QGD[&P\%B-"0W@\G@\79$XOO1:!$[@!X Z)T,D)S-J /I Y#^$2'CA?UX M&#U:P.D=F3A]F#F0(0(8G@XP7TUL',@(@H]-%TBP<)I(MLD+%X8=I\0()TT47VQ7> M9=7$CFV%*=8E 1EHS>J4D"^ZR,(H R>,+8)9#0FR0Q=9#[:\MVG$[+Z06693 M\9I KO.*I8T%^UF\V#O.!A>\'(Y'DCLY0I_5=UEYF=RP;V%\AJ&.7;3.X8 M(S>V8%KQ6M+P(!EXV$V%S'.^S[;5;6]M52J5B:2>1CQ("1ZR$B:V3%J_[V<] MR @>LA'B8JG9SZ(L0T8O[U3E01+PD"4 UL _/!<3$H.'+(:&*IB<+%_=#$ASP3(GFG M'+*M8@E_W[8&D'D"[!42,)JU)43(00&R@^"&P7W20\A"(;*%/FT8]CM<3,A" M(;*%:@W#/*"F4%;MYVY%&4(6"I$M!/8.-0N%D(7"4[8X]7L3LE!X MS!9GR SE6:U\"\'E]U/V./6IAMP3GK3'J4TUY)[P*#U.;,^4%A;2)O)RY/PP M[2XFY)[PJ%V/HYW]#A<3"-D]S9C_L%V9UHOR)D]S1C_O=6HHL)62C"[H"@:-8L%(&O@6%W0(V8AKS?478OH01;J(5OHP[)V8ZW9@PS4PW[W M&%K@)F'K9WWB]W-B)!R>I5RVM7!^OHJM3>+8.FC M/;VVXPG-DIDBYA)Q1JA 7/X!^H2 QY=R:,9]>QIV^VY8?!X/IV%5[<:Q^U77PWI7CLUPUW;E M=#ZR:?MC,YZ7_;;NFO5[LRVU+)=1][D.Q'8G1#O M1*"WH-Y"H+>@WD*@MTP>M@GT%M1;"/06U%L(]!;46PCT%M1;"/06U%L(]!;4 M6PCT%M1;"/16U%L)]%;46PGT5M1;"?36R]G4!O1[V=0&]'O9U ;T>]G4!O MGWRL)-#;46\GT-M1;R?0VU%O)]#;46\GT#M0[R#0.U#O(- [4.\@T#M0[R#0 M.U#O(- [4.\@T#LF/YL0Z!VH=Q#H':AW$.@=J'<0Z)U1[TR@=T:],X'>&?7. M!'IGU#L3Z)U1[_R3>@_CUZ$,UY[O-5[_)ZD>S^>6Z^4OR^^=D[OW@G-]6S$\ M_0502P,$% @ 38.G4A^=A6\) @ V"H !, !;0V]N=&5N=%]4>7!E M&ULS=K-3N,P% 7@5ZFR18WKWS"(L@&V XMY 4]RVT9-8LMV.^7M<5) MFA%4H"+-V31J;=]SXRM]JU[_>O(49X>^&^*RV*3DKQB+]89Z&TOG:<@K*Q=Z MF_+7L&;>UEN[)B86"\-J-R0:TCR--8J;ZSM:V5V79O>'_'-LW; L G6QF-T> M-XY9R\)ZW[6U37F=[8?FGY3Y2T*93TY[XJ;U\2)O*-B[">/*QP$OYQ[V%$+; MT.S1AO33]GD7.W0LIJ>.8GFZQ#L]NM6JK:EQ]:[/1\KH ]DF;HA2WY7'HA>G MDU.^83I^\K/SIS*G O/.Q^!\S!,+]/6XUY&,I^<^%Z*0VM.O^):82Y_]?C1. MNZ'FD]GY>O^XL)WF$=GT./^._Y[Q6_TO]B% ^I @?2B0/C1('P:DCPJDCTN0 M/GZ ],$7*(V@B,I12.4HIG(45#F*JAR%58[B*D>!E:/(*E!D%2BR"A19!8JL M D56@2*K0)%5H,@J4&05*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4626* MK I%5H4BJT*15:'(JE!D52BR*A19%8JL"D56A2*K1I%5H\BJ4635*+)J%%DU MBJP:15:-(JM&D56CR&I09#4HLAH460V*K 9%5H,BJT&1U:#(:E!D-2BR5BBR M5BBR5BBR5BBR5O]3UM_.;;\Y?GJ6O6V'UWPV_:'UYAE02P$"% ,4 " !- M@Z=2!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P M+GAM;%!+ 0(4 Q0 ( $V#IU)+@*)G[P "L" 1 " M :\ !D;V-0&UL4$L! M A0#% @ 38.G4F[D"EQ"!0 G14 !@ ("!#@@ 'AL M+W=O 8 " @88- !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G4DWO MMB5D!0 VQ0 !@ ("!)Q@ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ 38.G4C"FM(&X!P YQX !@ M ("!32@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ 38.G4L5BY+!D"P VB$ !D ("!KD, 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G M4B[\IJOE! 8 P !D ("!W%H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G4J\%&X47!@ \1, M !D ("![FL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G4F3_5R<. P W < !D M ("!^7@ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 38.G4EM.QLZU#0 /BT !D ("!AX8 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G4E9* M"L\3"@ 6!H !D ("!$9T 'AL+W=O&PO=V]R:W-H965TL !X;"]W;W)K&UL4$L! A0#% @ 38.G4JC"*F'R @ F @ !D M ("!/+L 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 38.G4HXOSJN. @ 7P8 !D ("! M$<< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 38.G4B\W@0-A! .! !D ("!C- 'AL+W=O&UL4$L! A0#% @ 38.G4B*W$8@# M P :@< !D ("!^MH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G4H@92/8*!P 5A@ !D M ("!0^4 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 38.G4MC=E:5% P [0D !D ("![?, M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M38.G4NLZ*(_W P 2PX !D ("!_?T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G4@YCMBT; P "PL !D M ("! !8! 'AL+W=O&PO=V]R:W-H M965T 0!X;"]W;W)K&UL4$L! M A0#% @ 38.G4JAA73@, P N@@ !D ("!KR$! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G M4D4R[MY;!0 >QH !D ("!,RP! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G4F"D#QB @ 7 8 M !D ("!.S@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G4H;.9$>?! K1$ !D M ("!%T$! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 38.G4L'(3\)4 P F H !D ("!)4T! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G4@,4 M,C-= P %0P !D ("!.%@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38.G4N,KX1K1 P JA !D M ("!&6(! 'AL+W=O&PO M=V]R:W-H965T7!E&UL4$L%!@ !2 %( =18 ,5W 0 $! end XML 87 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 236 386 1 false 92 0 false 6 false false R1.htm 00090 - Document - Document And Entity Information Sheet http://www.amphastar.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.amphastar.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.amphastar.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 00500 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 10101 - Disclosure - General Sheet http://www.amphastar.com/role/DisclosureGeneral General Notes 8 false false R9.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10301 - Disclosure - Revenue Recognition Sheet http://www.amphastar.com/role/DisclosureRevenueRecognition Revenue Recognition Notes 10 false false R11.htm 10401 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders Sheet http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholders Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders Notes 11 false false R12.htm 10501 - Disclosure - Segment Reporting Sheet http://www.amphastar.com/role/DisclosureSegmentReporting Segment Reporting Notes 12 false false R13.htm 10601 - Disclosure - Customer and Supplier Concentration Sheet http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentration Customer and Supplier Concentration Notes 13 false false R14.htm 10701 - Disclosure - Fair Value Measurements Sheet http://www.amphastar.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 10801 - Disclosure - Investments Sheet http://www.amphastar.com/role/DisclosureInvestments Investments Notes 15 false false R16.htm 10901 - Disclosure - Goodwill and Intangible Assets Sheet http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 16 false false R17.htm 11001 - Disclosure - Inventories Sheet http://www.amphastar.com/role/DisclosureInventories Inventories Notes 17 false false R18.htm 11101 - Disclosure - Property, Plant, and Equipment Sheet http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipment Property, Plant, and Equipment Notes 18 false false R19.htm 11201 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 19 false false R20.htm 11301 - Disclosure - Debt Sheet http://www.amphastar.com/role/DisclosureDebt Debt Notes 20 false false R21.htm 11401 - Disclosure - Income Taxes Sheet http://www.amphastar.com/role/DisclosureIncomeTaxes Income Taxes Notes 21 false false R22.htm 11501 - Disclosure - Stockholders' Equity Sheet http://www.amphastar.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 22 false false R23.htm 11601 - Disclosure - Employee Benefits Sheet http://www.amphastar.com/role/DisclosureEmployeeBenefits Employee Benefits Notes 23 false false R24.htm 11701 - Disclosure - Commitments and Contingencies Sheet http://www.amphastar.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 24 false false R25.htm 11801 - Disclosure - Litigation Sheet http://www.amphastar.com/role/DisclosureLitigation Litigation Notes 25 false false R26.htm 11901 - Disclosure - Subsequent Events Sheet http://www.amphastar.com/role/DisclosureSubsequentEvents Subsequent Events Notes 26 false false R27.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPolicies 27 false false R28.htm 30303 - Disclosure - Revenue Recognition (Tables) Sheet http://www.amphastar.com/role/DisclosureRevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.amphastar.com/role/DisclosureRevenueRecognition 28 false false R29.htm 30403 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Tables) Sheet http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersTables Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Tables) Tables http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholders 29 false false R30.htm 30503 - Disclosure - Segment Reporting (Tables) Sheet http://www.amphastar.com/role/DisclosureSegmentReportingTables Segment Reporting (Tables) Tables http://www.amphastar.com/role/DisclosureSegmentReporting 30 false false R31.htm 30603 - Disclosure - Customer and Supplier Concentration (Tables) Sheet http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationTables Customer and Supplier Concentration (Tables) Tables http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentration 31 false false R32.htm 30703 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.amphastar.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.amphastar.com/role/DisclosureFairValueMeasurements 32 false false R33.htm 30803 - Disclosure - Investments (Tables) Sheet http://www.amphastar.com/role/DisclosureInvestmentsTables Investments (Tables) Tables http://www.amphastar.com/role/DisclosureInvestments 33 false false R34.htm 30903 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssets 34 false false R35.htm 31003 - Disclosure - Inventories (Tables) Sheet http://www.amphastar.com/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.amphastar.com/role/DisclosureInventories 35 false false R36.htm 31103 - Disclosure - Property, Plant, and Equipment (Tables) Sheet http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentTables Property, Plant, and Equipment (Tables) Tables http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipment 36 false false R37.htm 31203 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilities 37 false false R38.htm 31303 - Disclosure - Debt (Tables) Sheet http://www.amphastar.com/role/DisclosureDebtTables Debt (Tables) Tables http://www.amphastar.com/role/DisclosureDebt 38 false false R39.htm 31403 - Disclosure - Income Taxes (Tables) Sheet http://www.amphastar.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.amphastar.com/role/DisclosureIncomeTaxes 39 false false R40.htm 31503 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.amphastar.com/role/DisclosureStockholdersEquity 40 false false R41.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 41 false false R42.htm 40301 - Disclosure - Revenue Recognition (Analysis of the Chargeback Provision) (Details) Sheet http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails Revenue Recognition (Analysis of the Chargeback Provision) (Details) Details http://www.amphastar.com/role/DisclosureRevenueRecognitionTables 42 false false R43.htm 40302 - Disclosure - Revenue Recognition (Analysis of Product Return Liability) (Details) Sheet http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails Revenue Recognition (Analysis of Product Return Liability) (Details) Details http://www.amphastar.com/role/DisclosureRevenueRecognitionTables 43 false false R44.htm 40401 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Narrative) (Details) Sheet http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersNarrativeDetails Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Narrative) (Details) Details http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersTables 44 false false R45.htm 40402 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details) Sheet http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details) Details http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersTables 45 false false R46.htm 40501 - Disclosure - Segment Reporting (Selected Financial Information by Reporting Segment) (Details) Sheet http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails Segment Reporting (Selected Financial Information by Reporting Segment) (Details) Details http://www.amphastar.com/role/DisclosureSegmentReportingTables 46 false false R47.htm 40502 - Disclosure - Segment Reporting (Summary of Net Revenues by Product Segment) (Details) Sheet http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails Segment Reporting (Summary of Net Revenues by Product Segment) (Details) Details http://www.amphastar.com/role/DisclosureSegmentReportingTables 47 false false R48.htm 40503 - Disclosure - Segment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details) Sheet http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails Segment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details) Details http://www.amphastar.com/role/DisclosureSegmentReportingTables 48 false false R49.htm 40504 - Disclosure - Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details) Sheet http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details) Details http://www.amphastar.com/role/DisclosureSegmentReportingTables 49 false false R50.htm 40601 - Disclosure - Customer and Supplier Concentration (Details) Sheet http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails Customer and Supplier Concentration (Details) Details http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationTables 50 false false R51.htm 40701 - Disclosure - Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details) Sheet http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details) Details http://www.amphastar.com/role/DisclosureFairValueMeasurementsTables 51 false false R52.htm 40801 - Disclosure - Investments (Held-to_Maturity) (Details) Sheet http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails Investments (Held-to_Maturity) (Details) Details http://www.amphastar.com/role/DisclosureInvestmentsTables 52 false false R53.htm 40901 - Disclosure - Goodwill and Intangible Assets (Summary of Intangible Assets) (Details) Sheet http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails Goodwill and Intangible Assets (Summary of Intangible Assets) (Details) Details http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables 53 false false R54.htm 40902 - Disclosure - Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details) Sheet http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwillDetails Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details) Details http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables 54 false false R55.htm 41001 - Disclosure - Inventories (Details) Sheet http://www.amphastar.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://www.amphastar.com/role/DisclosureInventoriesTables 55 false false R56.htm 41101 - Disclosure - Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details) Sheet http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details) Details http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentTables 56 false false R57.htm 41201 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables 57 false false R58.htm 41301 - Disclosure - Debt (Schedule of Debt) (Details) Sheet http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails Debt (Schedule of Debt) (Details) Details http://www.amphastar.com/role/DisclosureDebtTables 58 false false R59.htm 41401 - Disclosure - Income Taxes (Summary of Income Before Taxes) (Details) Sheet http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeBeforeTaxesDetails Income Taxes (Summary of Income Before Taxes) (Details) Details http://www.amphastar.com/role/DisclosureIncomeTaxesTables 59 false false R60.htm 41501 - Disclosure - Stockholders' Equity (Share Buyback Program) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails Stockholders' Equity (Share Buyback Program) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 60 false false R61.htm 41502 - Disclosure - Stockholders' Equity (The 2015 Equity Incentive Plan) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails Stockholders' Equity (The 2015 Equity Incentive Plan) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 61 false false R62.htm 41503 - Disclosure - Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 62 false false R63.htm 41504 - Disclosure - Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 63 false false R64.htm 41505 - Disclosure - Stockholders' Equity (Summary of Option Activity) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails Stockholders' Equity (Summary of Option Activity) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 64 false false R65.htm 41506 - Disclosure - Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 65 false false R66.htm 41507 - Disclosure - Stockholders' Equity (Summary of Nonvested Options) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails Stockholders' Equity (Summary of Nonvested Options) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 66 false false R67.htm 41508 - Disclosure - Stockholders' Equity (Restricted Stock Units) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails Stockholders' Equity (Restricted Stock Units) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 67 false false R68.htm 41509 - Disclosure - Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 68 false false R69.htm 41510 - Disclosure - Stockholders' Equity (The 2018 ANP Equity Incentive Plan) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails Stockholders' Equity (The 2018 ANP Equity Incentive Plan) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 69 false false R70.htm 41511 - Disclosure - Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details) Sheet http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details) Details http://www.amphastar.com/role/DisclosureStockholdersEquityTables 70 false false R71.htm 41601 - Disclosure - Employee Benefits (Details) Sheet http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails Employee Benefits (Details) Details http://www.amphastar.com/role/DisclosureEmployeeBenefits 71 false false R72.htm 41701 - Disclosure - Commitments and Contingencies (Purchase Commitments) (Details) Sheet http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails Commitments and Contingencies (Purchase Commitments) (Details) Details http://www.amphastar.com/role/DisclosureCommitmentsAndContingencies 72 false false R73.htm 41801 - Disclosure - Litigation (Details) Sheet http://www.amphastar.com/role/DisclosureLitigationDetails Litigation (Details) Details http://www.amphastar.com/role/DisclosureLitigation 73 false false R74.htm 41901 - Disclosure - Subsequent Events (Details) Sheet http://www.amphastar.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.amphastar.com/role/DisclosureSubsequentEvents 74 false false All Reports Book All Reports amph-20210331x10q.htm amph-20210331.xsd amph-20210331_cal.xml amph-20210331_def.xml amph-20210331_lab.xml amph-20210331_pre.xml amph-20210331ex311bc3af2.htm amph-20210331ex312400750.htm amph-20210331ex32127a626.htm amph-20210331ex32219a512.htm http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 true true JSON 92 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "amph-20210331x10q.htm": { "axisCustom": 0, "axisStandard": 34, "contextCount": 236, "dts": { "calculationLink": { "local": [ "amph-20210331_cal.xml" ] }, "definitionLink": { "local": [ "amph-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "amph-20210331x10q.htm" ] }, "labelLink": { "local": [ "amph-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "amph-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "amph-20210331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 564, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 10, "http://www.amphastar.com/20210331": 2, "http://xbrl.sec.gov/dei/2020-01-31": 8, "total": 20 }, "keyCustom": 37, "keyStandard": 349, "memberCustom": 50, "memberStandard": 39, "nsprefix": "amph", "nsuri": "http://www.amphastar.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document And Entity Information", "role": "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "amph:RevenueRecognitionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Revenue Recognition", "role": "http://www.amphastar.com/role/DisclosureRevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "amph:RevenueRecognitionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders", "role": "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholders", "shortName": "Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Segment Reporting", "role": "http://www.amphastar.com/role/DisclosureSegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Customer and Supplier Concentration", "role": "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentration", "shortName": "Customer and Supplier Concentration", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Fair Value Measurements", "role": "http://www.amphastar.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Investments", "role": "http://www.amphastar.com/role/DisclosureInvestments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Inventories", "role": "http://www.amphastar.com/role/DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Property, Plant, and Equipment", "role": "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipment", "shortName": "Property, Plant, and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Accounts Payable and Accrued Liabilities", "role": "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Debt", "role": "http://www.amphastar.com/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Income Taxes", "role": "http://www.amphastar.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Stockholders' Equity", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Employee Benefits", "role": "http://www.amphastar.com/role/DisclosureEmployeeBenefits", "shortName": "Employee Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11701 - Disclosure - Commitments and Contingencies", "role": "http://www.amphastar.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11801 - Disclosure - Litigation", "role": "http://www.amphastar.com/role/DisclosureLitigation", "shortName": "Litigation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11901 - Disclosure - Subsequent Events", "role": "http://www.amphastar.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "amph:SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "amph:SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "amph:ScheduleOfChargebackLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.amphastar.com/role/DisclosureRevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "amph:ScheduleOfChargebackLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Tables)", "role": "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersTables", "shortName": "Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_qjfxrtvbhUOqk_UjWl0srg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.amphastar.com/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_qjfxrtvbhUOqk_UjWl0srg", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Segment Reporting (Tables)", "role": "http://www.amphastar.com/role/DisclosureSegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Customer and Supplier Concentration (Tables)", "role": "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationTables", "shortName": "Customer and Supplier Concentration (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.amphastar.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Investments (Tables)", "role": "http://www.amphastar.com/role/DisclosureInvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "amph:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "amph:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Inventories (Tables)", "role": "http://www.amphastar.com/role/DisclosureInventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Property, Plant, and Equipment (Tables)", "role": "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentTables", "shortName": "Property, Plant, and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "role": "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Debt (Tables)", "role": "http://www.amphastar.com/role/DisclosureDebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Income Taxes (Tables)", "role": "http://www.amphastar.com/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "amph:ScheduleOfChargebackLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_0MJQI3xx1EWJCRBGWSohEw", "decimals": "-3", "first": true, "lang": null, "name": "amph:RevenueRecognitionWholesalerChargebacks", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Revenue Recognition (Analysis of the Chargeback Provision) (Details)", "role": "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails", "shortName": "Revenue Recognition (Analysis of the Chargeback Provision) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "amph:ScheduleOfChargebackLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "lang": null, "name": "amph:RevenueRecognitionWholesalerChargebacksProvisionRelatedToSalesInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "3", "first": true, "lang": null, "name": "amph:ProductReturnRatePercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_zp7gL24xDUa2qzd_ttgGPg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Revenue Recognition (Analysis of Product Return Liability) (Details)", "role": "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails", "shortName": "Revenue Recognition (Analysis of Product Return Liability) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "3", "first": true, "lang": null, "name": "amph:ProductReturnRatePercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_zp7gL24xDUa2qzd_ttgGPg", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_amph_EmployeeAndNonEmployeeStockOptionsMember_Qsk2CQHKW0qWF5jFGCEjmg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Narrative) (Details)", "role": "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersNarrativeDetails", "shortName": "Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_amph_EmployeeAndNonEmployeeStockOptionsMember_Qsk2CQHKW0qWF5jFGCEjmg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details)", "role": "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "shortName": "Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_WNFxtS-TdECZUm-ThqiVMw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Segment Reporting (Selected Financial Information by Reporting Segment) (Details)", "role": "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "shortName": "Segment Reporting (Selected Financial Information by Reporting Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_WNFxtS-TdECZUm-ThqiVMw", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Segment Reporting (Summary of Net Revenues by Product Segment) (Details)", "role": "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "shortName": "Segment Reporting (Summary of Net Revenues by Product Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementBusinessSegmentsAxis_amph_FinishedPharmaceuticalProductsSegmentMember_us-gaap_SubsegmentsAxis_amph_EnoxaparinMember_xBhXmgaip0S7EFvyStDxlA", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "amph:ScheduleOfDepreciationDepletionAndAmortizationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40503 - Disclosure - Segment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details)", "role": "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "shortName": "Segment Reporting (Depreciation and Amortization Expense by Reporting Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "amph:ScheduleOfDepreciationDepletionAndAmortizationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40504 - Disclosure - Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details)", "role": "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails", "shortName": "Segment Reporting (Summary of Revenues and Long-Lived Assets by Geographic Region) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_mL3hQ9we2ESCE0NpQWPnzQ", "decimals": "INF", "first": true, "lang": null, "name": "amph:NumberOfMajorCustomersWholesaleDrugDistributors", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_NeSo95ZbrUOhW_Y5R1E8zA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Customer and Supplier Concentration (Details)", "role": "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails", "shortName": "Customer and Supplier Concentration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_mL3hQ9we2ESCE0NpQWPnzQ", "decimals": "INF", "first": true, "lang": null, "name": "amph:NumberOfMajorCustomersWholesaleDrugDistributors", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_NeSo95ZbrUOhW_Y5R1E8zA", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lmPLBn3H106P8MjLjNqO1g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details)", "role": "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails", "shortName": "Fair Value Measurements (Fair Values of the Company's Financial Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lmPLBn3H106P8MjLjNqO1g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Investments (Held-to_Maturity) (Details)", "role": "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails", "shortName": "Investments (Held-to_Maturity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "amph:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Goodwill and Intangible Assets (Summary of Intangible Assets) (Details)", "role": "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets (Summary of Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "amph:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_0MJQI3xx1EWJCRBGWSohEw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details)", "role": "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwillDetails", "shortName": "Goodwill and Intangible Assets (Summary of Changes in the Carrying Amount of Goodwill) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Inventories (Details)", "role": "http://www.amphastar.com/role/DisclosureInventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details)", "role": "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "shortName": "Property, Plant, and Equipment (Summary of Property, Plant, and Equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "amph:AccruedCustomerFeesAndRebates", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "role": "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "amph:AccruedCustomerFeesAndRebates", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Debt (Schedule of Debt) (Details)", "role": "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails", "shortName": "Debt (Schedule of Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Income Taxes (Summary of Income Before Taxes) (Details)", "role": "http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeBeforeTaxesDetails", "shortName": "Income Taxes (Summary of Income Before Taxes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_zp7gL24xDUa2qzd_ttgGPg", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aG9IMgy_iUu2oHUsbbmUjA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aG9IMgy_iUu2oHUsbbmUjA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Stockholders' Equity (Share Buyback Program) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails", "shortName": "Stockholders' Equity (Share Buyback Program) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_8_4_2020_us-gaap_ShareRepurchaseProgramAxis_amph_November2014ShareRepurchasePlanMember_DLp8hT3xp0OFdy1h6CLWSA", "decimals": "-5", "lang": null, "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_us-gaap_PlanNameAxis_amph_The2015EquityIncentivePlanMember_iSffefobLU6P7EsCYPzHng", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41502 - Disclosure - Stockholders' Equity (The 2015 Equity Incentive Plan) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails", "shortName": "Stockholders' Equity (The 2015 Equity Incentive Plan) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_us-gaap_PlanNameAxis_amph_The2015EquityIncentivePlanMember_iSffefobLU6P7EsCYPzHng", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41503 - Disclosure - Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "shortName": "Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_PlanNameAxis_amph_EmployeeStockPurchasePlan2014Member_Gc0ysvgi5UOjmSwYip2t1Q", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_zp7gL24xDUa2qzd_ttgGPg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41504 - Disclosure - Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails", "shortName": "Stockholders' Equity (Key Assumptions Used in Determining Fair Value of Options Granted) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_zp7gL24xDUa2qzd_ttgGPg", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_0MJQI3xx1EWJCRBGWSohEw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41505 - Disclosure - Stockholders' Equity (Summary of Option Activity) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails", "shortName": "Stockholders' Equity (Summary of Option Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_0MJQI3xx1EWJCRBGWSohEw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_qjfxrtvbhUOqk_UjWl0srg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41506 - Disclosure - Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails", "shortName": "Stockholders' Equity (Information Relating to Option Grants and Exercises) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_0MJQI3xx1EWJCRBGWSohEw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41507 - Disclosure - Stockholders' Equity (Summary of Nonvested Options) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails", "shortName": "Stockholders' Equity (Summary of Nonvested Options) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_0MJQI3xx1EWJCRBGWSohEw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41508 - Disclosure - Stockholders' Equity (Restricted Stock Units) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "shortName": "Stockholders' Equity (Restricted Stock Units) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_poIXO4F18UCoKX-HKInxag", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VA24Svfb6EO4geLypZUzGg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41509 - Disclosure - Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "shortName": "Stockholders' Equity (Information Relating to RSU Grants and Deliveries) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VA24Svfb6EO4geLypZUzGg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41510 - Disclosure - Stockholders' Equity (The 2018 ANP Equity Incentive Plan) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails", "shortName": "Stockholders' Equity (The 2018 ANP Equity Incentive Plan) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_srt_TitleOfIndividualAxis_amph_EmployeeMember_us-gaap_PlanNameAxis_amph_Anp2018EquityIncentivePlanMember_mG7D8kkEv0eff2El-MaiFQ", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_FtVgny8l-UGeebLItJ10Vg", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "lang": null, "name": "us-gaap:GainLossOnDispositionOfAssets1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41511 - Disclosure - Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details)", "role": "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails", "shortName": "Stockholders' Equity (Share-Based Compensation Expense Included in the Statement of Operations) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Y1wCnFauoUGG5wnrbl3rxg", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_zp7gL24xDUa2qzd_ttgGPg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Employee Benefits (Details)", "role": "http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails", "shortName": "Employee Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_zp7gL24xDUa2qzd_ttgGPg", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualObligation", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41701 - Disclosure - Commitments and Contingencies (Purchase Commitments) (Details)", "role": "http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails", "shortName": "Commitments and Contingencies (Purchase Commitments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_amph_CommitmentsToPurchaseEquipmentAndRawMaterialsMember_lwtEvN3Pz0yyOlw8uXdZ-A", "decimals": "-5", "lang": null, "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "As_Of_3_31_2021_KkGq3oos50unMrFXLNJdVg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LitigationReserve", "reportCount": 1, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41801 - Disclosure - Litigation (Details)", "role": "http://www.amphastar.com/role/DisclosureLitigationDetails", "shortName": "Litigation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_2_9_2021_To_2_9_2021_srt_LitigationCaseAxis_amph_BrenesVsInternationalMedicationSystemsLimitedMember_JERdbEN92UmS2BzlulDcMQ", "decimals": "-5", "lang": null, "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VJqNhq5d2E6hWIy7vqnbvA", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_5_1_2021_To_5_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_amph_NanjingHanxinPharmaceuticalTechnologyCoLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WQhrxvllp0K_G-3KimSvsg", "decimals": "2", "first": true, "lang": null, "name": "amph:OwnershipPercentageAfterSpinoffTransaction", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_zp7gL24xDUa2qzd_ttgGPg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41901 - Disclosure - Subsequent Events (Details)", "role": "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_5_1_2021_To_5_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_amph_NanjingHanxinPharmaceuticalTechnologyCoLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WQhrxvllp0K_G-3KimSvsg", "decimals": "2", "first": true, "lang": null, "name": "amph:OwnershipPercentageAfterSpinoffTransaction", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_zp7gL24xDUa2qzd_ttgGPg", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - General", "role": "http://www.amphastar.com/role/DisclosureGeneral", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "amph:SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "amph-20210331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_ZgSo-LWVW0SJI3yIXbsfOQ", "decimals": null, "first": true, "lang": "en-US", "name": "amph:SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 92, "tag": { "amph_AccruedCustomerFeesAndRebates": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued customer fees and rebates", "label": "Accrued customer fees and rebates" } } }, "localname": "AccruedCustomerFeesAndRebates", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "amph_AcquiredInternationalProductRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired International Product Rights [Member]", "label": "Acquired International Product Rights [Member]", "terseLabel": "Acquired international product rights" } } }, "localname": "AcquiredInternationalProductRightsMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "amph_AcquisitionLoanDueJune2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a secured term loan due June 2024 entered into with Cathay Bank in conjunction with an acquisition.", "label": "Acquisition Loan Due June2024 [Member]", "terseLabel": "Acquisition Loan - Due June 2024" } } }, "localname": "AcquisitionLoanDueJune2024Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_ActivePharmaceuticalIngredientSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the active pharmaceutical ingredient or API segment of the business.", "label": "Active Pharmaceutical Ingredient Segment [Member]", "terseLabel": "API" } } }, "localname": "ActivePharmaceuticalIngredientSegmentMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails" ], "xbrltype": "domainItemType" }, "amph_AmerisourceBergenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The major customer AmerisourceBergen.", "label": "Amerisource Bergen [Member]", "terseLabel": "AmerisourceBergen" } } }, "localname": "AmerisourceBergenMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "domainItemType" }, "amph_AmphastarPharmaceuticalsInc.VsAventisPharmaSaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about court case Amphastar Pharmaceuticals, Inc. Vs. Aventis Pharma, SA.", "label": "Amphastar Pharmaceuticals Inc. Vs Aventis Pharma Sa [Member]", "terseLabel": "Amphastar Pharmaceuticals, Inc. Vs Aventis Pharma, SA" } } }, "localname": "AmphastarPharmaceuticalsInc.VsAventisPharmaSaMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "domainItemType" }, "amph_Anp2018EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the 2018 ANP Equity Incentive Plan.", "label": "Anp2018 Equity Incentive Plan [Member]", "terseLabel": "The 2018 ANP Equity Incentive Plan" } } }, "localname": "Anp2018EquityIncentivePlanMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "amph_AnpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ANP [Member]", "label": "Anp [Member]", "terseLabel": "ANP" } } }, "localname": "AnpMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "amph_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfExcludedSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the weighted-average exercise price of the excluded securities, per share.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Exercise Price of Excluded Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfExcludedSecurities", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersNarrativeDetails" ], "xbrltype": "perShareItemType" }, "amph_BankOfNanjingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bank of Nanjing", "label": "Bank Of Nanjing [Member]", "terseLabel": "Bank of Nanjing" } } }, "localname": "BankOfNanjingMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_BrenesVsInternationalMedicationSystemsLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about Brenes's claim vs International Medication Systems Limited.", "label": "Brenes Vs International Medication Systems Limited [Member]", "terseLabel": "Brenes vs International Medication Systems, Limited" } } }, "localname": "BrenesVsInternationalMedicationSystemsLimitedMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "domainItemType" }, "amph_CardinalHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The major customer Cardinal Health.", "label": "Cardinal Health [Member]", "terseLabel": "Cardinal Health" } } }, "localname": "CardinalHealthMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "domainItemType" }, "amph_CathayBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Cathay Bank.", "label": "Cathay Bank [Member]", "terseLabel": "Cathay Bank" } } }, "localname": "CathayBankMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_ChinaMerchantBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans/Agreements with China Merchant Bank", "label": "China Merchant Bank [Member]", "terseLabel": "China Merchant Bank" } } }, "localname": "ChinaMerchantBankMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_CommitmentsToPurchaseEquipmentAndRawMaterialsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents commitments to purchase equipment and raw materials.", "label": "Commitments To Purchase Equipment And Raw Materials [Member]", "terseLabel": "Commitments to Purchase Equipment and Raw Materials" } } }, "localname": "CommitmentsToPurchaseEquipmentAndRawMaterialsMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "domainItemType" }, "amph_CoronavirusDisease2019PandemicPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Coronavirus Disease 2019 Pandemic.", "label": "Coronavirus Disease 2019 Pandemic [Policy Text Block]", "terseLabel": "COVID-19 Pandemic" } } }, "localname": "CoronavirusDisease2019PandemicPolicyTextBlock", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "amph_EastWestBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents East West Bank.", "label": "East West Bank [Member]", "terseLabel": "East West Bank" } } }, "localname": "EastWestBankMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_EmployeeAndNonEmployeeStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time.", "label": "Employee And Non Employee Stock Options [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeAndNonEmployeeStockOptionsMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersNarrativeDetails" ], "xbrltype": "domainItemType" }, "amph_EmployeeConsultantAndDirectorsStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An arrangement whereby an employee, consultant or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.", "label": "Employee Consultant And Directors Stock Options [Member]", "terseLabel": "Employee Consultant And Directors Stock Options" } } }, "localname": "EmployeeConsultantAndDirectorsStockOptionsMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "domainItemType" }, "amph_EmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individuals that are employees of the company.", "label": "Employee [Member]", "terseLabel": "Employees" } } }, "localname": "EmployeeMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "amph_EmployeeStockPurchasePlan2014Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the 2014 Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan2014 [Member]", "terseLabel": "2014 Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockPurchasePlan2014Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "amph_EnoxaparinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Enoxaparin", "label": "Enoxaparin [Member]", "terseLabel": "Enoxaparin" } } }, "localname": "EnoxaparinMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails" ], "xbrltype": "domainItemType" }, "amph_EpinephrineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Epinephrine [Member]", "label": "Epinephrine [Member]", "terseLabel": "Epinephrine" } } }, "localname": "EpinephrineMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails" ], "xbrltype": "domainItemType" }, "amph_EquipmentLineOfCreditDueSeptember2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment Line of Credit due September 2025", "label": "Equipment Line Of Credit Due September2025 [Member]", "terseLabel": "Equipment Line of Credit - Due September 2025" } } }, "localname": "EquipmentLineOfCreditDueSeptember2025Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_EquipmentLoanDueDecember2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment Loan - Due December 2022 [Member]", "label": "Equipment Loan Due December2022 [Member]", "terseLabel": "Equipment Loan - Due December 2022" } } }, "localname": "EquipmentLoanDueDecember2022Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_EquipmentLoanDueFebruary2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment Loan Due February 2024 [Member]", "label": "Equipment Loan Due February2024 [Member]", "terseLabel": "Equipment Loan - Due February 2024" } } }, "localname": "EquipmentLoanDueFebruary2024Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_EquipmentLoanDueJune2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment Loan Due June 2021 [Member]", "label": "Equipment Loan Due June2021 [Member]", "terseLabel": "Equipment Loan - Due June 2021" } } }, "localname": "EquipmentLoanDueJune2021Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_EquityInterestRetainedPostPrivatePlacement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity interest retained post private placement", "label": "Equity interest retained post private placement" } } }, "localname": "EquityInterestRetainedPostPrivatePlacement", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "amph_EverbrightBankOfChinaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans with China Everbright bank", "label": "Everbright Bank Of China [Member]", "terseLabel": "China Everbright Bank" } } }, "localname": "EverbrightBankOfChinaMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_FinishedPharmaceuticalProductsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the finished pharmaceutical products segments of the business.", "label": "Finished Pharmaceutical Products Segment [Member]", "terseLabel": "Finished Pharmaceutical Products" } } }, "localname": "FinishedPharmaceuticalProductsSegmentMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "amph_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "amph_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of finite-lived and indefinite-lived intangible assets, excluding goodwill, in total and by major class.", "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "amph_FrenchGovernmentLoan4DueDecember2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the French Government loan due December 2026.", "label": "French Government Loan4 Due December2026 [Member]", "terseLabel": "French Government Loan 4 - Due December 2026" } } }, "localname": "FrenchGovernmentLoan4DueDecember2026Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_FrenchGovernmentLoanDueJuly2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the French Government loan due July 2021.", "label": "French Government Loan Due July2021 [Member]", "terseLabel": "French Government Loan - Due July 2021" } } }, "localname": "FrenchGovernmentLoanDueJuly2021Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_FurnitureFixturesAndVehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total of 1) equipment such as desks, chairs) commonly used in offices and stores that have no permanent connection to the structure of a building or utilities and 2) vehicles.", "label": "Furniture Fixtures And Vehicles [Member]", "terseLabel": "Furniture, fixtures, and automobiles" } } }, "localname": "FurnitureFixturesAndVehiclesMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "amph_GlucagonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glucagon", "label": "Glucagon [Member]", "terseLabel": "Glucagon" } } }, "localname": "GlucagonMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails" ], "xbrltype": "domainItemType" }, "amph_IncomeTaxRefundAndDeposits": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds and deposits of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Tax Refund And deposits", "terseLabel": "Income tax refunds and deposits" } } }, "localname": "IncomeTaxRefundAndDeposits", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "amph_IncreaseDecreaseInIncomeTaxRefundDepositsAndPayable": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Income Tax Refund, Deposits, and Payable", "label": "Increase Decrease In Income Tax Refund, Deposits, and Payable", "negatedLabel": "Income tax refunds, deposits, and payables, net" } } }, "localname": "IncreaseDecreaseInIncomeTaxRefundDepositsAndPayable", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amph_IndefiniteLivedIntangibleAssetsIncludingGoodwillGross": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "amph_IntangibleAssetsGrossIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of indefinite-lived intangible assets and goodwill.", "label": "Indefinite Lived Intangible Assets Including Goodwill Gross", "terseLabel": "Subtotal, Original Cost" } } }, "localname": "IndefiniteLivedIntangibleAssetsIncludingGoodwillGross", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amph_IndefiniteLivedIntangibleAssetsIncludingGoodwillNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of indefinite-lived intangible assets and goodwill.", "label": "Indefinite Lived Intangible Assets Including Goodwill Net", "terseLabel": "Subtotal, Net Book Value" } } }, "localname": "IndefiniteLivedIntangibleAssetsIncludingGoodwillNet", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amph_IntangibleAssetsGrossIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, including goodwill.", "label": "Balance, Original Cost", "totalLabel": "Balance, Original Cost" } } }, "localname": "IntangibleAssetsGrossIncludingGoodwill", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amph_InternationalMedicationSystemsUkLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International Medication Systems (UK) Limited [Member]", "label": "International Medication Systems Uk Limited [Member]", "terseLabel": "International Medication Systems (UK) Limited" } } }, "localname": "InternationalMedicationSystemsUkLimitedMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "amph_LidocaineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lidocaine [Member]", "label": "Lidocaine [Member]", "terseLabel": "Lidocaine" } } }, "localname": "LidocaineMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails" ], "xbrltype": "domainItemType" }, "amph_LineOfCreditDueAugust2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility with China Merchant Bank due August 2021", "label": "Line Of Credit Due August2021 [Member]", "terseLabel": "Line of Credit - Due August 2021" } } }, "localname": "LineOfCreditDueAugust2021Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_LineOfCreditDueOctober2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility with Bank of Nanjing due October 2021", "label": "Line Of Credit Due October2021 [Member]", "terseLabel": "Line of Credit - Due October 2021" } } }, "localname": "LineOfCreditDueOctober2021Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_McKessonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The major customer McKesson.", "label": "Mc Kesson [Member]", "terseLabel": "McKesson" } } }, "localname": "McKessonMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "domainItemType" }, "amph_MortgagePayableDueAugust2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents mortgage payable Due August 2027 secured by the building at the reporting entity's Canton, Massachusetts location.", "label": "Mortgage Payable Due August2027 [Member]", "terseLabel": "Mortgage Payable - Due August 2027" } } }, "localname": "MortgagePayableDueAugust2027Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_MortgagePayableDueJune2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Payable - Due June 2027 [Member]", "label": "Mortgage Payable Due June2027 [Member]", "terseLabel": "Mortgage Payable - Due June 2027" } } }, "localname": "MortgagePayableDueJune2027Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_MortgagePayableDueMay2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Payable - Due May 2021", "label": "Mortgage Payable Due May2021 [Member]", "terseLabel": "Mortgage Payable - Due May 2021" } } }, "localname": "MortgagePayableDueMay2021Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_MortgagePayableDueOctober2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Payable - Due October 2026 [Member]", "label": "Mortgage Payable Due October2026 [Member]", "terseLabel": "Mortgage Payable - Due October 2026" } } }, "localname": "MortgagePayableDueOctober2026Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_NaloxoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Naloxone [Member]", "label": "Naloxone [Member]", "terseLabel": "Naloxone" } } }, "localname": "NaloxoneMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails" ], "xbrltype": "domainItemType" }, "amph_NanjingHanxinPharmaceuticalTechnologyCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Nanjing Hanxin Pharmaceutical Technology Co., Ltd., or Hanxin.", "label": "Nanjing Hanxin Pharmaceutical Technology Co Ltd [Member]", "terseLabel": "Hanxin" } } }, "localname": "NanjingHanxinPharmaceuticalTechnologyCoLtdMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "amph_NoncashOperatingLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease in noncash investing or financing activities.", "label": "Noncash Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "NoncashOperatingLeaseRightOfUseAsset", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amph_November2014ShareRepurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "November 2014 share repurchase plan.", "label": "November2014 Share Repurchase Plan [Member]", "terseLabel": "November 2014 Share Repurchase Plan" } } }, "localname": "November2014ShareRepurchasePlanMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails" ], "xbrltype": "domainItemType" }, "amph_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of major customers.", "label": "Number Of Major Customers", "terseLabel": "Number of major customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "integerItemType" }, "amph_NumberOfMajorCustomersWholesaleDrugDistributors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of major customers that are wholesale distributors of the reporting entity's products.", "label": "Number Of Major Customers, Wholesale Drug Distributors", "terseLabel": "Number of major customers that are wholesale distributors" } } }, "localname": "NumberOfMajorCustomersWholesaleDrugDistributors", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "integerItemType" }, "amph_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from operating lease.", "label": "Operating Lease Right Of Use Asset Amortization", "terseLabel": "Operating lease right-of-use asset amortization" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amph_OperatingLeaseRightOfUseAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease, net of present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Right Of Use Assets And Liabilities Net", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseRightOfUseAssetsAndLiabilitiesNet", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amph_OtherEffectiveTaxRateProvisionBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other effective tax rate provision (benefit)", "label": "Other Effective Tax Rate Provision (Benefit)" } } }, "localname": "OtherEffectiveTaxRateProvisionBenefit", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "amph_OtherFinishedPharmaceuticalProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Finished Pharmaceutical Products [Member]", "label": "Other Finished Pharmaceutical Products [Member]", "terseLabel": "Other Finished Pharmaceutical Products" } } }, "localname": "OtherFinishedPharmaceuticalProductsMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails" ], "xbrltype": "domainItemType" }, "amph_OwnershipPercentageAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership interest acquired.", "label": "Ownership Percentage Acquired", "terseLabel": "Percentage of ownership interest acquired" } } }, "localname": "OwnershipPercentageAcquired", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "amph_OwnershipPercentageAfterSpinoffTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership in investment after spin-off transaction.", "label": "Ownership Percentage After Spinoff Transaction", "terseLabel": "Ownership after transaction" } } }, "localname": "OwnershipPercentageAfterSpinoffTransaction", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "amph_PaymentsForDepositsAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow related to payments and other deposits not otherwise defined in the taxonomy.", "label": "Payments For Deposits And Other Assets", "negatedLabel": "Payment of deposits and other assets" } } }, "localname": "PaymentsForDepositsAndOtherAssets", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amph_PhytonadioneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phytonadione [Member]", "label": "Phytonadione [Member]", "terseLabel": "Phytonadione" } } }, "localname": "PhytonadioneMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails" ], "xbrltype": "domainItemType" }, "amph_PrimatenemistMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primatene Mist Member", "label": "Primatenemist [Member]", "terseLabel": "Primatene Mist" } } }, "localname": "PrimatenemistMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "amph_ProceedsFromPaymentsForIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsNetOfWithholdingTaxPayments": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total cash inflow or outflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises, net of withholding tax payments upon issuance to employees. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.", "label": "Proceeds From Payments For Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options, Net Of Withholding Tax Payments", "negatedLabel": "Proceeds from equity plans, net of withholding tax payments" } } }, "localname": "ProceedsFromPaymentsForIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsNetOfWithholdingTaxPayments", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "amph_ProductReturnAccrualCurrent": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date for estimated refunds due to goods returned by customers (other than under warranty provisions). For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Return Accrual, Current", "terseLabel": "Accrued product returns, current portion", "verboseLabel": "Return accrual included in accounts payable and accrued liabilities" } } }, "localname": "ProductReturnAccrualCurrent", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "amph_ProductReturnAccrualNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Product Return Accrual, Non-Current", "label": "Product Return Accrual, Non-Current", "terseLabel": "Return accrual included in other long-term liabilities" } } }, "localname": "ProductReturnAccrualNonCurrent", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "amph_ProductReturnRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the aggregate product return rate percentage of qualified sales.", "label": "Product Return Rate, Percentage", "terseLabel": "Aggregate product return rate" } } }, "localname": "ProductReturnRatePercentage", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails" ], "xbrltype": "percentItemType" }, "amph_RamirezVsAmphastarPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ramirez vs Amphastar Pharmaceuticals, Inc", "label": "Ramirez Vs Amphastar Pharmaceuticals Inc [Member]", "terseLabel": "Ramirez vs Amphastar Pharmaceuticals, Inc" } } }, "localname": "RamirezVsAmphastarPharmaceuticalsIncMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "domainItemType" }, "amph_ReserveForNetLossOnFirmPurchaseCommitments": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reserve for net loss on firm purchase commitments.", "label": "Reserve For Net Loss On Firm Purchase Commitments", "verboseLabel": "Accrued loss on firm purchase commitments" } } }, "localname": "ReserveForNetLossOnFirmPurchaseCommitments", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "amph_RestrictedShortTermInvestmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for restricted short-term investments.", "label": "Restricted Short-term Investments [Policy Text Block]", "terseLabel": "Restricted Short-Term Investments" } } }, "localname": "RestrictedShortTermInvestmentsPolicyTextBlock", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "amph_RestrictedStockUnitsIssuedAsCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Restricted Stock Units (RSUs) issued as compensation.", "label": "Restricted Stock Units Issued As Compensation [Member]", "terseLabel": "Restricted Stock Units Issued as Compensation" } } }, "localname": "RestrictedStockUnitsIssuedAsCompensationMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails" ], "xbrltype": "domainItemType" }, "amph_RevenueRecognitionDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for revenue recognition.", "label": "Revenue Recognition Disclosure [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionDisclosureTextBlock", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognition" ], "xbrltype": "textBlockItemType" }, "amph_RevenueRecognitionWholesalerChargebacks": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount the Company agrees to reimburse wholesalers for differences between the gross sales prices, at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company's various contractual arrangements with third parties such as hospitals and group purchasing organizations.", "label": "Revenue Recognition Wholesaler Chargebacks", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "RevenueRecognitionWholesalerChargebacks", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails" ], "xbrltype": "monetaryItemType" }, "amph_RevenueRecognitionWholesalerChargebacksCreditsIssuedToThirdParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents wholesaler chargeback credits issued to third parties during the period.", "label": "RevenueRecognitionWholesalerChargebacksCreditsIssuedToThirdParties", "negatedLabel": "Credits and payments issued to third parties" } } }, "localname": "RevenueRecognitionWholesalerChargebacksCreditsIssuedToThirdParties", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails" ], "xbrltype": "monetaryItemType" }, "amph_RevenueRecognitionWholesalerChargebacksProvisionRelatedToSalesInPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the wholesaler chargeback provision related to sales made in the current period.", "label": "Provision for chargebacks and rebates" } } }, "localname": "RevenueRecognitionWholesalerChargebacksProvisionRelatedToSalesInPeriod", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails" ], "xbrltype": "monetaryItemType" }, "amph_ScheduleOfChargebackLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The provision for chargebacks is a significant estimate used in the recognition of revenue. As part of its sales terms with wholesale customers, the Company agrees to reimburse wholesalers for differences between the gross sales prices, at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company's various contractual arrangements with third parties such as hospitals and group purchasing organizations. The Company estimates chargebacks at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback rates, and current contract pricing.", "label": "Schedule of Chargeback Liability [Table Text Block]", "terseLabel": "Schedule of chargeback and rebates provision analysis" } } }, "localname": "ScheduleOfChargebackLiabilityTableTextBlock", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "amph_ScheduleOfDepreciationDepletionAndAmortizationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of depreciation, depletion, and amortization of property and equipment costs.", "label": "Schedule Of Depreciation Depletion And Amortization [Table Text Block]", "terseLabel": "Schedule of depreciation and amortization expense by reporting segment" } } }, "localname": "ScheduleOfDepreciationDepletionAndAmortizationTableTextBlock", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "amph_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortizable finite-lived intangible assets, in total and by major class, including the gross carrying amount and accumulated amortization, and indefinite-lived intangible assets not subject to amortization, excluding goodwill, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Schedule Of Finite Lived And Indefinite Lived Intangible Assets By Major Class Table Text Block", "terseLabel": "Schedule of weighted-average life, original cost, accumulated amortization and net book value by major class" } } }, "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "amph_ScheduleOfProductReturnsLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Company's product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for estimated returns. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms.", "label": "Schedule of Product Returns Liability [Table Text Block]", "terseLabel": "Schedule of product return liability analysis" } } }, "localname": "ScheduleOfProductReturnsLiabilityTableTextBlock", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "amph_SeineNormandieWaterAgencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Seine-Normandie water agency.", "label": "Seine Normandie Water Agency [Member]", "terseLabel": "Seine-Normandie Water Agency" } } }, "localname": "SeineNormandieWaterAgencyMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "amph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards granted during the period.", "label": "RSUs granted (in Dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalFairValue", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails" ], "xbrltype": "monetaryItemType" }, "amph_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsNumberOfSharesOfCommonStockPerAward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of common shares the grantee is to receive at a specified future date for each Restricted Stock Unit (\"RSU\") awarded.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Number of Shares of Common Stock Per Award (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsNumberOfSharesOfCommonStockPerAward", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "amph_ShareRepurchaseAgreementOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of additional ownership interest from Share Repurchase Agreement.", "label": "Share Repurchase Agreement Ownership Percentage", "terseLabel": "Percentage of additional ownership interest from shares repurchase" } } }, "localname": "ShareRepurchaseAgreementOwnershipPercentage", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "amph_SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the reporting entity's significant accounting policies, excluding its policy for revenue recognition.", "label": "Significant Accounting Policies Excluding Revenue Recognition Policy Text Block", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesExcludingRevenueRecognitionPolicyTextBlock", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "amph_StockIssuedDuringPeriodValueEquityPlans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued under equity plans.", "label": "Stock Issued During Period Value Equity Plans", "terseLabel": "Issuance of common stock in connection with the Company's equity plans" } } }, "localname": "StockIssuedDuringPeriodValueEquityPlans", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "amph_The2015EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the 2015 Equity Incentive Plan.", "label": "The2015 Equity Incentive Plan [Member]", "terseLabel": "The 2015 Equity Incentive Plan" } } }, "localname": "The2015EquityIncentivePlanMember", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "amph_WorkingCapitalLoanDueJune2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of Credit - Due June 2021", "label": "Working Capital Loan Due June2021 [Member]", "terseLabel": "Line of credit - Due June 2021" } } }, "localname": "WorkingCapitalLoanDueJune2021Member", "nsuri": "http://www.amphastar.com/20210331", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "C [N]", "terseLabel": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "country_FR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "F [R]", "terseLabel": "FRANCE" } } }, "localname": "FR", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U [S]", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r393", "r394", "r400", "r401", "r553" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r393", "r394", "r400", "r401" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investee Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case Type [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r204", "r288", "r291", "r528" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r204", "r288", "r291", "r528" ], "lang": { "en-us": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r201", "r202", "r288", "r290", "r527", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r201", "r202", "r288", "r290", "r527", "r539", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r206", "r447" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable And Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable, Net" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r23", "r207", "r208" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r17", "r492", "r512" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r19", "r492", "r512" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Long-term reserve for income tax liabilities" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r37", "r255" ], "calculation": { "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r62", "r63", "r64", "r515", "r533", "r534" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r61", "r64", "r65", "r122", "r123", "r124", "r399", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r354" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r122", "r123", "r124", "r351", "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r316", "r318", "r357", "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Share-based compensation expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r318", "r347", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated share based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r102", "r243", "r249" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization Of Intangible Assets", "terseLabel": "Amortization of product rights, trademarks, and patents" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r113", "r182", "r189", "r196", "r223", "r393", "r400", "r426", "r490", "r511" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r56", "r113", "r223", "r393", "r400", "r426" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r414" ], "calculation": { "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure, Recurring", "totalLabel": "Fair value measurement" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r319", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r406", "r410" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r313", "r314", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r107", "r108", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Capital expenditure included in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r107", "r108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Equipment acquired under finance leases" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r35", "r104" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r12", "r105", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r12", "r105", "r111", "r488" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r97", "r104", "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r97", "r429" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Certificates of Deposit, at Carrying Value", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates Of Deposit [Member]", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r283", "r284", "r285", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r262", "r263", "r264", "r272" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock; shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock; shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r277" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Common stock; shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value", "terseLabel": "Common stock: par value $0.0001; 300,000,000 shares authorized; 55,184,000 and 47,718,003 shares issued and outstanding as of March 31, 2021 and 54,760,922 and 47,495,439 shares issued and outstanding as of December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefits" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r68", "r70", "r71", "r77", "r502", "r521" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r163", "r164", "r204", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r163", "r164", "r204", "r424", "r425", "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r163", "r164", "r204", "r424", "r425", "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Customer and Supplier Concentration" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentration" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r163", "r164", "r204", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Major Customers" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r163", "r164", "r204", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Contractual Obligation", "verboseLabel": "Total debt" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails", "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails", "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r83", "r113", "r223", "r426" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r162", "r204" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r17", "r18", "r491", "r493", "r509" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument", "terseLabel": "Debt" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r46", "r115", "r278", "r279", "r280", "r281", "r440", "r441", "r443", "r508" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred Compensation Liability, Current and Noncurrent", "terseLabel": "Deferred compensation plan liabilities" } } }, "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Deferred compensation plan assets" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r364", "r365" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r364", "r365" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r102", "r253" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense", "terseLabel": "Depreciation of property, plant, and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r102", "r177" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract Type [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r57", "r58", "r408", "r464" ], "calculation": { "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "negatedLabel": "Interest rate swaps related to variable rate loans", "terseLabel": "Interest rate swap, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtNarrativeDetails", "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r407", "r409", "r411", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders", "terseLabel": "Net income (loss) per share attributable to Amphastar Pharmaceuticals, Inc. stockholders:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r78", "r127", "r128", "r129", "r130", "r131", "r135", "r137", "r148", "r149", "r150", "r154", "r155", "r503", "r522" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in Dollars per share)", "terseLabel": "Net income (loss) per share - basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r78", "r127", "r128", "r129", "r130", "r131", "r137", "r148", "r149", "r150", "r154", "r155", "r503", "r522" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in Dollars per share)", "terseLabel": "Net income (loss) per share - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r151", "r152", "r153", "r156" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r429" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax benefit as a percentage of income before income taxes", "verboseLabel": "Income tax provision as a percentage of income before income taxes" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeBeforeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and related benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r122", "r123", "r124", "r126", "r132", "r134", "r157", "r224", "r277", "r282", "r351", "r352", "r353", "r374", "r375", "r431", "r432", "r433", "r434", "r435", "r436", "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r414", "r415", "r416", "r420" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities measured on a recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r309", "r415", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r414", "r415", "r417", "r418", "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r294", "r296", "r301", "r309", "r415", "r454" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r294", "r296", "r301", "r309", "r415", "r455" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r309", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r419", "r421" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r111", "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r445", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Equipment under Finance Leases" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r444" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset", "verboseLabel": "Finance lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r215", "r218", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails", "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsOwnedCorporateDebtAtFairValue": { "auth_ref": [ "r486" ], "calculation": { "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of firm holdings in corporate fixed income securities. Includes pledged and unpledged holdings.", "label": "Financial Instruments, Owned, Corporate Debt, at Fair Value", "terseLabel": "Corporate and municipal bonds" } } }, "localname": "FinancialInstrumentsOwnedCorporateDebtAtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted-Average Life (Years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r248" ], "calculation": { "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r244", "r246", "r248", "r251", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r248", "r484" ], "calculation": { "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r244", "r247" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r248", "r483" ], "calculation": { "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Finite-Lived Intangible Assets, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Definite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r111", "r438" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r102" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss (gain) on impairment and disposal of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r237", "r238", "r489" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill recognized" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwillDetails", "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r239", "r240", "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Currency translation and other adjustments" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r81", "r113", "r182", "r188", "r192", "r195", "r198", "r223", "r426" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross Profit:", "terseLabel": "Gross profit (loss):" } } }, "localname": "GrossProfitAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HeldToMaturitySecurities": { "auth_ref": [ "r210", "r212", "r499" ], "calculation": { "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity", "totalLabel": "Amortized Cost" } } }, "localname": "HeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "auth_ref": [ "r214", "r217" ], "calculation": { "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails": { "order": 1.0, "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "auth_ref": [ "r213", "r216", "r499" ], "calculation": { "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails": { "order": 2.0, "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity, Fair Value", "terseLabel": "Fair Value" } } }, "localname": "HeldToMaturitySecuritiesFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesTextBlock": { "auth_ref": [ "r215", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity [Table Text Block]", "terseLabel": "Schedule of securities classified as held-to-maturity" } } }, "localname": "HeldToMaturitySecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r75", "r182", "r188", "r192", "r195", "r198", "r485", "r500", "r505", "r524" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (loss) before income taxes", "totalLabel": "Income (loss) before income taxes", "verboseLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeBeforeTaxesDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]", "terseLabel": "Income (loss) before income taxes:" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeBeforeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r368", "r369", "r372", "r376", "r378", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r114", "r133", "r134", "r180", "r366", "r377", "r379", "r525" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeBeforeTaxesDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r72", "r111", "r362", "r363", "r369", "r370", "r371", "r373", "r540" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Deferred Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r99", "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r101" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r101" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r101" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Changes in deferred taxes, net" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r101" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r101" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Changes in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": { "auth_ref": [ "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r150" ], "calculation": { "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares", "terseLabel": "Incremental shares from equity awards" } } }, "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r245", "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived intangible assets, Original Cost", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r245", "r250" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "totalLabel": "Balance, Net Book Value", "verboseLabel": "Goodwill and intangible assets, net" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r73", "r176", "r439", "r442", "r504" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r95", "r98", "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid, net of capitalized interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r52" ], "calculation": { "http://www.amphastar.com/role/DisclosureInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFirmPurchaseCommitmentLoss": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss recognized on firm purchase commitment for inventory.", "label": "Inventory, Firm Purchase Commitment, Loss" } } }, "localname": "InventoryFirmPurchaseCommitmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r55" ], "calculation": { "http://www.amphastar.com/role/DisclosureInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails", "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r54" ], "calculation": { "http://www.amphastar.com/role/DisclosureInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Raw materials and supplies" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r53" ], "calculation": { "http://www.amphastar.com/role/DisclosureInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory adjustment to reflect net realizable value" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r85", "r175" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r222", "r523" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "verboseLabel": "Short-Term Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r414" ], "calculation": { "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Short-term investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r220", "r487", "r506", "r538" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvement" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Litigation" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r113", "r190", "r223", "r394", "r400", "r401", "r426" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r113", "r223", "r426", "r496", "r518" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r113", "r223", "r394", "r400", "r401", "r426" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r41", "r115" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line Of Credit Facility Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r48", "r265" ], "calculation": { "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Accrued litigation settlement" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Costs and expenses" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r18", "r275", "r493", "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r18" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term debt, net of current portion", "terseLabel": "Long-term debt and finance leases, net of current portion" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails", "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Capital Lease Obligations, Current", "terseLabel": "Less current portion of long-term debt and finance leases", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtScheduleOfDebtDetails", "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation" } } }, "localname": "LossContingencyInformationAboutLitigationMattersAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r51", "r113", "r223", "r426", "r495", "r517" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling Interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Bonds [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net cash provided by financing activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r97", "r100", "r103" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r66", "r69", "r76", "r103", "r113", "r125", "r127", "r128", "r129", "r130", "r133", "r134", "r147", "r182", "r188", "r192", "r195", "r198", "r223", "r426", "r501", "r520" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss) attributable to Amphastar Pharmaceuticals, Inc.", "totalLabel": "Net income (loss) attributable to Amphastar Pharmaceuticals, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r66", "r69", "r133", "r134", "r396", "r403" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net income (loss) attributable to non-controlling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "negatedLabel": "Net loss attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and dilutive numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r122", "r123", "r124", "r282", "r389" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Non-operating income (expenses)", "totalLabel": "Total non-operating (expenses) income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-operating (expenses) income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating (income) expenses:", "terseLabel": "Operating (income) expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r182", "r188", "r192", "r195", "r198" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r445" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r445" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Long-term operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r444" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r405" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "General" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGeneral" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r10", "r44" ], "calculation": { "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r60", "r62", "r427", "r428", "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Gains and (losses) of intercompany foreign currency transactions" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r59" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc., net of income taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r67", "r70", "r391", "r392", "r398" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.", "verboseLabel": "Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc." } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r391", "r392", "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "terseLabel": "Income tax expense allocated to other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income (expenses), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Amphastar Stockholders' Equity [Member]" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities." } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r93" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchase of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "auth_ref": [ "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.", "label": "Payments to Acquire Additional Interest in Subsidiaries", "terseLabel": "Payments for additional ownership interest" } } }, "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r211" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of short-term investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r90" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases and construction of property, plant, and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r293", "r295", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r315" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Employee Benefits" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureEmployeeBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.", "label": "Pension Cost (Reversal of Cost)", "terseLabel": "Pension Cost" } } }, "localname": "PensionExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureEmployeeBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r319", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value", "terseLabel": "Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r33", "r34" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r92" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r91" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from private placement", "verboseLabel": "Proceeds from the private placement of ANP" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturity of short-term investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "auth_ref": [ "r88" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale of Short-term Investments", "terseLabel": "Sales of short-term investments, net" } } }, "localname": "ProceedsFromSaleOfShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r91", "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Cash received" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r66", "r69", "r96", "r113", "r125", "r133", "r134", "r182", "r188", "r192", "r195", "r198", "r223", "r391", "r395", "r397", "r403", "r404", "r426", "r505" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeTaxesSummaryOfIncomeBeforeTaxesDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r37", "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r259", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant, and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r36", "r254" ], "calculation": { "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Total property, plant, and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r256", "r519" ], "calculation": { "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Total property, plant, and equipment, net", "verboseLabel": "Property, plant, and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails", "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r13", "r256" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant, and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r13", "r254" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Public Utilities Inventory Type [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "auth_ref": [ "r20", "r494", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.", "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "auth_ref": [ "r20", "r494", "r514" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Purchase Commitment Excluding Longterm Commitment [Domain]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "auth_ref": [ "r20", "r494", "r514" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.", "label": "Purchase Commitment, Excluding Long-term Commitment [Table]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r187", "r192" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of net revenues in the finished pharmaceutical products segment" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r94" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Principal payments on long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r361", "r554" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndInvestments": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.", "label": "Restricted Cash and Investments", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r3", "r12", "r110" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r536", "r537" ], "calculation": { "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments At Fair Value", "terseLabel": "Restricted short-term investments" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsCurrent": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.", "label": "Restricted Investments, Current", "terseLabel": "Restricted short-term investments" } } }, "localname": "RestrictedInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r282", "r354", "r516", "r532", "r534" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r122", "r123", "r124", "r126", "r132", "r134", "r224", "r351", "r352", "r353", "r374", "r375", "r529", "r531" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r74", "r113", "r173", "r174", "r187", "r193", "r194", "r200", "r201", "r204", "r223", "r426", "r505" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Net Revenue", "netLabel": "Net revenues", "terseLabel": "Net Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Net revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer and Supplier Concentration" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SalesReturnsAndAllowancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.", "label": "Sales Returns And Allowances [Member]", "terseLabel": "Product returns" } } }, "localname": "SalesReturnsAndAllowancesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r163", "r204" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "Net Revenues" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of accounts payable and accrued liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net income (loss) per share calculation" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of the statutory federal income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r318", "r346", "r356" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]", "terseLabel": "Schedule of recorded share-based compensation expense under all plans" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of changes in carrying amounts of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Held-to-maturity Securities [Line Items]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "auth_ref": [ "r215", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity [Table]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r30", "r31", "r32" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "Schedule of the summary of nonvested options status" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r37", "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule of accounts receivable and net revenues by major customer" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureCustomerAndSupplierConcentrationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r80", "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of net revenues and carrying values of long-lived assets by geographic region" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r74", "r203" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfRevenuesAndLongLivedAssetsByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r182", "r185", "r191", "r241" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r182", "r185", "r191", "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of financial information by reporting segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Schedule of Share-based Compensation, Activity [Table Text Block]", "terseLabel": "Schedule of information relating to RSU grants and deliveries" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r319", "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r324", "r335", "r338" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of the summary of option activity under all plans" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of key assumptions to determine fair value of options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r169", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r198", "r204", "r526" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segment [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r169", "r171", "r172", "r182", "r186", "r192", "r196", "r197", "r198", "r199", "r200", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]" } } }, "localname": "SegmentReportingInformationRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling, distribution, and marketing", "terseLabel": "Selling, distribution, and marketing expense" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling And Marketing Expense [Member]", "terseLabel": "Selling, distribution and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation [Member]" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r101" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Total Fair Market Value of RSUs Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "RSUs forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "RSUs granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "RSUs vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Average volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBasedCompensationExpenseIncludedInStatementOfOperationsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Total RSUs outstanding at the end of the period", "periodStartLabel": "Total RSUs outstanding at the beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquity2015EquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Additional Disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at the end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at the end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Options expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "netLabel": "Options granted (in dollars per share)", "terseLabel": "Weighted-average grant date fair value (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Schedule of information relating to options grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r326", "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding Options, End of period", "periodStartLabel": "Outstanding Options, Beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding Exercise Price (in dollars per share)", "periodStartLabel": "Outstanding Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r317", "r322" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Options exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Options expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Options cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r341", "r355" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average expected life in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityKeyAssumptionsUsedInDeterminingFairValueOfOptionsGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Exercisable remaining contractual term (in Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Nonvested at end of period", "periodStartLabel": "Nonvested at beginning of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedLabel": "Options forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Options forfeited (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at end of period (in dollars per share)", "periodStartLabel": "Nonvested at beginning of period (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding Contractual Term (in Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2018AnpEquityIncentivePlanDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquityRestrictedStockUnitsDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Total fair value of the options vested during the year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToOptionGrantsAndExercisesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Options vested (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Shares Paid for Tax Withholding for Share Based Compensation", "terseLabel": "Stock surrendered to fulfill tax withholding obligations" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityInformationRelatingToRsuGrantsAndDeliveriesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r16", "r497", "r498", "r510" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r169", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r198", "r204", "r241", "r258", "r260", "r261", "r526" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingDepreciationAndAmortizationExpenseByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSelectedFinancialInformationByReportingSegmentDetails", "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r50", "r122", "r123", "r124", "r126", "r132", "r134", "r157", "r224", "r277", "r282", "r351", "r352", "r353", "r374", "r375", "r431", "r432", "r433", "r434", "r435", "r436", "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r122", "r123", "r124", "r157", "r482" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureInventoriesDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfChargebackProvisionDetails", "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails", "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfNonvestedOptionsDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r21", "r22", "r277", "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity2014EmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross", "verboseLabel": "Issuance of common stock in connection with the Company's equity plans (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r277", "r282", "r329" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": { "auth_ref": [ "r22", "r277", "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "Stock Issued During Period, Shares, Treasury Stock Reissued", "terseLabel": "Issuance of treasury stock in connection with the Company's equity plans (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "auth_ref": [ "r21", "r22", "r277", "r282", "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "terseLabel": "Issuance of treasury stock in connection with the Company's equity plans" } } }, "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Increase authorized for share buyback program" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r27", "r28", "r113", "r209", "r223", "r426" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Amphastar Pharmaceuticals, Inc. stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r113", "r122", "r123", "r124", "r126", "r132", "r223", "r224", "r282", "r351", "r352", "r353", "r374", "r375", "r389", "r390", "r402", "r426", "r431", "r432", "r436", "r530", "r531" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r112", "r282", "r287" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSegmentReportingSummaryOfNetRevenuesByProductSegmentDetails", "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r437", "r449" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails", "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r437", "r449" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r437", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails", "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r437", "r449" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureLitigationDetails", "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r448", "r450" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.", "label": "Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions", "terseLabel": "Ownership percentage" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosures of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r215", "r218", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySFinancialAssetsAndLiabilitiesDetails", "http://www.amphastar.com/role/DisclosureInvestmentsHeldTomaturityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r49", "r283" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r22", "r277", "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired (in Shares)", "negatedLabel": "Treasury stock acquired (in Shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r49", "r283", "r286" ], "calculation": { "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r277", "r282", "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Treasury stock acquired" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureStockholdersEquityShareBuybackProgramDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r158", "r159", "r160", "r161", "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseRightsMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Legal right to use or benefit from the use of natural resources or access. Examples include, but are not limited to, drilling rights, water rights, air rights, timber cutting rights and route authorities.", "label": "Use Rights [Member]", "terseLabel": "Land-use rights" } } }, "localname": "UseRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r116", "r120" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r119" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Credits issued to third parties" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r116", "r117", "r118", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "Valuation Allowances And Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)", "terseLabel": "Provision for product returns" } } }, "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r116", "r117", "r118", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureRevenueRecognitionAnalysisOfProductReturnLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Net effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r136", "r150" ], "calculation": { "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average shares outstanding - diluted", "verboseLabel": "Diluted (in Shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average shares used to compute net income (loss) per share attributable to Amphastar Pharmaceuticals, Inc. stockholders:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r135", "r150" ], "calculation": { "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in Shares)", "terseLabel": "Weighted-average shares outstanding-basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.amphastar.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.amphastar.com/role/DisclosureIncomeLossPerShareAttributableToAmphastarPharmaceuticalsIncStockholdersCalculationOfBasicAndDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2062-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2538-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2538-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2574-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2597-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2600-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "54", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2603-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4578-108314" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r287": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r315": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r405": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r438": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35711157&loc=d3e42546-110969" }, "r487": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r506": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r538": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r555": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r556": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r557": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r558": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r559": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" } }, "version": "2.1" } ZIP 93 0001297184-21-000031-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001297184-21-000031-xbrl.zip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�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end